









A thesis submitted in the fulfilment of the requirements for the degree of 
Doctor of Philosophy 








Introduction:  Oral drug delivery systems such as polymeric nanoparticles are used to 
improve therapies that utilize biomacromolecules like proteins and peptides.  Surface 
modifications of polymeric nanoparticles play a crucial role in the interactions with the 
intestinal epithelium.  Cell-penetrating peptides (CPPs) are short cationic amino acid sequences 
that can be utilized to enhance interactions between polymeric nanoparticles and cells.  In this 
thesis, surface-modified polymeric nanoparticles are prepared using a nanoprecipitation method 
and a zero-length crosslinking reaction for the covalent conjugation of CPPs to polymeric 
nanoparticles.  Three CPPs with a distinct architecture, namely the short RRH, the long linear 
TAT and the branched bTAT were exploited.  Further, the nanoparticles were characterised and 
the influence of the CPP architecture on cellular uptake was investigated. 
Methods:  A bulk nanoprecipitation and a microfluidics method were compared for the 
formulation of uniform poly-lactic-co-glycolic acid (PLGA) nanoparticles using a design of 
experiments study.  CPP-tagged PLGA nanoparticles were formulated using a post-
microfluidics and an in situ microfluidics conjugation approach developed for the first time.  
The physiochemical characteristics and morphology of PLGA and CPP-tagged PLGA 
nanoparticles were analysed with dynamic light scattering, laser Doppler electrophoresis, 
Fourier-transform infrared spectroscopy and transmission electron microscopy (TEM).  The 
distribution of CPPs on PLGA nanoparticles was further elucidated with small angle X-ray 
scattering (SAXS) after gold labelling of the CPP-tagged PLGA nanoparticles.  PLGA and 
CPP-tagged PLGA nanoparticles were prepared using a fluorophore-labelled PLGA for in vitro 
cell culture studies.  The cell toxicity and interactions of the fluorophore-labelled PLGA and 
CPP-tagged PLGA nanoparticles with HeLa and Caco-2 cells were investigated using flow 




Results:  PLGA nanoparticles intended for oral drug delivery and formulated with 
microfluidics showed a size of 151.2 ± 1.2 nm (PDI 0.149 ± 0.014) and had superior size 
characteristics in comparison to the bulk nanoprecipitation method resulting in PLGA 
nanoparticles with a size of 184.0 ± 3.9 nm (PDI 0.110 ± 0.007).  The covalent conjugation of 
CPPs with different architectures tuned the surface charge of CPP-tagged PLGA nanoparticles 
from negative to slightly positive (-24 to +5 mV).  This trend in change of surface charge was 
observed for both preparation methods, the post-microfluidics and the in situ microfluidics 
conjugation approach.  After analysis with TEM and SAXS, it was found that the distribution 
of CPPs on PLGA nanoparticles depends on the preparation approach.  The in situ microfluidics 
conjugation approach showed a distribution of the CPPs throughout the PLGA nanoparticles, 
whereas the post-microfluidics conjugation approach indicated a surface arrangement of the 
CPPs on the PLGA nanoparticle surface.  In vitro cell culture studies using HeLa and Caco-2 
cells revealed association rather than uptake of the CPP-tagged PLGA nanoparticles. 
Conclusion:  Microfluidics and CPPs of different architecture were successfully 
utilized for the formulation of surface-modified polymeric nanoparticles with a tuneable surface 
charge. For nanoparticle-cell interactions to occur e.g. at the nano-bio interface, the surface 
charge of nanoparticles plays a crucial role. Further investigation of nanoparticle-cell 
interactions can aid to gain a better understanding of how the well-characterised CPP-tagged 
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 Nanoparticles as oral drug delivery systems 
The metric scale categorizes materials according to their dimensions, and 
pharmaceutical research utilizes both micro- and nano-sized particles for application in 
delivering therapeutic compounds to patients.  Micro- and nanoparticles are used as drug 
delivery systems for the treatment of cancer (Derakhshandeh et al., 2007; Dong et al., 2019; 
Jaimes-Aguirre et al., 2017), diabetes (Sharma et al., 2015), bacterial infections (Sonam et al., 
2014), for vaccine delivery (Bailey et al., 2017; Kaneko et al., 2018) or as diagnostic agents 
(Zhu et al., 2019).  The term ‘nano’ refers to structures between 1 and 100 nm, but nanoparticles 
more commonly include structures of up to 1000 nm in one dimension (Farokhzad and Langer, 
2009).  The application of nanoparticles for drug delivery via the oral route of administration is 
a simple approach and results in good patient compliance since self-administration of the drug 
delivery system is convenient for the patient (Date et al., 2016). 
 
For therapeutic applications, proteins and peptides are often referred to as 
biopharmaceuticals or biomacromolecules and they are of interest due to their high efficiency, 
low toxicity and good tolerance after administration (Malhaire et al., 2016; Thwala et al., 2017).  
The main challenge for oral delivery of proteins and peptides, however, is their fragility in the 
gastrointestinal tract (GIT) (Malhaire et al., 2016).  There are three main hurdles 
biomacromolecules encounter before reaching the cell surface where uptake into the body can 
occur.  These hurdles are (i) the changes in pH that occur throughout the GIT and alter the 
ionisation status of the molecules, (ii) the presence of enzymes in the lumen and within 
epithelial cells that can degrade biomacromolecules and (iii) the mucus layer covering the apical 
surface of the epithelium that acts as a diffusion barrier to absorption (Kristensen and Nielsen, 
2016).  In addition, the physicochemical characteristics of biomacromolecules including a high 
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molecular weight, hydrophilicity and enzymatic instability contribute to a low oral 
bioavailability (< 1%) and poor permeability after oral administration (Bourganis et al., 2017; 
Date et al., 2016; Thwala et al., 2017). 
 
A strategy to overcome low bioavailability and physicochemical instability is the 
encapsulation of biomacromolecules in drug delivery systems.  Drug delivery systems are a 
diverse group of carriers including liposomes (Kastner et al., 2015), micelles (Capretto et al., 
2012), lipid-polymer hybrid nanoparticles (Kim et al., 2012) and polymeric nanoparticles 
(Jaimes-Aguirre et al., 2017).  Nanoparticles can be used to shield proteins and peptides against 
the harsh environment in the GIT and to assist the transport of therapeutics across the intestinal 
epithelium (Malhaire et al., 2016).  Polymeric nanoparticles are characterised by prolonged 
stability in an acidic environment, low toxicity and targeted delivery abilities (Lee et al., 2016).  
Three key advantages of polymeric nanoparticles as an oral drug delivery system have been 
identified.  The encapsulation of drug in polymeric nanoparticles improves the bioavailability 
of the drug (Bobo et al., 2016), and facilitates controlled release of encapsulated drug from the 
polymer matrix (Banik et al., 2016; Jaimes-Aguirre et al., 2017).  A third advantage is that 
surface modification increases the stability of the polymeric nanoparticles in in vitro and in vivo 
conditions and the targeting of specific tissue as the site of action for the encapsulated drug 
(Banik et al., 2016; Torchilin, 2014). 
 
 Polymeric delivery systems 
Polymeric materials for production of nanoparticles for drug delivery can be obtained 
from natural sources like albumin, alginate and chitosan or can be of synthetic origin (Zhang et 
al., 2013).  Synthetic polymers can be divided into biodegradable polymers like poly(ε-
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caprolactone) and poly(lactic-co-glycolic acid) (PLGA) and non-degradable polymers such as 
polyacrylates (Zhang et al., 2013).  The polymer used for the formation of nanoparticles has a 
major influence on the physicochemical characteristics of the formulated polymeric 
nanoparticles and needs to be chosen carefully to suit the needs of the application (Bobo et al., 
2016).  The focus of this thesis is on PLGA as a biodegradable polymer for oral drug delivery 
systems due its biocompatibility and low toxicity and the approval of the polymer for human 
applications by the FDA (Food and Drug Administration US) and EMA (European Medicine 
Agency) (Danhier et al., 2012; Masood, 2016). 
 
 Poly(lactic-co-glycolic acid) 
A copolymer is defined by the presence of two different monomer units repeating in the 
polymer chain (Scott and Penlidis, 2017).  The physicochemical characteristics of copolymers 
depend on the incorporated monomers and show a wide range of characteristics due to the 
combination of individual monomer properties (Scott and Penlidis, 2017).  From a chemical 
point of view, PLGA is a copolymer (Masood, 2016), but more commonly in scientific 
publications it is referred to as a polymer and this nomenclature will also apply for this thesis. 
 
The PLGA polymer consists of two monomers, namely lactic acid and glycolic acid, 
and can be synthesised by direct polycondensation of the monomers or ring-opening 
polymerisation of the cyclic diesters lactide and glycolide (Figure 1.1) (Avgoustakis, 2008).  
Poly lactic acid (PLA) is a hydrophobic polymer due to methyl side groups in the molecule and 
provides a slow rate of degradation over the period of weeks (Makadia and Siegel, 2011; 
Steinbach et al., 2016).  Poly glycolic acid (PGA) on the other hand is a hydrophilic polymer 
and shows faster degradation because of hydrolytic instability (Makadia and Siegel, 2011).  In 
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a physiological environment, PLGA is degraded through hydrolysis of the ester bonds (Figure 
1.1) and the monomers are further metabolized via the Krebs cycle, which leads to minimal 
systemic toxicity (Avgoustakis, 2008; Danhier et al., 2012). 
 
 
Figure 1.1.  Structure and reaction of cyclic monomers used for the synthesis of PLGA and the 
structure of monomers after hydrolysis of the PLGA polymer (Avgoustakis, 2008; Makadia and 
Siegel, 2011). 
 
The characteristics of the PLGA polymer, including degradation rate and solubility, are 
influenced by the molecular weight and ratio of the monomers, the end-group (either acid or 
ester-end groups) on the monomer as well as the shape of the polymer chain (Makadia and 
Siegel, 2011; Park et al., 2019).  A higher molecular weight PLGA and a higher amount of 
lactic acid units result in slower degradation of the polymer (Park, 1995; Wu and Wang, 2001).  
In particular, the solubility of PLGA depends on the ratio of lactic acid and glycolic acid 
monomers. With an increasing number of lactic acid monomers and a decreasing number of 
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glycolic acid monomers, the physicochemical characteristics change from being soluble in 
fluorinated solvents to common organic solvents like acetone (Park et al., 2019). 
 
 Preparation of polymeric nanoparticles 
Polymeric nanoparticles formulated with the PLGA polymer can increase the systemic 
absorption after oral administration of small molecular weight drugs with different structures 
and hydrophilicities as well as larger molecules like insulin, heparin and vaccines (Mante et al., 
2016).  Efficient production of nanoparticles for drug delivery applications is increasingly 
important to ensure that the benefits of these delivery systems are translated from ‘bench to 
bedside’. 
 
 Bulk preparation methods 
The formulation of nanoparticles is commonly performed with bulk preparation 
methods, which use volumes between 5 and 50 mL in an appropriate vessel (Babos et al., 2018; 
Haggag et al., 2018).  There are a number of preparation methods like dialysis, interfacial 
polymerisation, salting out and spray-drying that are less frequently used for the preparation of 
nanoparticles (Allemann et al., 1993; Draheim et al., 2015; Kafka et al., 2009; Kostag et al., 
2010).  Reasons for the infrequent use of these methods include the requirement of special 
equipment, extensive washing, long production time (days) and unwanted side products.  In this 
Chapter, the focus is on the most common preparation methods including emulsion solvent 
evaporation, nanoprecipitation, nanoemulsions and supercritical fluids for the formulation of 
polymeric nanoparticles (Table 1.1). 
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Table 1.1.  Summary of bulk preparation methods for the formulation of polymeric 
nanoparticles.  PLGA = poly (lactic-co-glycolic acid), PCL = poly(ε-caprolactone), PLA = 
poly-L-lactic acid, PLLA-PEG = poly-L-lactic acid-poly (ethylene glycol), w/o = water/oil, 
w/o/w = water/oil/water. 
Preparation 
method 
Polymer Advantages Disadvantages Reference 
Emulsion solvent 
evaporation 







High energy use 
Time consuming 
Expensive 
(Babos et al., 
2018; Haggag et 
al., 2018; 













(Jara et al., 
2018; Vuddanda 















et al., 2018; 
Homs et al., 
























Zabihi et al., 
2014; Zhao et 
al., 2014b) 
 
The most common bulk method for the production of PLGA nanoparticles is the 
emulsification-based, double emulsion solvent evaporation method (Haque et al., 2018).  
Applying the water/oil/water (w/o/w) double emulsion solvent evaporation method (Figure 
1.2A), the polymer is dissolved in a water-miscible or immiscible organic solvent like 
chloroform, dichloromethane or ethyl acetate and a primary emulsion in aqueous solution is 
formed by high-energy sonication or homogenization (Haggag et al., 2018; Haque et al., 2018).  
The primary emulsion, water/oil (w/o), is then added dropwise to an aqueous solution 
containing stabilizer like polysorbate-80 or polyvinyl alcohol (PVA) (Jeevanandam et al., 2016; 
Masood, 2016).  For the production of the double emulsion, high-energy sonication or 
homogenization is applied and the secondary double emulsion is left for solvent removal at 
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room temperature resulting in formation of polymeric nanoparticles by solidification of the 
polymer (Arshad et al., 2015; Haggag et al., 2018; Haque et al., 2018).  The high-speed 
sonication or homogenization and the related energy that is introduced to form the emulsion 
represents a crucial step in order to obtain particles in the nano-scale size range (Quintanar-
Guerrero et al., 1998).  In addition, Haque et al. (2018) stated that the emulsification-based 
method is influenced by the grade and concentration of the polymer, the concentration of 
stabilizer, the volume of the aqueous and organic phases and the vessel geometry.  An 
alternative to this method is the single emulsion solvent evaporation method, which can be used 
to encapsulate hydrophobic or poorly water soluble drugs (Sharma et al., 2016; Vaidya et al., 
2019).  Using a single emulsion evaporation method, a w/o emulsion of polymer/drug mixture 
in an aqueous surfactant solution is produced by high-speed sonication or homogenization 
before solvent removal as described above (Figure 1.2B) (Sharma et al., 2016; Zu et al., 2019). 
 
 
Figure 1.2.  Schematic description of w/o/w double emulsion solvent evaporation (A) and o/w 
single emulsion solvent evaporation (B) method for the preparation of polymeric nanoparticles 
(Crucho and Barros, 2017). 
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Nanoemulsions have a droplet size of 20-200 nm and can be used for the production of 
polymeric nanoparticles with a size below 60 nm (Feiner-Gracia et al., 2018; Homs et al., 
2018).  In order to produce nanoemulsions, high-energy methods like sonication and high-
pressure homogenization can be applied (Homs et al., 2018).  Alternatively, low-energy 
methods, such as the phase inversion composition method, where nanoemulsions are produced 
by changing the solvent composition at a constant temperature can be used (Fornaguera et al., 
2015; Homs et al., 2018).  High-energy methods are cost-inefficient due to the use of high levels 
of energy, whereas low-energy methods can produce small and uniform droplets by stirring as 
they utilize the internal chemical energy of the system (Caldero et al., 2011; Solans and Solé, 
2012).  Nanoparticles are then obtained from the nanoemulsion by solvent removal under 
reduced pressure or continuous stirring (Caldero et al., 2011; Feiner-Gracia et al., 2018). 
 
Another approach for the formation of nanoparticles utilizes supercritical fluids for the 
production of polymeric nanoparticles (Table 1.1) (Zabihi et al., 2014).  Using the supercritical 
anti-solvent technique, supercritical CO2 is introduced under pressure into the organic polymer 
solution, which is in a high-pressure tank containing liquid CO2 that acts as an anti-solvent 
(Zhao et al., 2014b).  Under these conditions, the velocity of the supercritical CO2 breaks the 
polymer solution apart and droplets are formed (Zhao et al., 2014b).  The quick mass transfer 
between the supercritical CO2 and organic solvent results in supersaturation and precipitation 
of the polymeric precursor to form nanoparticles (Kalani and Yunus, 2012; Zhao et al., 2014b). 
 
All of the methods described rely on residual solvent removal by magnetic stirring or 
under reduced pressure before collection of nanoparticles (Masood, 2016; Sharma et al., 2016).  
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The collected nanoparticles are then washed at least twice using centrifugation with either 
centrifugation at high speed or ultra-centrifugation and dialysis (Masood, 2016). 
 
 Nanoprecipitation 
Nanoprecipitation, also known as solvent displacement (Bairagi et al., 2018; Fessi et 
al., 1989), is the second most commonly used method for the formulation of polymeric 
nanoparticles (Table 1.1 and Figure 1.3A).  The method was first described by Fessi et al. 
(1989) and since then has been optimised and adapted for the production of polymeric 
nanoparticles with a small size (< 300 nm) and to encapsulate both hydrophobic and hydrophilic 
drugs (Bilati et al., 2005).  Using nanoprecipitation, nanoparticles are prepared by the dropwise 
addition of an organic solution of the polymer to an aqueous solution while the mixture is 
agitated (Derakhshandeh et al., 2007).  Suitable water-miscible organic solvents for use in the 
nanoprecipitation method include acetone, acetonitrile, ethanol and dimethylsulfoxide (Bilati 
et al., 2005).  The aqueous phase usually contains ionic and non-ionic surfactants like PVA and 
pluronics (Tefas et al., 2015).  After addition of the organic solvent to the aqueous phase, an 
emulsification process takes place due to agitation of the solutions and a colloidal dispersion 
with nanodroplets is formed (Derakhshandeh et al., 2007).  The nanodroplets are unstable and 
interfacial tension is decreased due to the rapid diffusion of the organic solvent towards the 
aqueous phase (Derakhshandeh et al., 2007).  This process is further supported by the addition 
of a surfactant added to the aqueous phase (Derakhshandeh et al., 2007).  The added surfactant 
acts as a stabilizer and reduces the interfacial tension between the organic and aqueous phase 
of the colloidal dispersion (Tefas et al., 2015).  Turbulence at the interface between the aqueous 
and organic phase due to differences of the interfacial tension are described by the Marangoni 
effect (Derakhshandeh et al., 2007; Fessi et al., 1989).  The Marangoni effect is a result of 
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variations in flow, diffusion and surface tension occurring at the interface of the two miscible 
solvents (Bilati et al., 2005).  Diffusion of the organic solvent reduces the local solubility of the 
polymer at the interface between the organic solvent and the aqueous phase resulting in 




Figure 1.3.  Schematic of the bulk nanoprecipitation method for the preparation of polymeric 
nanoparticles (A) and assembly of polymeric nanoparticles (B) during preparation using the 
nanoprecipitation method (Crucho and Barros, 2017; Karnik et al., 2008). 
 
After precipitation of the polymer, the formation of nanoparticles is described by 
classical nucleation theory, which is divided into three stages (i) nucleation, (ii) growth and (iii) 
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equilibrium (Figure 1.3B) (Jara et al., 2018).  Nucleation occurs when a local supersaturation 
of the polymer is achieved, meaning the concentration of the polymer is higher than its 
solubility (Jara et al., 2018).  During the nucleation phase, nuclei of dissolved polymer 
molecules are formed and can undergo a growth reaction with the addition of further polymer 
molecules (Lepeltier et al., 2014).  The last stage, equilibrium, is described by the formation of 
stable nanoparticles (Karnik et al., 2008).  In order to formulate small and uniform 
nanoparticles, the nucleation and growth processes need to be separated in time so that a high 
nucleation rate can yield a high number of small nuclei (Jara et al., 2018; Lince et al., 2008).  
The supersaturation state is influenced and controlled by the polymer concentration, type of 
solvent and removal time, mixing energy and type of mixing (Jara et al., 2018).  Further, the 
addition of surfactants is crucial as they act as a stabilizer to avoid aggregation after formation 
of monodisperse polymeric nanoparticles (Derakhshandeh et al., 2007; Tefas et al., 2015; 
Vuddanda et al., 2015). 
 
Even though the nanoprecipitation method is a simple preparation method (Jara et al., 
2018; Yadav and Sawant, 2010) and can be performed with basic laboratory equipment, the 
physical process behind the formation of the polymeric nanoparticles is complex.  The 
advantages and disadvantages of the nanoprecipitation method are summarised in Table 1.1.  
The main limitation of the nanoprecipitation method is the aggregation of nanoparticles and the 
low reproducibility of the method (Jara et al., 2018).  In order to overcome the limitations of 
the nanoprecipitation method, an optimisation of the method is necessary and can be performed 
using design of experiments (DoE).  The principles of a DoE study are described in detail in 
the introduction for Chapter 2.  An optimised nanoprecipitation method can be used to 
formulate uniform nanoparticles, yield higher encapsulation efficiency and drug loading and 
reduce costs and production times (Jara et al., 2018). 
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Each of the methods described up to this point are used for the preparation of polymeric 
nanoparticles and suitable for the encapsulation of hydrophilic and hydrophobic drugs, but the 
main drawback of these methods is the variation in particle size from batch-to-batch.  A recent 
advance in the production of nanoparticles is the use of microfluidics as a promising technique 
to improve the formulation of nanoparticles. 
 
 Microfluidics 
There are a plethora of nanoparticle carriers that have been developed for drug delivery, 
however, successful translation to a therapeutic product is often limited by the ability to 
consistently produce optimized, uniform nanoparticles with the potential for scale up of the 
manufacturing process under GMP (good manufacturing practice) conditions (Valencia et al., 
2012).  The application of microfluidic approaches can address the limitations of traditional 
bulk production methods.  Microfluidics makes use of intersecting microchannels, which enable 
nanolitre volumes of fluids to be mixed homogeneously or contacted in a precisely controlled 
environment (Khan et al., 2015; Whitesides, 2006).  While a wide range of microchannel 
configurations and flow types are used to prepare nanoparticles, a very common chemical 
process for the nanoparticle preparation in these devices is an ‘anti-solvent approach’.  Here, 
the organic solution containing nanoparticle precursor components and the aqueous solution 
are introduced into the microfluidic device at a pre-determined flow rate and flow rate ratio 
between aqueous and organic reagents (Donno et al., 2017; Kolishetti et al., 2010).  The flow 
rate is the combined speed of the fluids within the microchannel and the flow rate ratio is the 
ratio between the two solvent streams in the microfluidic device.  Flow rate and flow rate ratio 
are discussed in more detail in Chapter 2, Section 2.1.3.  Mixing the organic solution with the 
anti-solvent (most often the aqueous solution) induces precipitation of the precursor 
 Chapter One 
38 
 
components as nanoparticles (Valencia et al., 2010).  The advantages of microfluidic devices 
include high reproducibility, control over the mixing process, the possibility of automation and 
the mixing of fluids at high speed (Kang et al., 2005; Williams et al., 2008), enabling the rapid 
production of nanoparticles.  The key improvement of using a microfluidic device instead of a 
bulk, macro-scale reaction vessels for the production of nanomedicines is the potential for 
formulation of uniform nanoparticles (Jafarifar et al., 2017). 
 
1.3.3.1 Types of microfluidics mixer 
The mixing of small volumes of fluids in a microfluidic channel can be achieved using 
devices with a range of different designs.  There is a great variety of commercially available 
microfluidic devices and individual microfluidic devices can be designed and manufactured 
with soft lithography in the laboratory to suit specific production requirements.  The most 
commonly used microchannel design is hydrodynamic flow-focusing (HFF).  HFF devices can 
have a planar 2D geometry or a 3D geometry (Figure 1.4A and B) (Othman et al., 2015) and 
can be used for the formulation of a variety of nanoparticles made of PLGA (Bramosanti et al., 
2017; Kang et al., 2013; Ortiz de Solorzano et al., 2016) and other polymers (Laulicht et al., 
2008; Liu et al., 2015; Min et al., 2014).  In microfluidic devices, interfacial forces between the 
fluids are dominant and diffusion-related mass transfer of the molecules is limited to the 
interface between the fluids, which leads to greater control over the mixing process (Jahn et al., 
2004; Whitesides, 2006).  With the 2D geometry device, fluids are injected concurrently 
through three inlets.  A central stream of a water-miscible organic solvent containing the 
nanoparticle precursor components and drug is focussed horizontally by lateral fluid streams of 
the aqueous anti-solvent introduced perpendicular to the central stream (Figure 1.4A) (Kang et 
al., 2013).  In a 2D HFF device, nanoparticle aggregation can occur at the wall of the 
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microfluidic channel (Figure 1.4A, cross section) and interfere with the ability to control the 
size of nanoparticles and also increase internal pressure in the device by blocking the 
microchannel (Kang et al., 2013; Othman et al., 2015).  However, by using a 3D HFF device a 
more efficient mixing can be achieved because the solvent stream, introduced through a 
capillary, is surrounded by the anti-solvent stream, avoiding aggregation of the polymer at the 




Figure 1.4.  Illustration of the flow pattern of fluids in different microfluidic devices used for 
the formulation of nanoparticles. (A) 2D and (B) 3D hydrodynamic flow-focusing 
microchannel, (C) droplet-based microchannel and (D) microchannel with a staggered 
herringbone mixer (SHM) channel design (Streck et al., 2019c). 
 
A second common design that can be used for microfluidic mixing is a droplet-based 
microfluidic system (Figure 1.4C).  With this approach, emulsion droplets are formed by using 
two immiscible fluids, e.g. water and oil, and a capillary microfluidic device (Utada et al., 2007; 
Wang et al., 2011).  Single, uniform droplets are generated when coaxial flow is induced by 
reducing the diameter of the inner capillary, which is embedded in the outer capillary (Utada et 
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al., 2007).  The formed droplets have a spherical shape due to surface tension and act as a micro-
reactor for the formulation of nanoparticles in the emulsion (Wang et al., 2011).  This approach 
can be used for the formulation of polymeric nanoparticles, nanocrystals and liposomes (Wang 
et al., 2011). 
 
Finally, passive mixers can be incorporated as a structural element within the 
microchannel to induce a turbulent flow of the fluids (Capretto et al., 2013).  One of the most 
common passive mixers in microfluidic devices is the staggered herringbone mixer (SHM) (Du 
et al., 2010; Stroock et al., 2002).  The SHM is described as an in-groove pattern in the 
microchannel with an asymmetric herringbone shape (Figure 1.4D) (Du et al., 2010; Stroock et 
al., 2002).  The topology of the SHM disturbs the laminar flow of the fluids within the 
microchannel, causing mixing of fluids through chaotic advection (Du et al., 2010).  The main 
advantages of the SHM are the simplicity of the manufacturing process and the ability to 
achieve complete mixing of fluids at a low Reynolds number (Re) (Du et al., 2010).  The Re is 
a physical measurement of the viscous and inertial forces of fluids within a channel (Capretto 
et al., 2013).  At low Re, laminar flow is present and the fluids flow in a parallel pattern 
(Capretto et al., 2013).  In contrast, turbulences have a high Re and fluctuations and vortices of 
the fluids occur in these situations (Capretto et al., 2013).  Microvortices are able to increase 
the yield (g/hour) of nanoparticle formulations due to rapid convective mixing of the solvent 
and anti-solvent in the microchannel (Kim et al., 2012).  Other structural elements including a 
mixing spiral to create microvortices (Feng et al., 2017; Sun et al., 2015; Zhang et al., 2015) or 
a zigzag mixer can be added as passive mixers to the microchannel to reduce the mixing time 
(Valencia et al., 2010). 
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As mentioned earlier for the bulk preparation of nanoparticles, residual solvent removal 
is required before further use of polymeric nanoparticles produced with microfluidics e.g. in in 
vitro cell culture studies.  Processes like solvent removal with or without reduced pressure 
(Leung and Shen, 2018; Ortiz de Solorzano et al., 2016), filtration through a 0.2 µm membrane 
(Donno et al., 2017; Kolishetti et al., 2010), ultrafiltration (Kolishetti et al., 2010), centrifugal 
filtration (Lim et al., 2014b), centrifugation (Xie and Smith, 2010) or ultra-centrifugation 
(Amoyav and Benny, 2018) are applied individually or in combination to remove residual 
solvents. 
 
Scaling up the production of nanoparticles is necessary to formulate a sufficient amount 
of nanoparticles for in vivo studies and clinical applications (Baby et al., 2017).  The 
parallelization of 8-25 microfluidic channels can increase the productivity of nanoparticle 
production from 0.084 g/h to 75 g/h depending on the microfluidic device (Lim et al., 2014a; 
Min et al., 2014; Toth et al., 2017).  Other strategies to scale up the production of nanoparticles 
include increasing the flow rate or designing the microchannel to have a greater depth to 
increase the sample volume and yield (Baby et al., 2017; Liu et al., 2015). 
 
1.3.3.2 Optimisation of size and charge of polymeric nanoparticles 
The size of nanoparticles plays a crucial role in determining the therapeutic efficacy and 
biodistribution (Zhigaltsev et al., 2012), and generally small uniform nanoparticles are 
desirable, particularly for intravenous drug application.  Uniform and small nanoparticles can 
be obtained with a microfluidic approach and are characterized by a low polydispersity and a 
narrow size range (Capretto et al., 2013; Karnik et al., 2008).  Further, a uniform nanoparticle 
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size is advantageous for consistent release of encapsulated drugs, prediction of biodistribution 
and cellular uptake of nanoparticles (Xie and Smith, 2010). 
 
In order to influence the size of polymeric nanoparticles, sample-related parameters, 
like molecular weight and concentration of the polymer, organic solvents, surfactant 
concentration and channel dimensions can be varied to influence the size of polymeric 
nanoparticles prepared using microfluidics.  For example, an increase in size from 25 to 220 
nm for polymeric nanoparticles formulated with polyethylene glycol-poly(lactic-co-glycolic) 
acid (PEG-PLGA) polymer was found when the molecular weight of the PLGA polymer was 
increased from 10 to 95 K (Kang et al., 2013; Lim et al., 2014a; Min et al., 2014; Valencia et 
al., 2013).  Similarly, an increase in concentration of the PEG-PLGA polymer from 5 to 50 
mg/mL led to an increase in size of the resulting nanoparticles (Amoyav and Benny, 2018; 
Kang et al., 2013; Karnik et al., 2008; Lim et al., 2014a) and a similar observation was made 
for the PLGA polymer (Bramosanti et al., 2017; Karnik et al., 2008; Xu et al., 2017).  However, 
there are limits to these polymer characteristics in order to yield high quality nanoparticles.  
This is illustrated in a study by Min et al. (2014) who reported aggregation when PEG-PLGA 
with high molecular weight PLGA (PEG5k-PLGA55K) and at a high concentration (50 mg/mL) 
were used in combination with a low flow rate ratio (7:3, aqueous:organic) and low flow rates 
(< 0.08 mL/min).  A possible reason for aggregation is that at low flow rates, the Re is low, 
diffusive mixing is less efficient and aggregation of the non-precipitated polymer can occur 
(Min et al., 2014).  This demonstrates that several factors need to be considered to operate a 
microfluidic device without losing control over the size of nanoparticles and to avoid blocking 
of the microchannel (Liu et al., 2010).  From the studies performed to date, it seems that the 
influence of polymer concentration is more predominant than the influence of molecular weight 
in determining the size of the resulting polymeric nanoparticles (Lim et al., 2014a). 
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The organic solvent used to dissolve the polymer also influences the size of polymeric 
nanoparticles. In comparison to polymeric nanoparticles formulated with dimethyl sulfoxide 
(DMSO) as an organic solvent, smaller polymeric nanoparticles below 150 nm were obtained 
when acetonitrile or acetone were used (Bramosanti et al., 2017; Chiesa et al., 2018).  The 
reason proposed for this was that the higher viscosity of DMSO reduced the flow of the fluids 
at the interface between the aqueous and organic solutions in the microfluidic device, resulting 
in an increase in nanoparticle size (Bramosanti et al., 2017; Chiesa et al., 2018). 
 
The charge carried by polymeric nanoparticles is a key property that can influence in 
vivo performance and is determined by the functional groups present on the polymers that 
comprise the nanoparticles.  Modification to the polymer end group can be used to influence 
the surface charge of polymeric nanoparticles.  For example, by mixing neutral PEG with a 
methoxy (-OCH3) end group with negatively charged PEG comprising a carboxyl (-COOH) 
end group, the surface charge of nanoparticles was tuned between -5 and -20 mV (Valencia et 
al., 2013). 
 
Incorporation of stabilizers including PVA, sodium cholate or Tween®80 in the aqueous 
anti-solvent for use in microfluidics can influence the size of PLGA nanoparticles and the 
encapsulation efficiency of drugs (Morikawa et al., 2018).  The highest encapsulation efficiency 
of 18% for curcumin-loaded PLGA nanoparticles was achieved with 1% (w/v) PVA (Morikawa 
et al., 2018).  However, the nanoparticles showed a large size of around 200 nm.  In contrast, 
nanoparticles formulated with sodium cholate or Tween®80 had an encapsulation efficiency 
below 15% and a size below 120 nm (Morikawa et al., 2018).  Amoyav and Benny (2018) also 
investigated the influence of PVA on the size of PLGA-PEG nanoparticles and found that 
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smaller nanoparticles with a size of 130 nm were produced with increasing concentrations of 
PVA from 0.5 to 2% (w/v).  Surfactants such as PVA are needed to reduce the interfacial tension 
between the fluids and avoid aggregation of the newly formed nanoparticles (Amoyav and 
Benny, 2018). 
 
Baby et al. (2017) investigated the influence of the microchannel characteristics, width 
(y-dimension) and depth (z-dimension), of a 2D HFF device on the size of PEG-PLGA 
nanoparticles.  The size of PEG-PLGA55K nanoparticles increasing to 107 nm when the width 
of the microchannel was increased from 20 to 100 µm.  Further, an increased depth of the 
microchannel, 200 µm in comparison to 50 µm, decreased the size of the formulated 
nanoparticles by 40 nm at a flow rate ratio of 0.8 (Baby et al., 2017). 
 
Microfluidics is an efficient approach to tune the size of nanoparticles by altering 
sample-related parameters. In addition, the physicochemical characteristics of polymeric 
nanoparticles such as surface charge and decoration can be altered to enhance nanoparticle-cell 
interaction. 
 
 Modifications of polymeric nanoparticles 
The potential of nanoparticles to be effective drug carriers depends on their 
physiochemical properties, which determine interactions with the human body including 
cellular uptake, biodistribution and clearance (Banik et al., 2016; Griffin et al., 2016; von 
Roemeling et al., 2017).  Further, the biodistribution of polymeric nanoparticles depends on 
several characteristics of the drug delivery system including size, charge, surface modifications 
and the surface density of ligands (Farokhzad and Langer, 2009). 
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 Influence of size on cellular uptake and biodistribution 
As discussed earlier, the size of nanoparticles is influenced by the components used in 
their production such as the type of polymer (e.g. PLGA, chitosan) and surfactant (e.g. PVA) 
and by the selected preparation method (Banik et al., 2016; He et al., 2010; Partikel et al., 
2019).  The preferred pathway of cellular uptake is determined by the size of the nanoparticles, 
with smaller nanoparticles having a greater chance of uptake in comparison to larger 
nanoparticles (Griffin et al., 2016).  Nanoparticles with a size under 1 µm are internalized via 
phagocytosis and nanoparticles with a size under 200 nm can enter the cell via endocytosis 
(Sharma et al., 2015).  He et al. (2012) showed higher uptake of methyl methacrylate-chitosan 
nanoparticles with a size of 300 nm in comparison to nanoparticles with a size of 600 or 
1000 nm in a Caco-2 cell monoculture and co-culture with Raji B cells.  An explanation for this 
size-dependent behaviour is that with a larger size, the number of available pathways for uptake 
into cells is reduced (He et al., 2012).  Endocytic uptake pathways for nanoparticles include the 
clathrin-dependent and caveolae-dependent pathways as well as macropinocytosis (Dausend et 
al., 2008), which are further discussed in Section 1.5.2.  In a similar study, PLGA nanoparticles 
with a size of 170 nm showed greater uptake in Caco-2 cells in comparison to PLGA 
nanoparticles with a size above 300 nm (Gaumet et al., 2009), indicating that the size of 
polymeric nanoparticles is crucial to enhance cellular uptake. 
 
In addition, the size of polymeric nanoparticles influences their elimination from the 
body.  The main routes for elimination of nanoparticles include the kidneys, the lymphatic 
system and the reticuloendothelial system (RES) (Griffin et al., 2016; von Roemeling et al., 
2017).  The RES, more frequently referred to as the mononuclear phagocytic system (MPS), is 
the system responsible for the removal of nanoparticles from the blood vessels by macrophages 
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(Alexander-Bryant et al., 2013).  Nanoparticles circulating in the bloodstream are recognised 
by proteins called opsonins (Alexander-Bryant et al., 2013).  These proteins bind to the 
nanoparticle surface and make the particles available to be taken up by macrophages and further 
transported to liver and spleen (Alexander-Bryant et al., 2013; Danhier et al., 2012). 
Nanoparticles with a size above 200 nm are likely to be removed by the MPS, whereas smaller 
nanoparticles under 100 nm and with hydrophilic characteristics show fewer interactions with 
the MPS and can avoid elimination (Alexander-Bryant et al., 2013).  Nanoparticles with a size 
between 40-60 nm can exit blood vessels via fenestrated capillaries in the kidneys and in the 
intestine (Siafaka et al., 2016).  The pores in the renal fenestrated endothelium are up to 100 
nm in diameter and particles with a smaller size can pass through (von Roemeling et al., 2017). 
The route of elimination through the lymphatic system applies to nanoparticles with a size of 
600 nm or more and clearance occurs through liver and spleen (Bobo et al., 2016; Siafaka et 
al., 2016). 
 
 Effective surface charge 
The degree of surface charge associated with nanoparticles influences the stability of 
the nanoparticles and thus their tendency to aggregate.  Polymeric nanoparticles form a stable 
suspension if their zeta potentials are lower than -30 mV or higher than +30 mV, since the 
aggregation of nanoparticles is reduced due to electrostatic repulsion between the nanoparticles 
(Sonam et al., 2014; Tefas et al., 2015; Vasconcelos et al., 2015).  Depending on the design of 
the nanoparticles, their surface charge is able to influence the electrostatic interactions with the 
gastrointestinal mucus (Griffin et al., 2016). Mucin, a mucus protein, can immobilise charged 
nanoparticles because of hydrophobic interactions (Lundquist and Artursson, 2016).  
Nanoparticles with a surface charge between -10 and +10 mV show fewer interactions with the 
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cell membrane, whereas positively charged nanoparticles (> +15 mV) can help to improve the 
internalization due to the interactions with the negatively charged cell membrane (He et al., 
2010; Lundquist and Artursson, 2016).  After internalization, positively charged nanoparticles 
are also able to avoid degradation via lysosomes and locate in the perinuclear regions of cells 
(Danhier et al., 2012; Frohlich, 2016). 
 
 Surface modification 
The surface of nanoparticles can be modified and approaches such as the addition of 
PEG (Partikel et al., 2019), coating with chitosan (Cole et al., 2018) and attachment of ligands 
(Bartheldyova et al., 2018) are used (Figure 1.5). 
 
 
Figure 1.5.  The influence of size, charge and surface modification on the physicochemical 
properties of polymeric nanoparticles (Fenton et al., 2018; Torchilin, 2014).  CPPs = cell-
penetrating peptides, PEG = polyethylene glycol. 
 
Modification of nanoparticles with PEG attached to the nanoparticle wall is beneficial 
to achieve a longer blood circulation in order to increase the half-life of the nanoformulations 
in the bloodstream (Danhier et al., 2012).  The molecular weight and density of PEG chains on 
the nanoparticle surface influence the absorption of proteins leading to an inhibition of the 
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opsonisation process and the delayed clearance of the modified nanoparticles (Pelaz et al., 
2015; von Roemeling et al., 2017).  In addition, PEG decoration can enhance the mucus 
permeability, by preventing aggregation and reducing degradation of the nanoparticles (Griffin 
et al., 2016). 
 
The surface of polymeric nanoparticles can be modified by coating the nanoparticles 
with a charged polymer.  The coating of polymeric nanoparticles is based on an electrostatic 
interaction between the negatively charged nanoparticles and the positively charged chitosan 
(Czuba et al., 2018).  The blood circulation time of chitosan-coated polymeric nanoparticles is 
improved by hindrance of protein binding to the surface of the nanoparticles and prevention of 
phagocytic uptake (Abouelmagd et al., 2015).  After oral administration, the chitosan coating 
can act as a permeation enhancer due to the mucoadhesive properties of chitosan and by opening 
tight junctions between epithelial cells and increasing uptake (Cole et al., 2018; Lopes et al., 
2016; Sheng et al., 2015). 
 
Surface modification of nanoparticles with specific ligands, including proteins like 
transferrin and glycoprotein 1b and polysaccharides like hyaluronic acid, are advantageous for 
targeted delivery of drugs into epithelial, endothelial and cancer cells, respectively 
(Bartheldyova et al., 2018; Xu et al., 2013a; Zhu et al., 2016b).  Active targeting is achieved 
by binding of surface-modified nanoparticles to specific and overexpressed receptors on target 
cells or by extending the residence time and uptake (Danhier et al., 2012; Date et al., 2016). 
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 Cell-penetrating peptides 
Cell-penetrating peptides (CPPs) are membrane-permeable peptides with positive 
charges, dictated by the number of arginine and lysine amino acids in the peptide sequence 
(Jafari et al., 2015; Lonn and Dowdy, 2015).  CPPs are short amino acid sequences of 30 amino 
acids or less and also called protein transduction domains or Trojan peptides and show potential 
to enhance the delivery of cargos (Huang et al., 2013; Jafari et al., 2015; Lukanowska et al., 
2013; Zhang et al., 2016).  CPPs are characterised by the ability to cross cell membranes, such 
as the blood brain barrier and intestinal membrane, while also mediating the uptake of cargos 
due to the strong affinity of the CPPs to the lipid bilayer of cells (Feiner-Gracia et al., 2018; Su 
et al., 2009; Zhu et al., 2016a).  The translocation ability applies to the CPP on their own but 
also for conjugates of the CPPs with different cargos like polymeric nanoparticles (Feiner-
Gracia et al., 2018; Vasconcelos et al., 2015), liposomes (Shi et al., 2019), protein-based 
nanoparticles (van Oppen et al., 2019), macromolecules such as peptides, proteins (Kristensen 
et al., 2015), small interfering RNA (siRNA) and plasmid DNA (Künnapuu et al., 2019; Zhang 
et al., 2019) and fluorophores (Trehin et al., 2004).  CPP conjugates have been studied for the 
treatment of asthma, cardiovascular diseases, inflammation, cancer and stroke (Jones et al., 
2005). 
 
 Classification and specific properties of CPPs 
CPPs can be classified into different categories depending on the focus of the 
classification (Table 1.2).  Commonly CPPs are classified based on their physicochemical 
properties and divided in cationic, amphipathic and hydrophobic CPPs (Jafari et al., 2015).  
Further, CPPs are categorised by the origin of the peptide and can be either derived from natural 
proteins, chimeric combination of two different peptide motifs or synthesised as artificial 
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sequences of amino acids (Jafari et al., 2015; Zhu et al., 2016a).  The number of charges in the 
CPP sequence influences the penetration abilities of CPPs; with a comparatively small amount 
of positive charges leading to reduced cell internalization. In contrast, a high amount of positive 
charges can induce toxicity (Lonn and Dowdy, 2015). 
 
CPPs that are commonly used for drug delivery include TAT, polyarginine, penetratin 
and Xentry. The highly positively charged TAT is the most studied CPP and is derived from 
the human immunodeficiency virus trans-activating transcriptional activator (TAT) protein 
(Trehin et al., 2004).  The translocation abilities of the TAT protein were discovered by Green 
and Lowenstein as well as Frankel and Pabo in 1988 (Frankel and Pabo, 1988; Green and 
Loewenstein, 1988).  Later, Vives et al. (1997) identified that the amino acid residues number 
48-60 (GRKKRRQRRRPPQ) showed cell internalization on their own.  The number of arginine 
residues in the CPP sequence influences the transduction ability of the highly positively charged 
arginine-rich CPPs to deliver small molecules.  Synthetic CPPs with 6 to 12 arginine residues 
were found to achieve an efficient translocation into mouse macrophages and human skin 
fibroblasts (Futaki et al., 2001; van Oppen et al., 2019).  Further, polyarginines showed higher 
efficiency for the internalization in comparison to polyhistidines and polylysines (Mitchell et 
al., 2000).  Some CPPs are of special interest due do the fact that the peptide has been shown 
to have specific features in addition to translocation abilities.  Penetratin (Table 1.2) can cross 
the blood brain barrier (Xia et al., 2012) and Xentry (Table 1.2) can permeate into cancer cells 
such as HepG2 cells to deliver siRNA, which express syndecans, a group of heparan sulphate 
proteoglycans on the cell surface (Montrose et al., 2014b; Patel et al., 2019). 
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Over the years, additional categories for the classification of CPPs have emerged and 
include antimicrobial, activatable and cyclic CPPs. For example, transportan (Table 1.2) shows 
antimicrobial activity against Gram-positive and Gram-negative bacteria, which makes it 
attractive for conjugation with antibiotic drugs (Ruczyński et al., 2019).  Antimicrobial peptides 
have similar characteristics as CPPs, but a higher number of lysine residues in the sequence is 
beneficial for uptake into bacteria (Bahnsen et al., 2013).  Another class of CPPs are ‘activatable 
CPPs’, which are designed to release the functional CPP sequence from a polyanionic peptide 
after activation by enzymes (Farkhani et al., 2014).  Activatable CPPs are primarily used in 
cancer research and can be utilized for the visualisation of enzyme reactions by releasing 
imaging probes (Farkhani et al., 2014).  The CPP sequence plays a role in the cellular uptake 
and a modification of the amino acid sequence to form cyclic CPPs is believed to enhance the 
delivery capacity of CPPs and promote cellular uptake efficiency (Amoura et al., 2019; Patel 
et al., 2019).  A cyclic structure is formed by disulphide bonds between cysteine residues after 
introduction to the amino acid sequence at the N- and C-terminal ends (Amoura et al., 2019; 
Patel et al., 2019).  Cellular uptake, expressed as an increase in fluorescence in HeLa cells, of 
conjugates between cyclic R8 or TAT and the green fluorescence protein increased by 6-9 fold 
in comparison to the linear amino acid sequences of the CPPs (Patel et al., 2019). 
 
1.5.1.1 Sequence-modified cell-penetration peptides 
Optimisation of the CPP sequence is of great research interest and several studies have 
shown a positive impact on cell internalization when branched CPPs are used.  Limitations of 
linear CPPs include a low translocation efficiency, low target specificity and instability in the 
physiological environment (Monreal et al., 2015).  Modification of the CPP sequence results in 
new classes of CPPs with a variety of different architectures (Figure 1.6). 




Figure 1.6.  Classification of cell-penetrating peptides after modification of their sequence by 
adding branches, dimers, scaffolds and creating networks and dendrimers (Angeles-Boza et al., 
2010; Brock et al., 2018; Eggimann et al., 2014; Foerg et al., 2007; Jeong et al., 2016; Saleh et 
al., 2010; Yoo et al., 2017; Zhao et al., 2014a).  CPP = cell-penetrating peptide. 
 
New strategies to increase the number of positive charges associated with CPPs include 
the synthesis of more complex CPP analogues with additional cationic groups.  The 
dimerization of CPPs (Figure 1.6) showed improvements in cellular uptake, endosomal escape 
and cytotoxicity (Erazo-Oliveras et al., 2014; Monreal et al., 2015).  For example, the 
fluorescently labelled dimeric branched TAT peptide (TATp-D) led to an improved cellular 
uptake in HeLa cells, with a six- to seven-fold increase in fluorescence intensity compared to 
linear TAT at concentrations of 0.25 M (Monreal et al., 2015).  Another dimeric and 
fluorescent TAT (dfTAT) showed the ability of efficient cytosol delivery of a cell-impermeable 
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fluorophore after co-administration to HeLa cells (Erazo-Oliveras et al., 2014).  Further, the 
dimerization of the sC18 peptide (derived from the antimicrobial parent protein CAP 18), 
increased the fluorescence intensity of the sC18 dimer in HT-29-MTX-E12 cells (further 
referred to as HT-29 cells) by 10-fold in comparison to a linear sC18 (Hoyer et al., 2012).  In 
addition, the dimeric TAT-based CPPs, TATp-D and dfTAT, did not show cytotoxicity in HeLa 
at concentrations between 5-50 M and concentrations of the sC18 dimer up to 50 M did not 
show cytotoxicity in HT-29 cells (Erazo-Oliveras et al., 2014; Hoyer et al., 2012; Monreal et 
al., 2015).  
 
The CPP sequence can be modified by the introduction of side branches, formation of 
dendrimers, linkage of CPPs sequences via disulphide bonds and attachment of the CPP 
sequence to a peptide scaffold (Figure 1.6).  Side branches can either be single or multiple 
branches and can consist of specific amino acid sequences or can be non-natural amino acid 
sequences, depending on the application (Foerg et al., 2007; Saleh et al., 2010).  The formation 
of G1 to G3 dendrimers based on CPP sequences can increase the charges in the outer region 
of the peptide sequence (Zhao et al., 2014a).  A G3 dendrimer based on TAT with short 
dipeptide branches showed higher cell penetration, lower cytotoxicity in HeLa cells and better 
human serum stability in comparison to the linear CPP (Eggimann et al., 2014).  Cysteine can 
be used to link to CPPs via disulphide bonds when adjacent cysteine residues are present in the 
CPP sequence.  A branched TAT network made through disulphide bonds showed improved 
gene delivery ability and cyto-compatibility compared to the linear peptide TAT (Jeong et al., 
2016; Yoo et al., 2017).  CPPs can be conjugated to a peptide scaffold containing lysine or 
cysteine amino acids in order to achieve a branched structure (Angeles-Boza et al., 2010; Brock 
et al., 2018).  The peptide scaffold further serves for the conjugation of a fluorescent dye for 
detection purposes (Angeles-Boza et al., 2010; Brock et al., 2018).  Trimers of TAT on a 
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peptide scaffold showed locally increased concentrations (Angeles-Boza et al., 2010), and more 
efficient endocytosis in comparison to the monomeric TAT (Brock et al., 2018).  It is worth 
noting that these trimers of TAT on a peptide scaffold were only non-toxic to Hela cells at 
concentrations below 3 µM (Angeles-Boza et al., 2010; Brock et al., 2018). 
 
 Interactions between cell-penetrating peptides and cells 
CPPs have been studied for more than thirty years, starting with the discovery of TAT 
in 1988; however, their detailed cellular uptake mechanisms as drug delivery systems are still 
not completely understood.  Initially, it was believed that direct penetration was the main route 
for CPPs into cells but with further investigations also endocytosis was found as a pathway for 
CPP uptake (Silva et al., 2019).  The cellular uptake of CPPs is proposed to occur via non-
endocytic pathways or endocytic pathways (Birch et al., 2018b) and is influenced by the 
structure and concentration of the CPP, the delivery cargo, the bond with the delivery cargo, 
the detection label, temperature, cell type and lipid composition of the cell membrane (Cardoso 
et al., 2012; Hoyer et al., 2012; Hu et al., 2019; Hyrup Møller et al., 2015; Klein et al., 2017; 
Patel et al., 2019).  A rapid uptake or direct transduction through the cell membrane is observed 
when cells are incubated with higher concentration of CPPs due to a higher local concentrations 
of the CPPs on the cell membrane (Brock, 2014; Pan et al., 2016). 
 
The different models proposed for CPP uptake are based on the general assumption that 
the mechanism for translocation is through interactions between the positively charged CPPs 
and the negatively charged phosphate groups of the cell membrane (Hu et al., 2019).  
Specifically, the guanidinium ion that is present in arginine-rich CPP sequences interacts with 
the negatively charged functional groups on phospholipids, monosaccharides and proteins 
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present in the cell membrane (Borrelli et al., 2018; Su et al., 2009).  A study by Su et al. (2009) 
showed the importance of arginine and lysine amino acids in the CPP sequence by investigating 
the distance between penetratin and phospholipids, indicating a close contact of arginine and 
lysine with the phospholipids.  More recently, molecular simulations also showed strong 
attraction between CPPs and phospholipids, which is needed for translocation through the lipid-
rich cell bilayer (Gao et al., 2019). 
 
 
Figure 1.7.  Cellular uptake mechanisms of cell-penetrating peptides adapted from Guidotti et 
al. (2017) with permission from Elsevier. 
 
The non-endocytic pathways (direct translocation) include uptake in an energy 
independent manner via the inverted micelle, the carpet model or the pore model (Figure 1.7) 
(Derossi et al., 1996; Koren and Torchilin, 2012).  The inverse micelle model is based on the 
formation of an inverse micelle within the cell membrane, which incorporates the peptides on 
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the outside of the cell and releases the peptides on the inside of the cell (Su et al., 2009).  The 
carpet model is described by the adsorption of CPPs to the outer layer of the cell membrane in 
a parallel orientation (Binder and Lindblom, 2003; Clayton et al., 2006; Su et al., 2009).  With 
the presence of the CPPs on the surface of the cell membrane, the transmembrane electric field 
between the outer and inner membrane is disturbed resulting in the permeation of the CPP 
through the leakier cell membrane (Binder and Lindblom, 2003; Su et al., 2009).  After 
translocation of the CPP, an equilibrium of the CPP concentration between the outside and the 
inside of the cell supports the stabilization of the transmembrane electric field (Binder and 
Lindblom, 2003).  The carpet model was reported for penetratin and arginine-rich CPPs (Alves 
et al., 2008).  Two kinds of pores, barrel-stave and toroidal, are induced by CPPs (Clayton et 
al., 2006).  In the barrel-stave pore model, CPP monomers aggregate and form a bundle were 
the hydrophobic regions interact with the lipid compartments of the cell membrane and the 
hydrophilic regions of the bundle produce an aqueous pore (Clayton et al., 2006).  In contrast, 
the toroidal pore model relies on direct interactions of the hydrophilic and charged regions of 
the CPPs with the phospholipid head groups of the cell membrane (Clayton et al., 2006). 
 
To better understand the interactions on a molecular level, molecular simulation 
between a cell membrane model and CPPs are used (Gao et al., 2019; Hu et al., 2019).  
Molecular dynamic simulation of octa-arginine with a small hydrophilic cargo showed that the 
lifetime of a formed water pore within the membrane is longer and translocation of CPPs and 
cargo increased when the linker length is half the membrane thickness (Hu et al., 2019).  It is 
important to consider that linkers between CPPs and cargos can influence the cellular selectivity 
and linkers should be biodegradable (Hu et al., 2019).  The direct penetration mechanisms are 
preferred by CPPs with small cargos, whereas CPPs with larger cargos (peptides and proteins) 
prefer to enter the cell via endocytosis (Brock, 2014; Patel et al., 2019). 
 Chapter One 
58 
 
Endocytosis mechanisms including clathrin-dependent, caveolae-dependent, clathrin 
independent and caveolae independent uptake as well as macropinocytosis can be utilized by 
CPPs (Figure 1.7) (Gump et al., 2010; Koren and Torchilin, 2012).  For the clathrin-dependent 
endocytosis, clathrin coat protein complexes are expressed on the cell surface and binding of 
molecules induces endocytosis (Xu et al., 2013b).  Caveolae appear as invaginations on the cell 
surface and after binding to the cell surface molecules get trapped and internalised (Pelkmans 
and Helenius, 2002).  Macropinocytosis relies on the formation of membrane ruffles, which are 
able to fold back towards the cell membrane entrapping fluids and nanoparticles located on the 
cell surface (Reifarth et al., 2018; Xu et al., 2013b).  Cellular uptake via macropinocytosis is 
initiated by electrostatic interactions of the positively charged and arginine-rich CPPs with 
negatively charged molecules on the cell membrane (Gump et al., 2010).  The internalization 
of CPPs via endocytosis results in the formation of endosomes containing the CPPs (Jones, 
2007).  Therefore, after endocytosis it is important for the CPPs to escape the endosome in order 
to avoid degradation and to deliver the cargo (Silva et al., 2019).  Possible mechanisms include 
release through endosomal acidification or interaction of the CPPs with the endosomal 
membrane (Fischer et al., 2004; Silva et al., 2019). 
 
Apart from the uptake pathway of CPPs, there are three crucial steps to consider for 
successful internalization.  First, the CPP needs to bind to the components of the cell membrane 
and secondly the binding needs to be followed by the absorption through the hydrophobic cell 
membrane.  Lastly, a breakage of the bond between the cell membrane and the CPP needs to 
occur in order to release the CPP into the cytoplasm (Herce et al., 2014).  These steps are crucial 
for a translation of CPPs from in vitro and in vivo studies to clinical studies and the development 
of commercial products. 
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The number of CPPs in the clinic and in clinical trials is low due to a limited 
understanding of the molecular mechanisms for the uptake of CPPs into cells (Gao et al., 2019; 
Klein et al., 2017).  CPPs are captured in endosomes after endocytosis and the low cytoplasmic 
delivery efficiency, as well as the low bioavailability and selectivity, make translation to the 
clinic difficult (Klein et al., 2017).  Clinical trials are mainly reported for CPP-drug conjugates 
and the reasons for discontinuing clinical trials include low stability and poor efficiency of 
CPPs in vivo and toxicity introduced by excipients (Habault and Poyet, 2019).  For the efficient 
delivery of CPPs and cargos into cells, it is crucial to understand the uptake mechanisms and 
localization processes within the cells and ensure the functionality of the cargo is protected until 
it reaches the site of action (Huang et al., 2015). 
 
 Association of cell-penetrating peptides with cargos 
The association of CPPs with cargo includes either a physical mixture of both 
components or formation of a covalent bond between CPP and cargo (Figure 1.8) (Liu et al., 
2013).  Both approaches, non-covalent and covalent conjugation, aim to increase the delivery 
efficiency of cargos and are used for a variety of different cargos (Huang et al., 2015). 
 
 




Figure 1.8.  Possible cell-penetrating peptide cargos and schematic of non-covalent (A) and 
covalent (B) interactions between polymeric nanoparticles and CPPs (Guidotti et al., 2017; 
Streck et al., 2019c) (With permission from Elsevier).  CPP = cell-penetrating peptide. 
 
Using a physical mixture, CPPs and cargos are co-administered in order to enhance the 
cellular interactions of the cargo (Bu et al., 2015).  The main non-covalent binding approaches 
include electrostatic interactions and the formation of ionic complexes between anionic and 
cationic molecules or streptavidin-biotin interactions and metal-affinity interactions between 
CPPs and cargos (Huang et al., 2015).  Electrostatic interaction based on opposite charges can 
be formed between CPPs and macromolecules as well as polymeric nanoparticles and CPPs 
(Figure 1.8A) (Bu et al., 2015; Liu et al., 2013).  CPPs were found to enhance absorption of 
biomarcomolecules (e.g. insulin) by co-administration with excess concentrations of CPPs 
(Kamei et al., 2009).  Using electrostatic interactions, CPPs should be present in excess to 
ensure binding to oppositely charged cargos.  Any potential instability of the physical mixture 
 Chapter One 
61 
 
also needs to be considered due to interactions with competing ions in the GIT (Liu et al., 2013).  
Further, CPPs have been used for in vivo gene and protein delivery after complexation or 
condensation of CPPs with siRNA or antigens and studies in mice have shown that these CPP 
delivery systems were able to inhibit the influenza virus replication and reduced tumour growth 
of lung epithelial cells that were transformed with human papillomavirus (Shahbazi and 
Bolhassani, 2018; Zhang et al., 2019).  Electrostatic interactions between negatively charged 
PLA or PLGA nanoparticles and positively charged CPPs can enhance the delivery of 
CPP/messenger RNA polyplexes and encapsulated drugs (Bu et al., 2015; Cai et al., 2017; 
Coolen et al., 2019). 
 
The covalent linkage between CPPs and cargos depends on the cargo that is bound to 
the CPP.  Proteins and peptides are most commonly conjugated to CPPs by gene fusion utilizing 
bacterial expression of recombinant fusion peptides between CPPs and therapeutic peptides or 
proteins (Kristensen et al., 2015).  For the conjugation of drug molecules, proteins and 
fluorescent dyes for tracking of CPP-cargo formulations, chemical reactions like click 
chemistry reactions are used (Patel et al., 2009; Ruczyński et al., 2019; Trehin et al., 2004).  
Other binding strategies for cargos to CPPs include covalent linkage via hydrazine and 
disulphide bonds (Hu et al., 2019).  The linkage of small molecules to the CPP sequence should 
preferably leave amino acids towards the C-terminus protonated, in order to preserve the 
activity of CPP and cargo, the uptake abilities, and to avoid unwanted toxicity (Ruczyński et 
al., 2019).  Covalent conjugation between CPPs and the above mentioned cargos results in well-
defined molecules and enables predictions of the chemical structure and the activity of the 
conjugates (Kristensen et al., 2015; Patel et al., 2019).  Recent studies have shown that the 
position of the conjugation in the CPPs sequence is crucial since this influences if a compound 
shows biological activity e.g. against bacteria (Patel et al., 2019). 
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Different bioconjugation reactions can be used to functionalize polymeric nanoparticles 
with CPPs. A covalent linkage between CPPs and nanoparticles can be produced by 
bioconjugation reactions between polymers and CPPs (Figure 1.8B).  Typical bioconjugation 
reactions are the formation of a thiol-maleimide bond by thiol-amine coupling (Nam et al., 
2002; Steinbach et al., 2016; Xia et al., 2012) and formation of an amide bond by carbodiimide 
conjugation (Egusquiaguirre et al., 2015).  Arginine-rich CPPs are well-established for the 
surface modification of polymeric nanoparticles or inorganic nanoparticles and less frequently 
for the surface modification of liposomes (Figure 1.8) (Bartczak and Kanaras, 2011; Gullotti 
and Yeo, 2012; Shi et al., 2019).  As part of the introduction to Chapter 2, these reactions will 
be explained in more detail (Section 2.1.4). 
 
To confirm surface modification, surface charge is frequently used to assess the 
conjugation of polymeric nanoparticles with CPPs (Coolen et al., 2019; Moku et al., 2019).  
Changes in surface charge from a negative surface charge of unmodified polymeric 
nanoparticles to a slightly negative or positive surface charge can indicate successful 
conjugation of CPPs, depending on the exact composition of the nanoparticle formulation with 
CPPs (Gartziandia et al., 2016; Liu et al., 2013; Xu et al., 2013a).  Additionally, techniques 
including Fourier-transform infrared spectroscopy (FTIR), nuclear magnetic resonance and X-
ray photoelectron spectroscopy (XPS) are used to investigate covalent binding (Bu et al., 2015; 
Liu et al., 2013; Xia et al., 2012).  For example, using XPS the elemental composition of the 
modified nanoparticles is investigated and the presence of nitrogen indicates the modification 
of the surface with CPPs (Liu et al., 2013; Xia et al., 2012). FTIR spectroscopy will be 
discussed further in Section 2.1.4. 
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Surface modification of polymeric nanoparticles to enhance delivery of encapsulated 
macromolecules is a prudent approach that does not alter the bioactivity of the encapsulated 
macromolecule (Jain and Jain, 2015; Liu et al., 2013).  CPPs have been conjugated to the 
surface of polymeric nanoparticles to increase cellular uptake via the ocular and oral routes of 
drug administration (Chiu et al., 2015; Vasconcelos et al., 2015; Zhu et al., 2016a).  In this 
thesis, the focus is on microfluidics for the preparation of polymeric nanoparticles and the 
conjugation of CPPs with different architecture to alter the surface properties of polymeric 
nanoparticles and exploit the influence of the CPP architecture on cellular uptake. 
 
 Thesis aims 
Despite the vast amount of research conducted in pharmaceutical formulation science, 
there is still a need for the improvement of drug delivery systems to successfully translate the 
research from bench to bedside.  Therefore, the overall aim of this thesis was to design, 
characterise and evaluate an oral drug delivery system with polymeric nanoparticles decorated 
with CPPs of different architectures for the ability to enhance cellular uptake. 
 
The use of microfluidics for the formulation of polymeric nanoparticles results in the 
preparation of small and uniform nanoparticles with a good reproducibility.  Here, a traditional 
bulk method and a microfluidics method were compared to investigate if microfluidics is 
advantageous over a traditional bulk approach for the formulation of PLGA nanoparticles 
(Chapter 2).  Further, the conjugation of CPPs with different architecture to the surface of 
PLGA nanoparticles leads to a change in the physicochemical properties of the nanoparticles.  
Therefore, PLGA nanoparticles were modified with CPPs of different architecture using the 
post-microfluidics conjugation approach and the influence of the CPP architecture on the 
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physicochemical properties such as size and surface charge of the CPP-tagged PLGA 
nanoparticles was studied (Chapter 2). 
 
To gain a better understanding of the surface modification and distribution of CPPs on 
PLGA nanoparticles a second preparation method, an in situ microfluidics conjugation 
approach, for the formulation of the CPP-tagged PLGA nanoparticles was designed.  The 
translation of the conjugation reaction from a post-microfluidics to an in situ microfluidics 
conjugation approach should change the CPP distribution on PLGA nanoparticles.  The 
influence of CPP architecture and the conjugation approach on the distribution of CPPs on 
PLGA nanoparticles were elucidated with transmission electron microscopy and small angle 
X-ray scattering (Chapter 3). 
 
To investigate the cellular uptake and interactions of CPP-tagged PLGA nanoparticles 
with the nano-bio interface, in vitro studies with two different cell lines were performed.  CPP-
tagged PLGA nanoparticles are expected to show greater cellular uptake than unmodified 
PLGA nanoparticles due the surface modification with CPPs.  Further, the role of the CPP 
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 Introduction 
The physicochemical characteristics of drug delivery systems depend on the preparation 
method and optimization of preparation-related parameters supports the design of well-defined 
nanoparticles.  Further, surface modifications of polymeric nanoparticles are crucial to increase 
interactions with cells and the utilization of CPPs for this purpose is described in this Chapter. 
 
 Design of experiments 
Experimental research carried out in the pharmaceutical sciences often follows a ‘trial 
and error’ approach (Singh et al., 2011a; Singh et al., 2011b).  Using ‘trial and error’ methods 
means that one variable is adjusted at the time and incrementally, whereas all other parameters 
remain constant (Singh et al., 2011a; Singh et al., 2011b).  The main drawback of applying this 
approach to the formulation of drug delivery systems is that the true optimum of the input 
factors may not be able to be identified (Singh et al., 2011a; Singh et al., 2011b).  In addition, 
optimization based on changing one variable at the time does not guarantee that the relation and 
dependency of the input factors on the output response of the process can be shown.  The DoE 
approach is a powerful alternative used to design experiments efficiently and to show the effect 
of input factors alone and in combination on the output responses. 
 
DoE is described as finding mathematical relations between various input factors and 
an output response of a process or system (Mandenius and Brundin, 2008).  The applications 
of DoE studies are broad and include biotechnological processes such as antioxidant extraction 
from plants (Sonchus oleraceus L.) (Ou et al., 2014), enzyme production in relation to the 
composition of bacteria culture media and pharmaceutical technology processes such as the 
formulation of nanoparticles (Hanrahan and Lu, 2006).  In general, a specific software, e.g. 
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MODDE, Design-Expert or Mini-Tab, is used to analyse the defined input factors and output 
responses simultaneously to predict an experimental scheme (Bairagi et al., 2018; Kastner et 
al., 2014; Patel et al., 2016; Singh et al., 2011a).  The use of a DoE for optimisation of a process 
is greatly supported by advantages including the requirement of only a small number of 
experiments, minimized experimental bias, and an environmentally friendly and cost-effective 
aspect due to better use of resources, materials and time (Singh et al., 2011a; Singh et al., 
2011b).  However, there are also disadvantages, which need to be addressed to make sure the 
DoE is performed correctly.  The disadvantages of a DoE, including a lack of process 
knowledge and inappropriate selection of variables, need to be overcome by judging the process 
in question critically (Mandenius and Brundin, 2008).  However, when used correctly, DoE can 
contribute to the investigated process by giving direction to the optimal parameters with a 
minimum number of experiments and variation of more than one variable at the time. 
 
After definition of the input factors and output responses, a mathematical design for the 
performance of the DoE study is selected.  The applied designs for the DoE commonly include 
two- or three-level factorial (Derakhshandeh et al., 2007; Vuddanda et al., 2015), central 
composite (Water et al., 2015) and Box Behnken designs (Figure 2.1) (Bairagi et al., 2018; 
Patel et al., 2016).  The aim is to identify the input factors that have a significant influence on 
the output response (Bairagi et al., 2018).  The experiments are performed in a random order to 
decrease the appearance of systematic errors and to avoid that expectations about the results of 
the experiment are likely to influence the experimenter (Mandenius and Brundin, 2008).  In 
addition, the gathering of triplicate data at a specific centre point allows the determination of 
the experimental error when the same experimental parameters are used.  The mathematical 
models to analyse the obtained output responses include a multiple linear regression (MLR) or 
a partial least square regression (PLS) model.  The MLR model is used for processes that show 
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a relationship between the independent input factors and one output response (Kastner et al., 
2014).  The PLS model is used if a correlation between one or more input factors in the process 
are found (Mandenius and Brundin, 2008).  The generated mathematical models are evaluated 
by either one-way analysis of variance (ANOVA) for the comparison of groups or two-way 
ANOVA to investigate the effect of separate factors and identify any interactive effects 
(Hanrahan and Lu, 2006).  In addition, the relationship between the input factors and output 
responses can be visualized graphically to support the explanation of the relationships 
(Vuddanda et al., 2015).  The data can either be shown in a 3D response surface plot or a 2D 
contour plot (Singh et al., 2011a; Singh et al., 2011b).  Both plots show the correlation and 
interactions between the independent input factors and their influence on the output response 
(Bairagi et al., 2018; Vuddanda et al., 2015).  In particular, mathematical trends of the input 
factors shown in the response surface plot allow determination of the optimal settings for the 
experiment (Yadav and Sawant, 2010). 
 
 
Figure 2.1.  Schematic representations of two-level factorial design (A), central composite 
design (B) and Box-Behnken design (C) for three different input factors (Hanrahan and Lu, 
2006; Mandenius and Brundin, 2008). 
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 Design of experiments for bulk and microfluidics preparation of nanoparticles 
Previous studies have utilized a DoE approach to optimise the nanoprecipitation method 
for the preparation of polymeric PLGA nanoparticles.  In a bulk method, the relevant input 
factors identified by DoE approaches include the concentration of the polymer, the 
concentration and kind of surfactant, the ratio between organic and aqueous phase, and the 
addition of a co-solvent to the aqueous phase (Figure 2.2) (Bozkir and Saka, 2005; 
Derakhshandeh et al., 2007; Patel et al., 2016; Sonam et al., 2014; Vuddanda et al., 2015; 
Yadav and Sawant, 2010).  The output responses include size, polydispersity index (PDI) and 
zeta potential of the polymeric nanoparticles as well as the drug encapsulation efficiency (EE) 
(Figure 2.2) (Bairagi et al., 2018; Bozkir and Saka, 2005; Derakhshandeh et al., 2007; Patel et 
al., 2016; Sonam et al., 2014; Yadav and Sawant, 2010). 
 
 
Figure 2.2.  Influence of input factors on the output responses for the preparation of PLGA 
nanoparticles using a bulk nanoprecipitation method (Bairagi et al., 2018; Patel et al., 2016; 
Sonam et al., 2014; Tefas et al., 2015; Vuddanda et al., 2015; Yadav and Sawant, 2010).  PDI 
= polydispersity index, EE = encapsulation efficiency. 
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Size and PDI of PLGA nanoparticles are influenced by the concentration of the polymer, 
with a higher polymer concentration having a positive effect on size leading to the formation 
of larger PLGA nanoparticles (Patel et al., 2016; Sonam et al., 2014; Tefas et al., 2015; 
Vuddanda et al., 2015).  The viscosity of the organic solution is increased with higher polymer 
concentrations, slowing down the diffusion of the dissolved polymer from the coarse emulsion 
droplets towards the aqueous phase, and increasing the chance of collision between 
nanoparticles in the organic phase resulting in the formation of larger nanoparticles (Patel et 
al., 2016; Sonam et al., 2014; Tefas et al., 2015).  Further, size and PDI of PLGA nanoparticles 
are decreased with higher surfactant concentrations due to the reduction of the interfacial 
tension between the aqueous and organic phase (Patel et al., 2016; Sonam et al., 2014).  With 
a higher ratio of aqueous to organic solution, the formulation of smaller PLGA nanoparticles is 
achieved as coalescence of organic solvents droplets in the aqueous phase can be prevented 
(Patel et al., 2016; Sonam et al., 2014).  The surface charge of PLGA nanoparticles is found be 
more negative with higher concentrations of the PLGA polymer used (Tefas et al., 2015), 
whereas higher surfactant concentrations resulted in PLGA nanoparticles with a less negative 
zeta potential (Bairagi et al., 2018; Tefas et al., 2015).  Finally, a higher polymer and surfactant 
concentration as well as the addition of a co-solvent increases the encapsulation efficiency of 
hydrophilic (Patel et al., 2016; Yadav and Sawant, 2010) and hydrophobic drugs (Bairagi et al., 
2018; Sonam et al., 2014). 
 
As described in Chapter 1, a variety of microfluidic devices have been used for the 
preparation of polymeric nanoparticles, micelles, nanogels and liposomes (Capretto et al., 2012; 
Chiesa et al., 2018; Kastner et al., 2014; Water et al., 2015).  However, there have been few 
DoE studies performed on the optimisation of microfluidic methods for the preparation of 
nanoparticles.  The used designs include full factorial designs (Capretto et al., 2012; Chiesa et 
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al., 2018) and a central composite design (Water et al., 2015) to evaluate the influence of 
microfluidics-related parameters on nanoparticle size and drug encapsulation.  The production 
of PLGA nanoparticles and liposomes using a SHM was optimised using a DoE (Chiesa et al., 
2018; Kastner et al., 2014).  Both, PLGA nanoparticles and liposomes showed a size ≤ 200 nm 
at higher flow rate ratios (5:1) between the aqueous and organic phase (Chiesa et al., 2018; 
Kastner et al., 2014).  The same correlation between size and flow rate ratio was found for 
polymeric micelles prepared with a 2D HFF device (Capretto et al., 2012).  Encapsulation of 
poorly soluble drugs in liposomes and peptides in hydrophilic nanogels has been reported to be 
higher at flow rates around 2 mL/min (Kastner et al., 2014; Water et al., 2015).  The above-
mentioned examples of DoE studies for the bulk and microfluidic methods show that the 
optimisation of method-related parameters is crucial for the preparation of nanoparticles.  The 
method-related parameters have an influence on size, polydispersity and encapsulation 
efficiency of drugs in the nanoparticles and thus define the suitability of formulated 
nanoparticles as drug delivery systems. 
 
 Optimisation of size of polymeric nanoparticles 
The microfluidics-related parameters; flow rate and flow rate ratio have an impact on 
the size of polymeric nanoparticles produced with microfluidics and general considerations are 
discussed below. 
 
The flow rate is described as the combined speed of the fluids within the microchannel. 
Generally, an increase in flow rate of the fluids within the microchannel leads to the formation 
of polymeric nanoparticles with a size between 40 and 160 nm depending on the microfluidic 
device utilized (Figure 2.3) (Lim et al., 2014b; Min et al., 2014; Morikawa et al., 2018).  This 
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effect is predominantly noticeable for polymeric nanoparticles formulated with concentrations 
between 10 and 30 mg/mL of the biodegradable polymer PEG-PLGA with a specific molecular 
weight (PEG5k-PLGA55k) (Min et al., 2014) and for PLGA polymers with different monomer 
ratios (75/25 and 50/50) (Amoyav and Benny, 2018; Morikawa et al., 2018).  Faster flow rates 
are advantageous due to rapid mixing within the microchannel (Min et al., 2014) and assists 
with the homogenous nucleation of the polymer at low polymer concentrations.  Amoyav and 
Benny (2018) formulated small nanoparticles with a size of 40 nm at a flow rate of 0.7 mL/min 
using a 2D HFF microfluidic device.  In addition, at faster flow rates the mixing time of the 
fluids is below the aggregation time of the polymer and blocking of the microchannel due to 
aggregation of the polymer is reduced (Lim et al., 2014a; Min et al., 2014).  Taken together, 
these influences mean that faster flow rates give rise to smaller nanoparticles. 
 
 
Figure 2.3.  Generalized correlation between microfluidics-related parameters and the size of 
the resulting polymeric nanoparticles formulated with PLGA (10 mg/mL, co-polymer ratio 
75:25 and 50:50) and PEG-PLGA (10 to 30 mg/mL) (Lim et al., 2014b; Min et al., 2014; 
Morikawa et al., 2018).  Arrows indicate an increase in flow rate or flow rate ratio (Streck et 
al., 2019c). 
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The flow rate ratio is described as the ratio between the two solvent streams (anti-solvent 
or aqueous phase and organic solution) in the microfluidic device and can have a significant 
influence on the size distribution of polymeric nanoparticles.  Polymeric nanoparticles prepared 
using HFF microfluidic devices with PEG5k-PLGA10-27k (Lim et al., 2014a) and PLGA 
(Bramosanti et al., 2017) showed a decrease in size when the amount of anti-solvent was 20 to 
50 times larger than the amount of organic polymer solution (Figure 2.3) (Bramosanti et al., 
2017; Lim et al., 2014a; Liu et al., 2015).  The decrease in size at higher flow rate ratios was 
attributed to the reduced width of the organic solvent stream and diffusive mixing occurring in 
a more controlled way (Liu et al., 2015).  Most of the microfluidics studies for the preparation 
of PLGA or PEG-PLGA nanoparticles have been performed based on a ‘trial and error’ 
approach.  The utilization of a DoE approach aids in simultaneously evaluating the influence 
of microfluidics-related parameters on the formulation of PLGA nanoparticles.  The DoE study 
performed in this thesis contributes to a better understanding of the parameters required to 
produce nanoparticles with a size below 200 nm.  This has not yet been described in the 
published literature for PLGA (50:50). 
 
 Conjugation of biomacromolecules and polymers 
Bioconjugation reactions are defined by the formation of a covalent bond between two 
compounds through the use of reactive crosslinking reagents (Hermanson, 2013a).  Crosslinkers 
are molecules that exploit reactive groups of compounds to facilitate the conjugation reaction 
(Hermanson, 2013a).  Common bioconjugation reactions between polymeric nanoparticles and 
proteins or peptides include the maleimide reaction, the EDC/sulfo-NHS zero-length 
crosslinking reaction and streptavidin-biotin affinity reaction (Yadav et al., 2011). The 
maleimide reaction requires the presence of a thiol group (often a free cysteine) in the protein 
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or peptide sequence and a maleimide moiety on the polymer (Cox et al., 2019; Gullotti and 
Yeo, 2012).  The thiol group reacts with the maleimide moiety and forms a thioether bond 
(Figure 2.4A) (Yadav et al., 2011).  The EDC/sulfo-NHS reaction is a zero-length crosslinking 
reaction were a covalent bond between two compounds is formed directly without any bridging 
groups (Hermanson, 2013c).  This reaction is especially suitable for the conjugation of peptides 
to nanoparticles due to the solubility of the reagents EDC and sulfo-NHS in the aqueous 
environment and the maintenance of the native structure of biomacromolecules in this 
environment (Totaro et al., 2016; Yadav et al., 2011).  For the zero-length crosslinking reaction, 
the carboxyl group of the polymer is activated with EDC and sulfo-NHS to form a sulfo-reactive 
ester intermediate that can react with a primary amine present in the N-terminus or side chain 
of the peptide sequence to form a covalent amide bond (Figure 2.4B) (Hermanson, 2013c; 
Yadav et al., 2011).  One disadvantage is the formation of side products including EDC-urea, 
anhydrides of o-acylisourea and N-acylisourea, which are competing with the formation of the 
desired amide bond if EDC is used in excess (Hermanson, 2013c; Totaro et al., 2016).  The 
streptavidin-biotin affinity reaction is based on the strong affinity of streptavidin to biotin and 
is a non-covalent bioconjugation reaction (Figure 2.4C) (Hermanson, 2013b; Yadav et al., 
2011).  The main advantage of this bioconjugation reaction is that the affinity of streptavidin to 
biotin is not influenced by the conjugation to other proteins or labels (Hermanson, 2013b; 
Yadav et al., 2011). 
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Figure 2.4.  Schematic of maleimide reaction (A), EDC/sulfo-NHS zero-length crosslinking 
reaction (B) and streptavidin-biotin affinity reaction (C) for the surface conjugation of 
nanoparticles (Hermanson, 2013c; Nam et al., 2002; Xu et al., 2013a). 
 
Surface modifications via a covalent linkage are preferred over adsorption interactions 
since protein or ligand desorption can be prevented and the loss of targeting ability is avoided 
(Cox et al., 2019).  The covalent bond has two main advantages; (i) the selectivity of binding 
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is improved and (ii) the displacement of surface proteins by serum proteins after in vivo 
administration or during purification process is prevented (Cox et al., 2019). 
 
Mass spectrometry (MS) can be used for identification analysis of a wide range of 
compounds.  The combination of MS with the soft ionisation method matrix assisted laser 
desorption ionisation (MALDI) and a time of flight (TOF) detector is an analytical tool for the 
characterisation of peptides, proteins polymers and biomolecules with a large molecular weight 
(Bilati et al., 2005; Kafka et al., 2011).  Using MALDI-TOF, MS samples are co-crystallised 
with excess of matrix before the sample matrix mixture is activated by laser energy to achieve 
vaporisation (Kafka et al., 2011).  In the gas phase, proton transfer from the matrix to the sample 
results in single charge ions that are analysed by the detector according to their velocity 
depending on their mass to charge ratio (Kafka et al., 2011).  The qualitative analysis of peptides 
with MALDI-TOF MS offers high sensitivity, a small sample amount and rapid sample 
preparation in addition to the analysis of a wide mass range (Bilati et al., 2005).  Previously, 
MALDI-TOF MS was used successfully to investigate the conjugation between the poly(ethyl-
cyanoacrylate) nanoparticles (PECA) and the gonadotropin releasing hormone (GnRH) 
analogue, D-Lys6-GnRH, showing that ethyl-cyanoacrylate monomer units were co-
polymerised with the D-Lys6-GnRH via histidine residues in the peptide sequence (Kafka et al., 
2009). 
 
The successful conjugation of biomacromolecules to polymeric nanoparticles can be 
analysed using Fourier-transform infrared (FTIR) spectroscopy.  FTIR spectroscopy uses 
infrared radiation to measure the wavelength and intensity of the absorbed radiation by a sample 
(Kong and Yu, 2007).  Using attenuated total reflectance (ATR)-FTIR, the infrared beam passes 
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through a Germanium or ZnSe crystal, which is optically dense and has a high reflection index 
(Shai, 2013).  The crystal supports internal reflectance of the infrared beam, which can leave 
the crystal and penetrate into the sample to a depth of 0.5-5 µm (Shai, 2013).  With FTIR, the 
type of chemical bond (single or double) and the quality of the bond vibration (stretch or bend) 
can be assessed (Shai, 2013).  The amide I bond vibration between 1700-1600 cm-1 is primarily 
related to the C=O stretch within the peptide sequence (Kong and Yu, 2007; Shai, 2013).  In 
the wavenumber range between 1575-1480 cm-1 the amide II bond vibration is located, which 
is related to the in-plane NH-bending and CN stretching of molecules/peptides/proteins (Kong 
and Yu, 2007).  Infra-red radiation absorbed by amide bonds leads to a total amount of nine 
characteristics bands in peptides and proteins, with the amide I and II vibrations being the most 
prominent ones (Kong and Yu, 2007). 
 
 Chapter aims 
In this Chapter, the preparation of polymeric nanoparticles using a traditional bulk 
method and a microfluidics method is highlighted.  The two preparation methods were 
optimised using a DoE approach and compared to evaluate the uniformity of the formulated 
PLGA nanoparticles.  Further, PLGA nanoparticles prepared with the microfluidics method 
were surface-modified with CPPs of different architectures (Figure 2.5), to alter their 
physicochemical properties.  The three CPPs have a distinct architecture, namely a short, a long 
linear and a branched architecture.  The modified nanoparticles were characterized for their 
suitability as a drug delivery system to enhance uptake after oral administration. 
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 Materials 
Poly(DL-lactide-co-glycolide) (PLGA) 50:50, ester terminated, MW 15,980 Da, was 
supplied by Durect Lactel (Cupertino, CA, USA).  Acetonitrile (ACN) (HPLC grade) was 
supplied by Merck (Darmstadt, Germany).  Mowiol® 4-88 (polyvinyl alcohol, PVA, MW 
31,000), 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) (purity > 99.5%), 
N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) (purity > 98%), 
trifluoroacetic acid (TFA, HPLC grade, purity > 99%), GRKKRRQK(RRH)K(RRH)K(RRH) 
(bTAT, custom synthesized, MW 2661.2 Da, purity > 95%), α-cyano-4-hydroxycinnamic acid 
(purity ≥ 99%) and ammonium phosphate were purchased from Sigma–Aldrich (St. Louis, MO, 
USA).  Snake Skin™ dialysis tubing (10 kDa MWCO) and sulfo-N-hydroxysulfosuccinimide 
(sulfo-NHS) were purchased from Thermo Fisher Scientific Australia Pty (Scoresby, 
Australia).  The peptides RRH (MW 467.3 Da, purity > 98%) and GRKKRRQRRR (TAT (48-
57), MW 1396.7 Da, purity > 98%) were custom synthesized by GLS (Shanghai, China) and 
used as supplied.  Distilled, ultra-pure water was produced using a Milli-Q® Water Millipore 
Purification System (Billerica, MA, USA). 
 
In this work, CPPs with three different architectures were designed for conjugation to 
PLGA nanoparticles to be able to investigate how the architecture of the CPPs influences cell 
uptake (Figure 2.5).  The short RRH was chosen due to previous work that showed 30% increase 
in cellular uptake in Caco-2 cells when RRH was conjugated to PECA nanoparticles in 
comparison to unmodified PECA nanoparticles (Chiu et al., 2015).  The long linear CPP was 
the widely investigated TAT peptide and the third CPP was custom designed and is 
subsequently referred to as branched TAT (bTAT). It has a modified TAT backbone with three 
RRH side branches (Figure 2.5). 
 
 Chapter Two 
79 
 
Figure 2.5.  Illustration of the architecture of the short (RRH), the long linear (TAT) and the 
branched CPP (bTAT: modified TAT backbone and three RRH branches). Amino acid single 
letter codes have been used for each peptide (R = arginine, H = histidine, G = glycine, K = 
lysine, Q = glutamine) (Streck et al., 2019a). 
 
 Methods 
 Design of experiments to optimize the preparation of PLGA nanoparticles using a bulk 
nanoprecipitation method 
A DoE study was used to identify the optimal concentration of PLGA and PVA as well 
as the stirring time for the bulk nanoprecipitation method.  The influence of stirring speed on 
the physicochemical nanoparticle characteristics was not investigated in the DoE study due to 
technical restrictions and the stirring speed was set to a constant value of 400 rpm.  MODDE 
GO 12 software (Umetrics, Umeå, Sweden) was used for the design and analysis of the 
experiments. After definition of the input parameters, a two-level full factorial design with a 
centre point for objective screening was used to define parameters for the individual 
experiments (Table 2.1).  The selected response parameters for the PLGA nanoparticles were 
size and PDI.  For the validation of how well the model fits the data (R2) and to validate the 
ability to predict new data (Q2), an ANOVA was performed.  Further, statistical testing included 
testing the regression model for significance to obtain a probability value (p), and a lack of fit 
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test to estimate the error of the model.  The statistical parameters were obtained at a 95% 
confidence interval. 
Table 2.1.  Input parameters for the DoE study to optimize the formulation of PLGA 
nanoparticles using a bulk nanoprecipitation method (Streck et al., 2019a). 
Parameters Level 
 -1 0 1 
PLGA concentration (mg/mL in ACN) 2 13.5 25 
PVA concentration (% (w/v)) 0.5 2.75 5 
Stirring time (h) 0.5 2.25 4 
 
 
 Preparation of polymeric nanoparticles using microfluidics 
PLGA nanoparticles were prepared using a NanoAssemblr® Benchtop Device 
(Precision NanoSystems, Vancouver, Canada) and the associated proprietary software.  The 
microchannel had a width of 200 µm and a height of 79 µm and was embedded in the 
microfluidic cartridge (Figure 2.6A).  The cartridge was made of propylene, viton and cyclic 
olefin copolymer and had dimensions of 6.6×5.5×0.8 cm (L×W×H).  The microchannel had 
two inlets in a Y-shaped configuration for the aqueous and organic solutions and was staggered 
in multiple layers to achieve a serpentine configuration of the microchannel.  Another feature 
of the microchannel was the asymmetric in-floor herringbone groove at the bottom of the 
microchannel, which induced a transverse flow in the microchannel (Stroock et al., 2002).  The 
herringbone feature was 50 µm thick and 31 µm high and orientated at a 45° angle to the length 
of the microchannel (Figure 2.6B) (Stroock et al., 2002; Zhigaltsev et al., 2012).  The 
NanoAssemblr® Benchtop Device contained two syringe pumps to control the total flow rate 
and flow rate ratio of the aqueous and organic solutions. 
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Figure 2.6.  Microfluidic cartridge used for the NanoAssemblr® Benchtop Device (A) and 
depth profile of herringbone feature (B) found within the microchannel (not to scale).  
Schematic of the herringbone feature was adapted from Belliveau et al. (2012).  The SHM 
section of the microchannel is 2.5 cm long and can hold a volume of 0.0004 mL. 
 
 Design of experiments study for microfluidics preparation of PLGA nanoparticles 
For the preparation of PLGA nanoparticles using microfluidics, a DoE study was used 
to screen for factors that influenced the size distribution and PDI of the resulting nanoparticles.  
A two-level full factorial design with a centre point was chosen to investigate the factors total 
flow rate and flow rate ratio at three different levels (-1, 0, 1) (Table 2.2).  The concentration 
of the organic PLGA solution in ACN and the concentration of the aqueous PVA solution were 
kept constant at 10 mg/mL (in ACN) and 2% (w/v), respectively (Table 2.2).  After preparation, 
the PLGA nanoparticle suspension was dialyzed overnight against ultra-pure water using a 
regenerated cellulose membrane with a 10 kDa MWCO. 
 
The experimental data were fitted with a MLR model using the MODDE GO 12 
software.  Interaction terms were determined by the addition of two-factor interactions to the 
model to investigate a beneficial contribution to the model quality.  The response surface plots 
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were generated using the MODDE GO software and used for interpretation of the data.  One-
way ANOVA was performed to validate how the model fits the data (R2) and to validate the 
ability to predict new data (Q2).  In addition, the regression of the model was tested for 
significance and the probability value p was obtained.  A lack of fit test was performed to 
estimate the errors in the model.  The statistical parameters were obtained at a 95% confidence 
interval. 
 
Table 2.2.  Input parameters for the DoE study for the formulation of PLGA nanoparticles using 
microfluidics (Streck et al., 2019b). FRR = flow rate ratio, TFR = total flow rate. 
Parameters Concentration 
PLGA concentration (mg/mL in ACN) 10 
PVA concentration (% (w/v)) 2 
 Levels 
 -1 0 1 
FRR (aqueous:organic) 1:1 6.5:1 12:1 
TFR (mL/min) 2 7 12 
 
 
 Bulk nanoprecipitation method for preparation of PLGA nanoparticles 
PLGA nanoparticles were prepared using a bulk nanoprecipitation method based on the 
description by Fessi et al. (1989) and optimised using DoE (Section 2.3.1).  Briefly, an organic 
PLGA solution (10 mg/mL in ACN) was added dropwise to a beaker containing 10 mL PVA 
(2% w/v in ultra-pure water) and the solvent was evaporated during magnetic stirring (400 rpm) 
for 2 h and 15 min.  The resulting PLGA nanoparticles were washed twice with ultra-pure water 
by centrifugation at 17,900 g for 10 min at room temperature and stored as suspension in ultra-
pure water at 4°C until required with a maximum storage time of 7 days.  Preliminary results 
showed that size, PDI and zeta potential of PLGA nanoparticles did not change over a storage 
time of 7 days at 4°C (Day 0: 144 ± 2 nm, 0.135 ± 0.001, -21 ± 2 mV; Day 7: 147 ± 5 nm, 0.198 
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± 0.065, -21 ± 2 mV).  PLGA nanoparticles were stored in aqueous solution, while stirring to 
avoid sedimentation if immediate use was restricted by equipment availability. 
 
 Microfluidics method for the preparation of PLGA nanoparticles 
PLGA nanoparticles were prepared using the NanoAssemblr® Benchtop Device with 
the optimised setting from the DoE (Section 2.3.3).  The aqueous PVA solution (2% w/v) was 
mixed with the organic PLGA solution (10 mg/mL in ACN) at a flow rate ratio 
(aqueous:organic) of 6:1 and a total flow rate of 10 mL/min.  PLGA nanoparticles were dialyzed 
overnight against ultra-pure water at room temperature using Snake Skin™ dialysis tubing (10 
kDa MWCO) and stored as suspension in ultra-pure water at 4°C until required with a 
maximum storage time of 7 days. 
 
 Preparation of surface-modified PLGA nanoparticles 
Prior to the surface modification, PLGA nanoparticles suspensions produced with the 
bulk nanoprecipitation or the microfluidics method (Section 2.3.4 and 2.3.5) were dialyzed 
overnight against ultra-pure water at room temperature using Snake Skin™ dialysis tubing 
(10 kDa MWCO). 
 
A zero-length crosslinking reaction for the conjugation of CPPs to the surface of PLGA 
nanoparticles was adapted from Egusquiaguirre et al. (2015) with some modifications. Briefly, 
500 µL of the PLGA nanoparticle suspension was diluted with HEPES buffer (0.025 M, pH 
6.4) to 1.5 mL and the nanoparticle suspension was gently stirred while adding 250 µL EDC 
(1.5 mM in ultra-pure water) and 250 µL sulfo-NHS (2 mM in ultra-pure water).  The stirring 
continued for 30 min at room temperature, before the solution was separated by ultra-
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centrifugation at 42,800 g for 15 min at 4°C.  The pellet, containing the activated nanoparticles, 
was re-suspended and diluted with HEPES buffer (0.025 M, pH 6.4) to a volume of 1.1 mL.  
To this suspension, 100 µL of the CPP solutions with varying concentrations of RRH (10, 50 
and 75 mM), TAT (2.9, 5.7, and 8.6 mM) and bTAT (4.5 mM and 6 mM) were added.  The 
mixture was left to incubate overnight at 4°C and was then separated by ultra-centrifugation at 
42,800 g for 15 min at 4°C.  The supernatant was aspirated and kept at 4°C until RP-HPLC 
analysis and the nanoparticle pellet was stored at 4°C until required with a maximum storage 
time of 7 days. 
 
 Mass spectrometry assessment of cell-penetrating peptides 
MALDI-TOF MS was used to analyse the three different CPPs; RRH, TAT and bTAT. 
CPPs were dissolved in 2 µL ultra-pure water and diluted with ACN to achieve concentrations 
of 0.5 mg/mL.  The organic CPPs solutions were mixed with freshly prepared α-cyano-4-
hydroxycinnamic acid (10 mg/mL with 1 µL 1 M ammonium phosphate and 1 µL 10% (v/v) 
TFA in ACN) matrix at a ratio of 2:1 (matrix:sample) before spotting on the Opti-TOF™ 
Sample Plate (Applied Biosystems, Framingham, MA, USA).  After the spots were air dried, 
the sample plate was inserted into the Applied Biosystems/MDS SCIEX 4800 MALDI 
TOF/TOF™ Analyzer and analysed in a positive ion reflector mode with 1000 shots per sample 
spot.  A calibration was performed using the calibrations spots on the sample plate of 5 peptides 
with different m/z (Insulin B chain m/z 3494.651, ACTH 18-39 m/z 2465.199, angiotensin II 
m/z 1046.542, P14R m/z 1533.858 and bradykinin 1-7 m/z 757.400). 
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 Characterization of PLGA and CPP-tagged PLGA nanoparticles 
Dynamic light scattering (DLS) was used to measure the Z-average diameter and PDI 
of the nanoparticles (Malvern® Nano ZS, Model Zen 3600, Malvern Instruments, Malvern, UK) 
equipped with a 633 nm laser and 173° detections optics.  Laser Doppler electrophoresis was 
used to measure zeta potential of the nanoparticles with the same instrument.  All samples were 
diluted to an appropriate concentration and triplicate measurements from three individual 
batches were taken. 
 
The morphologies of the PLGA and CPP-tagged PLGA nanoparticles, prepared using 
the bulk nanoprecipitation method and the microfluidics method, were investigated using 
transmission electron microscopy (TEM).  First, the carbon film on a 300 mesh copper grid was 
made hydrophilic by glow discharge in air (Aebi and Pollard, 1987).  Afterwards, 10 µL of the 
PLGA nanoparticle suspension was placed on the grid for 1 min and excess suspension was 
blotted before the grid was washed twice with ultra-pure water and stained to contrast the 
specimen with phosphotungstic acid (1% w/v, pH 6.8).  The samples were viewed on a Philips 
CM100 BioTWIN TEM (Philips Electron Optics, Eindhoven, The Netherlands) and the 
micrographs were recorded using a MegaView3 camera (Soft Imaging System, Münster, 
Germany). 
 
 Investigation of covalent binding between CPPs and PLGA conjugates 
To investigate any interactions between the CPPs and PLGA, FTIR spectra of PLGA 
polymer, CPPs and PLGA-CPP conjugates were recorded with a Varian 3100 FTIR (Varian, 
Palo Alto, CA, USA) using transmission mode and compared.  The spectra were obtained at 
wavenumbers between 400-4000 cm-1 with 64 scans per sample and a resolution of 4 cm-1.  The 
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PLGA-CPP conjugates were prepared using the zero-length crosslinking reaction. PLGA 
polymer was dissolved in ACN (10 mg/mL) and to a 1 mL solution of the polymer, 250 μL 
EDC (1.5 mM in ultra-pure water) and 250 μL of sulfo-NHS (2 mM in ultra-pure water) were 
added.  The mixture was gently stirred on a magnetic stirring plate for 30 min and then 
precipitated by adding 3 mL of ultra-pure water and separated by centrifugation at 3220 g for 
20 min at 8 °C (Karve et al., 2011).  The supernatant was removed and the pellet re-suspended 
in ACN. 200 μL of CPP solutions (50 mM RRH, 8.6 mM TAT and 4.5 mM bTAT HEPES 
(0.025 M, pH 6.4)) were added and incubated while gently stirred at room temperature for 
30 min.  The PLGA-CPP conjugates were precipitated again as described above and the pellet 
was dissolved in ACN at a 1:10 ratio (v/v). 
 
The PLGA polymer was dissolved in ACN at a concentration of 10 mg/mL and the 
CPPs were dissolved in 20 μL ultra-pure water and then diluted with ACN to the intended 
concentration (50 mM RRH, 8.6 mM TAT and 4.5 mM bTAT) before analysis. 
 
 Conjugation efficiency of CPPs tagged to PLGA nanoparticles 
The conjugation efficiency of the CPPs to the nanoparticles was obtained indirectly 
from the amount of CPPs remaining in the supernatant.  The supernatant was collected after 
overnight incubation of the activated nanoparticles with the different concentrations of the three 
CPPs as described in Section 2.3.6. 
 
CPP concentrations in the supernatant were quantified with validated RP-HPLC 
methods using the Agilent series 1200 HPLC system (Agilent Technologies, Santa Clara, CA, 
USA) with a reverse phase column (HiChrom ultrasphere 5 ODS, 250×4.6 mm, 5 µm particle 
size, 300 Å pore size (HiChrom, Theale, UK)) and a UV detector (G1314B) at wavelengths 
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between 214-220 nm.  The aqueous mobile phase contained 0.1% (v/v) TFA in ultra-pure water 
and the organic mobile phase contained 0.1% (v/v) TFA in ACN.  The CPPs in the supernatant 
were eluted by gradient (0 to 7% over 25 min for RRH, 0 to 13% over 37 min for TAT and 
12 to 22% over 25 min for bTAT) at a flow rate of 0.6 mL/min. The CPP concentration was 
quantified using peak integration and an individual standard curve was produced for each CPP. 
 
Equation (2-1) was used to calculate the conjugation efficiency of the different CPPs 
used in the study.  The conjugation efficiency was obtained by calculating the difference 
between the total concentration of CPPs added to the nanoparticle suspension and the measured 
concentration of CPPs in the supernatant after conjugation. 
 
Conjugation efficiency (%)=
Total conc. CPP- Measured conc. CPP
Total conc. CPP
× 100%  (2-1) 
 
 Validation of RP-HPLC method for CPPs 
A stock solution of RRH (1 mg/mL), TAT (1 mg/mL) and bTAT (1 mg/mL) was 
prepared daily and divided into two aliquots for the preparation of an independent set of 
standards and for the quality control samples (QCs).  In order to obtain a standard curve, stock 
solutions were diluted with HEPES buffer (0.025 M, pH 6.45) to concentrations within the 
range of the standard curve (RRH: 50-1000 µg/mL, TAT: 100-1000 µg/mL and bTAT: 50-
750 µg/mL).  The QCs were prepared with HEPES buffer (0.025 M, pH 6.45) at three different 
concentrations of 75, 250 and 750 µg/mL; 200, 450 and 900 µg/mL and 75, 350 and 600 µg/mL 
for RRH, TAT and bTAT, respectively.  The validation was carried out over three subsequent 
days with multiple injections of the QCs within one day.  The analysis of the validation included 
linearity of the standard curve, the inter- and intra-day precision and accuracy and sensitivity. 
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For the evaluation of the RP-HPLC methods of the CPPs, the coefficient of variance 
and the accuracy were calculated using Equations 2-2 and 2-3, respectively. 
 
𝐶𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 (%) =  
𝑆𝐷 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝑀𝑒𝑎𝑛 𝑠𝑎𝑚𝑝𝑙𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
× 100 (2-2) 
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 (%) =  
𝑀𝑒𝑎𝑛 𝑠𝑎𝑚𝑝𝑙𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
× 100   (2-3) 
 
The limit of quantification (LOQ) is characterised by a detector response 10 times as 
high as the noise level and the limit of detection (LOD) is characterised by a detector response 
3.3 times as high as the noise level.  The LOD and LOQ were calculated using Equations 2-4 
and 2-5 (FDA, 1997). 
 
𝐿𝑂𝐷 =  
(10 ∗ 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑦−𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡)
𝑠𝑙𝑜𝑝𝑒
     (2-4) 
𝐿𝑂𝑄 =  
(3.3 ∗ 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑦−𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡)
𝑠𝑙𝑜𝑝𝑒
    (2-5) 
 
 Statistical analysis 
All experiments were performed in triplicate and results are presented as mean ± 
standard deviation (SD).  Statistical analysis for the DoEs was performed using one-way 
ANOVA with MODDE GO 12 software.  Comparisons between single groups were made by 
performing a Student’s t test.  The reported p-values were considered statistically significant at 
p < 0.05.  
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 Results and Discussion 
 Optimal PLGA and stabilizer concentration for the formulation of PLGA nanoparticles 
determined by design of experiments (DoE) 
The size of nanoparticles plays a crucial role in cellular uptake and formulation of PLGA 
nanoparticles, with a size below 200 nm facilitating cellular uptake via endocytosis (Sharma et 
al., 2015).  In a DoE study, the influence of PLGA concentration, stabilizer concentration and 
stirring time on the size and PDI of PLGA nanoparticles was investigated.  The size and PDI of 
formulated PLGA nanoparticles obtained at the different levels of the input factors are 
summarized in Appendix I.  A response surface plot was used for model interpretation and 
represents the combined effect of alterations of the input factors on the output response (Bairagi 
et al., 2018; Yadav and Sawant, 2010).  The response surface plot obtained for the size of PLGA 
nanoparticles prepared using a bulk nanoprecipitation method showed that a low concentration 
of PVA (≥ 2%) and a low concentration of PLGA (< 15 mg/mL) were advantageous for the 
production of PLGA nanoparticles with a size of approximately 150 nm (Figure 2.7A).  The 
significant factors influencing the size of PLGA nanoparticles were the concentration of PLGA 
polymer, the concentration of PVA and the interaction term PLGA*PVA.  Stirring time was 
found to have no significant influence on the size and PDI of PLGA nanoparticles and a stirring 
time of 2 h and 15 min, equal to the centre point of the DoE, was selected for the preparation 
of PLGA nanoparticles.  With increasing concentrations of PLGA and PVA, size increased to 
approximately 200 nm.  This observation was similar to other studies that reported an increase 
in nanoparticle size of PLGA nanoparticles when increased concentrations of PLGA (Sonam et 
al., 2014; Tefas et al., 2015) and PVA (Patel et al., 2016; Sonam et al., 2014) were used. 
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The PDI of the formulated PLGA nanoparticles was highly dependent on the PLGA 
concentration and was not influenced by the PVA concentration (Figure 2.7B).  The response 
surface plot showed that the PDI of PLGA nanoparticles formulated using the bulk 
nanoprecipitation method was the lowest between 10 to 22 mg/mL of the PLGA polymer and 
increased towards higher PDI values outside of this PLGA concentration range.  This is in 
contrast to the literature, reporting increased PDI values with increasing polymer concentrations 
due to the formation of larger emulsion droplets (Patel et al., 2016).  The PDI indeed increased 
with PLGA polymer concentrations above 20 mg/mL, but also at concentrations below 5 
mg/mL of the PLGA polymer, which might be due to the instability of the formed PLGA 




Figure 2.7.  Response surface plots for the size (nm) (A) and polydispersity index (PDI) (B) of 
nanoparticles as a function of PLGA and PVA concentration for preparation of PLGA 
nanoparticles using the bulk nanoprecipitation method (Streck et al., 2019a). 
 
The PLS model of size and PDI for the formulation of PLGA nanoparticles was analysed 
with ANOVA to describe the quality of the model (Table 2.3).  The values for R2 and Q2 (Table 
2.3) were above the recommended values from the literature (R2 > 0.75, Q2 > 0.60) (Mandenius 
and Brundin, 2008) and provide support that the models of size and PDI produced with a bulk 
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nanoprecipitation method were able to fit the data and can be used to predict new data.  The p-
values for the regression of the models were < 0.05 and lack of fit p-values were either above 
or approximating 0.25, indicating that both models were significant and statistically good at a 
95% confidence interval. 
 
Table 2.3.  Summary of results for the statistical analysis of the size and polydispersity index 
models for the bulk nanoprecipitation method to produce PLGA nanoparticles (Streck et al., 
2019a). 
 R2 Q2 Regression Lack of fit Significant 
Size 0.963 0.806 > 0.001 0.442 Yes 
Polydispersity 
index 
0.869 0.763 0.006 0.234 Yes 
 
The response surface plots for size and PDI of the experimental data were used to select 
the parameters to produce optimized nanoformulations.  The selected optimized parameters 
from the response surface plot for further experiments were a PLGA concentration of 10 mg/mL 
and a PVA concentration of 2% (w/v). 
 
 Tuning the size and polydispersity of PLGA nanoparticles using microfluidics and 
design of experiments 
A DoE study was used to optimize the size and PDI of PLGA nanoparticles based on 
the microfluidics parameters total flow rate and flow rate ratio (aqueous:organic).  The size and 
PDI of formulated PLGA nanoparticles obtained at the different levels of the input factors are 
summarized in Appendix II.  To investigate the influence of flow rate ratio on the size and PDI 
of PLGA nanoparticles, the data were fitted with a MLR model to obtain the response surface 
plots (Mandenius and Brundin, 2008).  The response surface plots showed the relationship 
between the input parameters, flow rate ratio and total flow rate, and the response in size and 
PDI of the PLGA nanoparticles (Figure 2.8).  Data analysis with MODDE 12 GO software 
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further confirmed the significant factors for size and PDI were the flow rate ratio and the 
interaction term flow rate ratio*flow rate ratio.  Specifically, the interaction term flow rate 
ratio*flow rate ratio revealed that the ratio between the aqueous and organic solutions used for 
the preparation of the PLGA nanoparticles is of high importance for both size and PDI.  The 
response surface plots showed that at higher flow rate ratio (12:1), the PLGA nanoparticles had 
a smaller size, whereas at lower flow rate ratio (2:1), the PLGA nanoparticles showed an 
increase in size (Figure 2.8A).  The PDI was also highly dependent on the flow rate ratio, 
showing an increasing PDI with higher flow rate ratio (Figure 2.8B). 
 
 
Figure 2.8.  Response surface plots for the responses size (A) and PDI (B) as a function of the 
total flow rate (mL/min) and the flow rate ratio (aqueous:organic) for preparation of PLGA 
nanoparticles using the microfluidics method (Streck et al., 2019b). 
 
Therefore, the size and PDI of PLGA nanoparticles formulated with the NanoAssemblr® 
Benchtop Device depends strongly on the flow rate ratio between the aqueous and the organic 
solutions.  Higher flow rate ratio leads to a greater proportion of the aqueous solution with the 
organic solution being constantly diluted during mixing in the microchannel.  This is 
advantageous for the formation of uniform nanoparticles because the polymer molecules 
precipitate whilst isolated from each other.  Here, the observed PDI increases from 0.060 to 
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0.150 with higher flow rate ratio, however, since the PDI values are low and indicated a 
monodisperse nanoparticle size distribution, this effect was minimal.  A DoE study with 
liposomes comprising phospholipids prepared using the NanoAssemblr® Benchtop Device 
revealed that flow rate ratio had the largest impact on the size of the liposomes prepared 
(Kastner et al., 2014).  Similarly, Chiesa et al. (2018) reported that the flow rate ratio had a 
major influence on the size of PLGA nanoparticles formulated using a PLGA polymer with a 
monomer ratio of 75:25 (lactic acid:glycolic acid) and the NanoAssemblr® Benchtop Device. 
 
One-way ANOVA was used to identify the statistical significance of the model to 
describe size and PDI.  The R2 and Q2 values were calculated to determine how well the model 
fits the data and if the model is able to predict new data, respectively.  The results of the one-
way ANOVA (Table 2.4) revealed that the models were able to fit the experimental data.  The 
R2 and Q2 values for both models were higher than the recommended values from the literature 
(Mandenius and Brundin, 2008).  In addition, the regression p-values for both models are below 
0.05 indicating the significance of the models (Table 2.4).  The lack of fit test showed that the 
p-values were greater than 0.05 for both models and that the models had no statistical error 
(Table 2.4).  All statistical analysis for the size and PDI models were performed at a 95% 
confidence interval.  Overall, the models were highly accurate and had a good reliability and 
robustness.  Consequently, the models were used for the selection of parameters to further 
prepare PLGA nanoparticles using microfluidics.  A total flow rate of 10 mL/min and a flow 
rate ratio of 6:1 was found to yield PLGA nanoparticles with a size of 150 nm and a PDI below 
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Table 2.4.  Summary of results for the statistical analysis of the size and polydispersity index 
models for the microfluidics method to produce PLGA nanoparticles (Streck et al., 2019b). 
 R2 Q2 Regression Lack of fit Significant 
Size 0.994 0.992 < 0.001 0.052 Yes 
Polydispersity 
index 
0.929 0.907 0.012 0.499 Yes 
 
 
 Quality assessment of cell-penetrating peptides 
The quality of the CPPs obtained from external sources was confirmed using MALDI-
TOF MS.  The mass spectrum of the short CPP RRH showed the main RRH peak at a mass to 
charge ratio (m/z) of 468.2, which is equivalent the theoretical molecular weight of RRH 
(Figure 2.9A).  The main peaks of the long linear CPP TAT and the branched CPP bTAT were 
observed in the mass spectra with m/z of 1396.9 and 2661.7, respectively, which were 
equivalent to their theoretical molecular weight (Figure 2.9B and C).  Therefore, the three CPPs 
meet the required quality and were used for further studies. 
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Figure 2.9.  Mass spectra of the RRH (A), TAT (B) and bTAT (C) obtained with matrix assisted 
laser desorption ionisation-time of flight mass spectrometry analysis. 
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 Characterization of PLGA nanoparticles 
Unmodified PLGA nanoparticles prepared using the bulk nanoprecipitation method had 
a significantly larger size compared to PLGA nanoparticles prepared using microfluidics (Table 
2.5).  PLGA nanoparticles formulated with both methods were monodisperse, but the PDI of 
the PLGA nanoparticles was higher when prepared with the microfluidics method.  Patel et al. 
(2016) reported that a decrease in PDI was obtained with an increasing ratio between the 
aqueous and organic solutions from 3:1 to 6:1 for the formulation of cromolyn-loaded PLGA 
using a bulk nanoprecipitation method.  A similar observation was made in the present study 
where the bulk nanoprecipitation method with a higher ratio between the aqueous and organic 
phase (20:1) yielded nanoparticles with a lower PDI compared to the microfluidics method, 
where the ratio between the aqueous and organic phase was 6:1.  Using a higher ratio between 
the aqueous and organic phase during the preparation of polymeric nanoparticles results in a 
greater dilution of the organic polymer solution and the formed nanoparticles are less likely to 
aggregate.  The higher ratio of aqueous to organic phase in the bulk nanoprecipitation method 
did not reduce the size of PLGA nanoparticles and the formation of nanoparticles > 180 nm 
might be due to a polymer concentration above the critical polymer concentration (Lepeltier et 
al., 2014).  A concentration above the critical polymer concentration leads to the presence of 
amorphous polymer aggregates, which influence the size of prepared polymeric nanoparticles 
(Galindo-Rodríguez et al., 2005).  The zeta potential of PLGA nanoparticles prepared with the 
two methods was similar (Table 2.5) and a negative surface charge below -20 mV suggested 
the presence of negatively charged carboxyl groups on the surface of the PLGA nanoparticles 
(Vasconcelos et al., 2015).  The TEM micrographs revealed that PLGA nanoparticles with a 
spherical shape were obtained with both preparation methods (Figure 2.10A and C). 
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Table 2.5.  Characterization of PLGA and TAT-tagged PLGA nanoparticles prepared with the 
optimized parameters for the bulk nanoprecipitation method and with the microfluidics method 
(Streck et al., 2019a).  Data are means ± SD (n = 3 independent batches).  * p-value < 0.05 in 
comparison to the respective bulk method. 
 
The size of TAT-tagged PLGA nanoparticles prepared using a post-bulk and post-
microfluidics conjugation approach, increased in comparison to PLGA nanoparticles (Table 
2.5), suggesting the presence of the CPP on the surface of the PLGA nanoparticles (Vasconcelos 
et al., 2015).  The TAT-tagged PLGA nanoparticles produced using the microfluidics method 
were significantly smaller than TAT-tagged PLGA nanoparticles produced using the bulk 
nanoprecipitation method (Table 2.5).  Further, the TAT-tagged PLGA nanoparticles prepared 
with the bulk nanoprecipitation method showed a size of 200 nm with a standard deviation 
above ± 10 nm indicating a low batch-to-batch reproducibility (Table 2.5).  The zeta potential 
of TAT-tagged PLGA nanoparticles prepared in this study was between -4 to -6 mV (Table 
2.5).  Although there was a shift in zeta potential to become less negative after conjugation of 
TAT, the overall negative zeta potential indicated that negatively charged carboxyl groups of 
the PLGA polymer were still present on the surface and that the surface density of TAT was 
not sufficient to achieve a positive surface charge (Gullotti and Yeo, 2012).  The surface charge 
of the TAT-tagged PLGA nanoparticles in the present study was within the range of -7 to +3 
mV published in the literature for TAT conjugated to PLGA-PEG or PLGA nanoparticles with 
a size larger than 200 nm (Gartziandia et al., 2016; Xu et al., 2013a).  The conjugation 
efficiency of TAT to the PLGA nanoparticles was not different after production of the 
 Size ± SD (nm) PDI ± SD 




Unmodified PLGA nanoparticles 
Bulk 184.0 ± 3.9 0.110 ± 0.007 -23.0 ± 0.8 N/A 
Microfluidics 151.2 ± 1.2* 0.149 ± 0.014 -22.2 ± 0.5 N/A 
TAT-tagged PLGA nanoparticles 
Bulk 201.9 ± 12.5 0.136 ± 0.057 -6.0 ± 3.4 55.3 ± 0.7 
Microfluidics 172.4 ± 2.6* 0.164 ± 0.014 -4.3 ± 0.8 56.3 ± 1.0 
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nanoparticles using the bulk nanoprecipitation or microfluidics methods, with 55.3 ± 0.7% and 
56.3 ± 1.0% conjugation efficiency, respectively (Table 2.5). 
 
The morphology of the CPP-tagged PLGA nanoparticles did not change with the 
conjugation of TAT to PLGA nanoparticles prepared using the bulk nanoprecipitation or 
microfluidics methods (Figure 2.10B and E).  Similarly, the conjugation of RRH and bTAT to 
PLGA nanoparticles prepared using the microfluidics method did not influence the morphology 
of the nanoparticles (Figure 2.10D and F).  The microfluidics method was selected for further 
investigations of the utility of this method for producing CPP-tagged PLGA nanoparticles due 
to the smaller nanoparticle size yielded with better reproducibility by this method. 
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Figure 2.10.  Transmission electron micrographs of unmodified PLGA (A) and TAT-tagged 
PLGA nanoparticles (B) prepared using a bulk nanoprecipitation method and unmodified 
PLGA (C), RRH- (D), TAT- (E) and bTAT-tagged PLGA nanoparticles (F) prepared using the 
microfluidics method (Streck et al., 2019a).  
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 Investigation of binding between CPPs and PLGA polymer 
FTIR was used for the physicochemical characterization of the PLGA polymer, the three 
different CPPs and PLGA-CPP conjugates.  The FTIR spectrum of the PLGA polymer alone 
showed the characteristic C=O stretch of the carboxyl group at 1749 cm-1 and C-O ester 
stretches between 1167 and 1086 cm-1 (Figure 2.11).  The individual CPPs showed bands 
related to the amide I and II bond vibration at 1667-1659 and 1541-1560 cm-1, respectively 
(Figure 2.11).  The amide bond I and II vibrations were associated with the C=O stretching and 
N-H bending of the amide bonds between the individual amino acids of the CPPs (Haris and 
Severcan, 1999).  In addition, C-O ester stretch vibrations from the C-terminal amino acid of 
the CPPs were observed between 1202 and 1130 cm-1 (Figure 2.11). 
 
 
Figure 2.11.  Fourier-transform infrared spectra of PLGA polymer, the individual cell-
penetrating peptides (RRH, TAT, bTAT) and PLGA-CPP conjugates (Streck et al., 2019a). 
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PLGA nanoparticles tagged with CPPs were analysed using FTIR, however, the FTIR 
spectrum showed broad and weak FTIR bands, which made assignment of wavenumbers 
difficult.  Therefore, PLGA-CPP conjugates prepared by covalently attaching CPPs to the 
PLGA polymer were used to identify any interactions between the PLGA polymer and the 
CPPs.  The carboxyl group of the PLGA polymer and the primary amine of the CPPs were 
utilized to form a covalent bond using a zero-length crosslinking reaction (Hermanson, 2013c).  
Conjugation between the CPPs and PLGA polymer was confirmed with the observation of an 
amide I bond vibration in the CPP-PLGA conjugates at approximately 1635 cm-1.  The shift of 
the amide I bond vibration to a lower wavenumber in comparison to the amide I bond vibration 
in RRH, TAT and bTAT (1667-1659 cm-1) provided evidence of the successful formation of a 
covalent bond between these two components (Figure 2.11).  The FTIR spectra of the PLGA-
CPP conjugates also showed a C=O stretch at 1763 cm-1 for the carboxyl group of the PLGA 
polymer indicating that there were unconjugated carboxyl groups present. 
 
 Characteristics of CPP-tagged PLGA nanoparticles depends on the CPP architecture 
The influence of CPP architecture on the characteristics of CPP-tagged PLGA 
nanoparticles was investigated by conjugating CPPs to the surface of PLGA nanoparticles 
produced using microfluidics.  Unmodified PLGA nanoparticles had an average size of 150 nm 
and a zeta potential of -19 mV (Figure 2.12A and B).  With conjugation of each of the three 
different CPPs, the size of the nanoparticles increased, but the increase in size was independent 
of the concentration of CPP (Figure 2.12A).  The slight increase in size of the CPP-tagged 
PLGA nanoparticles could be attributed to the presence of CPPs.  Further, nanoparticles may 
increase in size due to swelling caused by the more hydrophilic surface of the CPP-tagged 
PLGA nanoparticles compared to unmodified PLGA nanoparticles (Feiner-Gracia et al., 2018). 
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Figure 2.12.  Size, polydispersity index (A) and zeta potential (B) of PLGA nanoparticles and 
CPP-tagged PLGA nanoparticles with different concentrations of CPPs (RRH, TAT, bTAT), 
prepared using the post-microfluidics conjugation approach.  Size is displayed as circles and 
triangles represent polydispersity (Streck et al., 2019a).  Data are means  SD (n = 3 
independent batches).  *p-value < 0.05 for the comparison of CPP-tagged PLGA nanoparticles 
with PLGA nanoparticles, ns = not significant. 
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The influence of different CPP concentrations on the physicochemical characteristics of 
CPP-tagged PLGA nanoparticles was evaluated to design nanoformulations with a diameter 
below 200 nm and a neutral zeta potential to be suitable for future investigations as oral drug 
delivery systems.  Studies have shown that PLGA nanoparticles with a size below 200 nm were 
taken up by Caco-2 cells to a higher extent compared to larger nanoparticles and that the surface 
charge of nanoformulations influences the electrostatic interactions with the negatively charged 
cell membrane (Danhier et al., 2012; Gaumet et al., 2009).  In the present study, the zeta 
potential of RRH-tagged PLGA nanoparticles shifted from -24 to -12 mV with increasing 
concentrations of RRH (Figure 2.12B).  The conjugation of TAT resulted in the formation of 
slightly negative TAT-tagged PLGA nanoparticles with a surface charge of -4 mV (Figure 
2.12B).  After conjugation of bTAT to the PLGA nanoparticles the zeta potential was slightly 
positive (+3 mV, Figure 2.12B).  The change in zeta potential can be explained by the 
architecture of the CPPs.  The CPPs are characterized by a short, long linear and branched 
architecture (Figure 2.5).  The number of amino acids and positive charges in the peptide 
sequence is increased with a longer and more complex architecture. RRH contains two positive 
charges in the peptide sequence, whereas TAT and bTAT contain eight and twelve positive 
charges, respectively.  The increase in positive charges for RRH > TAT > bTAT resulted in 
positively charged bTAT-tagged PLGA nanoparticles after the post-microfluidics conjugation 
approach. According to the PDI values, all CPP-tagged PLGA nanoparticles showed a 
monodisperse size distribution (Figure 2.12A) and no aggregation was observed.  This is in 
contrast to the literature, where highly negatively or positively charged nanoparticles with a 
zeta potential below -30 and above +30 mV are believed to be more stable because of stronger 
repulsion forces than between neutral charged nanoparticles with a zeta potential between -10 
and +10 mV (Sonam et al., 2014; Tefas et al., 2015; Vasconcelos et al., 2015).  This behaviour 
was reported for PLGA nanoparticles without surface modifications (Sonam et al., 2014; Tefas 
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et al., 2015).  CPP-tagged PLGA nanoparticles prepared in this study and TAT modified PLGA 
nanoparticles with a surface charge of above +20 mV (Vasconcelos et al., 2015) did not show 
aggregation.  Therefore, it is likely that the surface modification of PLGA nanoparticles with 
CPPs caused particle repulsion resulting in no aggregation at neutral surface charges. 
 
 Validation of RP-HPLC methods 
The RP-HPLC methods for the quantification of the concentration of three CPPs RRH, 
TAT and bTAT were validated and representative RP-HPLC chromatograms are shown in 
Figure 2.13.  The three CPPs were eluted with TFA containing mobile phases over 25 to 37 min 
and with an increasing concentration of the organic mobile phase at a rate of 0.5-1% per minute.  
The slow increase of the organic mobile phase supports the elution of the peptides as 
recommended in the literature (Scanlon and Finlayson, 2004).  Further, no interference between 
injection peaks, CPP peaks and solvent peaks was observed indicating a good selectivity of the 
RP-HPLC methods. 
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Figure 2.13.  Representative RP-HPLC chromatograms of RRH (100 µg/mL) (A), TAT (100 
µg/mL) (B) and bTAT (100 µg/mL) (C) eluted with the individual RP-HPLC methods for each 
CPP. 
 
Standard curves were obtained for five or six different concentrations of RHH, TAT and 
bTAT after plotting the peak area against the concentration of the peptide.  The average standard 
curve equation (including standard deviation for the slope and y-intercept) for RRH between 
50 and 1000 µg/mL was y = 13385x (± 1153) – 28110 (± 7280) (Appendix III), for TAT 
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between 100 and 1000 µg/mL was y = 40151x (± 417) + 84592 (± 130705) (Appendix III) and 
for bTAT between 50 and 7500 µg/mL was y = 17138x (± 46) + 383704 (± 63462) (Appendix 
III).  The average coefficient of regression (R2) was 1.0000 ± 0.00002, 0.9994 ± 0.0003 and 
0.9999 ± 0.0001 for RRH, TAT and bTAT, respectively.  The obtained R2 showed good 
linearity between the peak area and the concentration of the CPPs. Overall, the accuracy of the 
standard curve was not lower than 94% for all three peptides (Table 2.6).  The RP-HPLC 
chromatograms of RRH, TAT and bTAT showed the consistency of the peak shapes, the 
retention time and resolution over the concentration range used to obtain the standard curve 
(Appendix IV). 
 
Table 2.6.  Measured concentration (µg/mL), coefficient of variation (CV, %) and accuracy of 
standard curves obtained for the validation of RP-HPLC methods for RRH, TAT and bTAT. 









RRH 50 50.0 ± 1.7 3.4 100.0 
 100 100.1 ± 1.2 1.2 100.1 
 200 201.2 ± 2.2 1.1 100.6 
 300 299.6 ± 2.0 0.7 99.9 
 500 498.4 ± 2.1 0.4 99.7 
 1000 1000.7 ± 0.5 0.1 100.1 
TAT 100 94.0 ± 2.9 3.1 94.0 
 300 309.7 ± 9.4 3.0 103.2 
 500 509.0 ± 11.0 2.2 101.8 
 650 657.9 ± 4.7 0.7 101.2 
 800 806.6 ± 8.6 1.1 100.8 
 1000 995.4 ± 4.6 0.5 99.5 
bTAT 50 52.7 ± 0.7 1.4 105.5 
 100 97.5 ± 3.9 4.0 97.5 
 250 249.0 ± 4.1 1.6 99.6 
 500 500.7 ± 3.3 0.7 100.1 
 750 750.0 ± 2.1 0.3 100.0 
 
The precision and accuracy of the RP-HPLC methods for the three CPPs were further 
evaluated with the measurement of QCs.  The QCs were three selected concentrations (low, 
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medium and high) within the concentration range of the standard curve of each CPP and 
measurements were repeated three times within one day and on consecutive days to obtain intra- 
and inter-day variability.  Good repeatability and intermediate precision of the RP-HPLC 
methods for all three CPPs was shown with a coefficient of variation below 2% for the intra-
day and inter-day variability, respectively (Table 2.7) (FDA, 2001).  The RP-HPLC methods 
for the three CPPs were accurate as the accuracy was greater than 98% for the intra- and inter-
day variability (Table 2.7). 
 
Table 2.7.  Measured concentration (µg/mL), coefficient of variation (CV, %) and accuracy for 
intra- and inter-day values of quality control samples of RRH, TAT and bTAT for the validation 









RRH intra-day 75 74.7 ± 1.4 1.8 99.6 
 250 250.2 ± 2.4 0.9 100.1 
 750 743.2 ± 6.1 0.8 99.1 
RRH inter-day 75 74.7 ± 1.0 1.3 99.6 
 250 250.2 ± 2.6 1.0 100.1 
 750 743.2 ± 4.9 0.7 99.1 
TAT intra-day 200 196.7 ± 0.7 0.4 98.3 
 450 451.5 ± 1.5 0.3 100.3 
 900 894.0 ± 1.1 0.1 99.3 
TAT inter-day 200 197.4 ± 2.3 1.2 98.7 
 450 451.5 ± 3.6 0.8 100.3 
 900 894.0 ± 8.8 1.0 99.3 
bTAT intra-day 75 74.4 ± 1.0 1.4 99.2 
 350 353.5 ± 4.7 0.6 101.0 
 600 604.9 ± 2.6 0.4 100.8 
bTAT inter-day 75 74.6 ± 0.9 1.1 99.4 
 350 353.5 ± 3.3 0.9 101.1 
 600 604.6 ± 6.4 1.1 100.8 
 
The sensitivity of the RP-HPLC methods was determined by LOD and LOQ (Table 2.8).  
All three RP-HPLC methods have shown a high sensitivity and the different CPPs and can be 
quantified and detected at concentrations below 5.5 µg/mL (Table 2.8). 
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Table 2.8.  The limit of quantification and the limit of detection for the three different RP-
HPLC assays to quantify the concentration of each of the CPPs (Streck et al., 2019a). 
 
 
 Conjugation efficiency of CPPs with different architectures on PLGA nanoparticles 
The amount of CPPs binding to the surface of PLGA nanoparticles depends on the 
number of available carboxyl groups and the orientation of the CPP.  The number of binding 
sites on a single PLGA nanoparticle was estimated using the surface area of a PLGA 
nanoparticle and the Connolly surface area for the lactic acid monomer. The surface area of the 
lactic acid monomer was calculated from the Connolly surface, which describes the surface 
area of a molecule that is accessible to a solvent (Connolly, 1983).  The surface area of an 
average spherical PLGA nanoparticle with a diameter of 155 nm was calculated first (Equation 
2-6). 
 
𝑺𝒖𝒓𝒇𝒂𝒄𝒆 𝒂𝒓𝒆𝒂 = 4 × 𝜋 × 𝑟2 = 4 × π × 77.5 𝑛𝑚2 =  𝟕𝟓𝟒𝟕𝟕 𝒏𝒎𝟐 (2-6) 
π = 3.14159   r = radius 
 
Further, it was assumed that 50% of the surface area of a PLGA nanoparticle was 
occupied by the lactic acid monomer since a PLGA polymer with a monomer ratio of 50:50 
(lactic acid:glycolic acid) was used for the preparation of PLGA nanoparticles.  Therefore, the 




37739 𝑛𝑚2).  The number of binding sites on a PLGA nanoparticle was estimated by dividing 
 Limit of quantification (LOQ) µg/mL Limit of detection (LOD) µg/mL 
RRH 5.4 1.8 
TAT 3.1 1.0 
bTAT 2.7 0.9 
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the surface area of a PLGA nanoparticle occupied by lactic acid by the Connolly surface area 
of a lactic acid monomer (Equation 2-7) and was estimated to be greater than 16000. 
 
𝐵𝑖𝑛𝑑𝑖𝑛𝑔 𝑠𝑖𝑡𝑒𝑠 𝑜𝑛 𝑃𝐿𝐺𝐴 𝑁𝑃 =  
𝑆𝑢𝑟𝑓𝑎𝑐𝑒 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑙𝑎𝑐𝑡𝑖𝑐 𝑎𝑐𝑖𝑑 𝑜𝑛 𝑃𝐿𝐺𝐴 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒
𝐶𝑜𝑛𝑛𝑜𝑙𝑙𝑦 𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑙𝑎𝑐𝑡𝑖𝑐 𝑎𝑐𝑖𝑑 𝑚𝑜𝑛𝑜𝑚𝑒𝑟
  (2-7) 
𝐵𝑖𝑛𝑑𝑖𝑛𝑔 𝑠𝑖𝑡𝑒𝑠 𝑜𝑛 𝑃𝐿𝐺𝐴 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 =
37739 𝑛𝑚2
2.328 𝑛𝑚2
 =  16211 
NP = nanoparticle 
 
The three different CPPs have multiple primary amines that are likely to act as a binding 
site depending on their position in the CPP sequence (Figure 2.5).  The estimated amount of 
CPPs covalently attached to the surface available carboxyl groups of the PLGA nanoparticles 
was quantified by calculating the conjugation efficiency.  The conjugation efficiency for RRH, 
TAT and bTAT depended on the concentration of the CPPs added (Table 2.9).  The amount of 
RRH conjugated to the PLGA nanoparticles increased by 12-fold when the concentration of 
RRH was increased from 10 to 50 mM.  A further increase in the RRH concentration to 75 mM 
resulted in only a slight decrease in conjugation efficiency, suggesting that at 50 mM there was 
a saturation of the surface available carboxyl groups on the PLGA nanoparticles that can react 
with the primary amines in RRH.  The concentration of TAT conjugated to PLGA nanoparticles 
increased in a linear manner with increasing concentrations of the CPP.  The bTAT-tagged 
PLGA nanoparticles showed a similar concentration of bTAT conjugated to the surface of the 
PLGA nanoparticles as TAT (Table 2.9).  These results can be related to the structure of the 
CPPs.  The short CPP RRH showed the highest concentration of CPP on the surface, which is 
related to the amount of RRH that was added and the shorter amino acid sequence in comparison 
to the other two CPPs.  The concentrations of TAT and bTAT conjugated to the PLGA 
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nanoparticles were similar and the amount of CPP that can be conjugated might be limited 
because of the more complex and branched architectures of the CPPs, which induced steric 
hindrance between individual CPP molecules.  With the conjugation of TAT and bTAT to the 
surface of PLGA nanoparticles, it is possible that not all available binding sites would be used 
due to the orientation of the CPPs.  TAT has primary amines along the amino acid sequence 
and can, therefore, bind in an orientation perpendicular to the nanoparticle surface or with a 
more tangential orientation in relation to the nanoparticle surface.  A tangential orientation of 
the CPP may cover other binding sites on the surface of the PLGA nanoparticles since the 
tangential orientation covers more surface area. The same applies to the bTAT, which has 
primary amino acids in the long linear backbone and the short branches. 
 
Table 2.9.  Conjugation efficiencies and the equivalent concentrations of the CPPs tagged to 
PLGA nanoparticles (NPs) using different concentrations of CPPs prepared with a post-
microfluidics conjugation approach (Streck et al., 2019a).  Data are means  SD (n = 3 





 SD (%) 
CPP concentration 
 SD (µM) 
RRH-tagged PLGA NPs  
10  32.4 ± 0.8 0.25 ± 0.03 
50  74.4 ± 4.5 3.10 ± 0.19 
75  58.5 ± 6.0 3.66 ± 0.37 
TAT-tagged PLGA NPs  
2.9  57.6 ± 0.5 0.15 ± < 0.01 
5.7  56.3 ± 1.0 0.29 ± 0.01 
8.6  55.5 ± 0.8 0.43 ± 0.01 
bTAT-tagged PLGA NPs  
4.5  79.8 ± 0.3* 0.33 ± < 0.01 
6.0  45.4 ± 0.7 0.25 ± < 0.01 
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 Conclusion 
The DoE study of the bulk nanoprecipitation method showed that the PLGA polymer 
concentration and the surfactant concentration influenced the size and PDI of PLGA 
nanoparticles.  Using the microfluidics method, the DoE revealed that flow rate ratio has an 
influence on the size resulting in the formulation of smaller PLGA nanoparticles at higher flow 
rate ratio (aqueous:organic).  The successful conjugation of CPPs to the PLGA polymer was 
shown by the formation of amide bonds.  The CPP architecture determined the physicochemical 
characteristics and in particular, the zeta potential of the CPP-tagged PLGA nanoparticles.  The 
surface charge was tuned from negatively charged RRH- and TAT-tagged PLGA nanoparticles 
to slightly positively charged bTAT-tagged PLGA nanoparticles with the introduction of a 
branched CPP architecture.  The covalent attachment of CPPs to the PLGA polymer was 
confirmed with FTIR by identifying the formation of an amide I bond. The amount of CPPs 
tagged to PLGA nanoparticles increased with higher amounts of CPP added. 
 
Decoration of nanoparticles with CPPs of different architectures showed the ability to 
tune the surface charge of PLGA nanoparticles and further investigation will focus on the 
distribution of CPPs on PLGA nanoparticles (Chapter 3) and implication for the interactions 
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Light scattering techniques have been frequently applied for the characterisation of 
nanoparticles.  Dynamic light scattering is commonly used to evaluate the hydrodynamic 
diameter of nanoparticles and is also a standard technique for the quality control of 
nanoparticles (Brar and Verma, 2011).  To further gain knowledge about the internal structure 
and morphology of nanoparticles, radiation from other sources such as X-rays and electrons 
can be utilized and the application of X-ray scattering and electron microscopy for polymeric 
nanoparticles is further described in this Chapter. 
 
 Characterisation of polymeric nanoparticles using small angle X-ray scattering 
The shape and structure of nanoparticles and biomacromolecules can be probed by the 
utilization of X-ray techniques (Kikhney and Svergun, 2015; Li et al., 2016).  Small angle X-
ray scattering (SAXS) is a contrast method that uses X-rays to generate scattering patterns based 
on the electron density of a sample (Li et al., 2016; Putnam et al., 2007).  The applications of 
SAXS include the structural characterisation of lipid crystalline nanoparticles (Hong et al., 
2015), micelles (Sanada et al., 2013), polymeric nanoparticles (Jäger et al., 2018) and proteins 
(Zhang et al., 2007) in solution.  Further, SAXS can be used for time-resolved studies to monitor 
kinetic processes like the formation of liquid crystalline structures during the digestion of milk 
(Clulow et al., 2018) or the assembly of nanoparticles in a microfluidic device (Ghazal et al., 
2017). 
 
Synchrotron facilities can provide X-rays with higher energy for SAXS and longer 
sample-to-detector lengths than lab-based instruments, which is important for the investigation 
of nanoparticles with a diameter larger than 100 nm using SAXS.  A high quality of X-ray beam 
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used at synchrotron facilities is ensured as the radiation is generated by the acceleration of 
electrons close to the speed of light (Boyd and Rades, 2016).  To obtain the scattering profile 
of a sample, the sample solution is placed in a quartz capillary in the X-ray beam, illuminated 
with the X-ray beam and the scattered X-rays are recorded using a diode array detector (Figure 
3.1A) (Boyd and Rades, 2016).  For samples measured in solution, the scattering pattern of the 
pure solvent is obtained first and subtracted from the scattering pattern of the samples (Kikhney 
and Svergun, 2015).  With this approach, the influence of the solvent is removed and the 
scattering pattern of the sample remains for further evaluation of the shape and size of the 
sample (Kikhney and Svergun, 2015; Putnam et al., 2007).  Generally, particles are randomly 
distributed in solution and this behaviour results in an isotropic or radially scattering pattern 
(Putnam et al., 2007), which is recorded and averaged by the 2D detector and plotted as a 1D 
scattering curve with the scattering intensity I (q) on the y-axis against the scattering vector, q, 
on the x-axis (Figure 3.1B) (Kikhney and Svergun, 2015). 
 




Figure 3.1.  Schematic of the sample set up for small angle X-ray scattering with the detection 
of scattering patterns (A) and a small angle X-ray scattering plot showing information about 
the sample structure deduced from the scattering curve (B) (Li et al., 2016; Luo et al., 2019b).  
2θ = scattering angle, I (q) = scattering intensity, q = scattering vector. 
 
To obtain the scattering curve, each pixel of the recorded isotropic scattering pattern is 
converted to one scattering angle using the pixel size of the detector and the sample-to-detector 
distance (Li et al., 2016).  The 1D scattering curve contains information about the size, shape 
and internal structure of the sample (Figure 3.1B) (Augsten et al., 2008; Putnam et al., 2007) 
as well as molecular weight and particle volume (Kikhney and Svergun, 2015).  Analysis of the 
scattering data can be performed by using the Guinier approximation, which shows a linear 
relationship in the lower q region between log (I (q)) and q2, to determine the radius of gyration 
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(Rg) as a measurement of particle size (Putnam et al., 2007).  In the higher q regions (q > 0.05 
Å-1), the Porod approximation, where the scattering shows a decay of the scattering curve (q-4), 
can be observed (Li et al., 2016).  The Porod approximation is based on the assumption that the 
electron density of two compounds in a two-phase system, e.g. particles and buffer, is different 
(Ruland, 1971).  The higher q regions provide information for surface area calculation of 
particular systems of inorganic, polymeric and porous materials (Li et al., 2016).  The pair 
distribution function p(r) is calculated by Fourier transformation of the scattering data and based 
on the distance between the electrons of the material within the sample, and information about 
the diameter and shape e.g. of particles can be obtained (Kikhney and Svergun, 2015; Putnam 
et al., 2007). 
 
In order to obtain high quality data with SAXS, it is crucial to consider the influence of 
the X-ray exposure time on the sample and the influence of the concentration of the sample on 
the scattering profile.  Using synchrotron-based SAXS, the exposure time can vary from 
fractions of a second to minutes, and shorter exposure reduces the risk of radiation damage to 
the sample (Kikhney and Svergun, 2015).  Further, the use of a flow cell instead of a static 
solution and reduced X-ray energy avoids radiation damage (Jeffries et al., 2015).  The 
concentration of the sample can be increased in SAXS experiments to gain a better signal-to-
noise ratio due to higher scattering intensities (Kikhney and Svergun, 2015).  One drawback of 
high sample concentrations, however, is the decrease in the inter-particle distance and therefore 
the possibility of an unwanted contribution of scattering to the scattering in the low q region, 
influencing the radius of gyration (Franke et al., 2012; Kikhney and Svergun, 2015). 
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Small angle neutron scattering (SANS) and SAXS are complementary scattering 
techniques utilizing either the scattering of neutrons or electrons (Di Cola et al., 2016).  Similar 
to SAXS, SANS is a non-invasive technique that can also be used to investigate structure and 
interactions of soft matters including liposomes (Hofmann et al., 2010), polymeric 
nanoparticles (Desgouilles et al., 2003), polymeric micelles (Yang et al., 2015), core-shell 
nanoparticles with a metallic core and polymeric shell (Luo et al., 2019b) and cyclic peptide-
polymer conjugates (Koh et al., 2016).  Neutrons interact with the atomic nucleus of elements 
and result in a scattering contrast that varies greatly between elements and isotopes (Lopez et 
al., 2018).  The significant scattering contrast between hydrogen and its isotope deuterium is 
particularly important and deuterated solvents are often used in SANS experiments (Grillo, 
2008).  The contrast of a system, e.g. polymeric nanoparticles in a dispersant, can be varied by 
deuteration of specific molecules or by changing the amount of D2O and H2O in the solvent 
mixture during preparation (Di Cola et al., 2016; Yang et al., 2015). 
 
The combined application of SANS and SAXS can aid to acquire data on the 
hydrophobic core and the hydrophilic shell of colloids including micelles (Manet et al., 2011) 
and liposomes (Di Cola et al., 2016).  SANS can provide information about the hydrophobic 
structure, whereas SAXS is sensitive towards polar groups.  Therefore, in this thesis SAXS was 
used to study the distribution of gold labelled CPPs.  The used CPPs contain polar and charged 
amino acids in their sequence leading to increased hydrophilicity on the surface of polymeric 
nanoparticles after conjugation. 
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 Imaging of nanoparticles to reveal morphology 
Imaging of viral particles, nanoparticles and cells is achieved by using microscopic 
techniques including electron microscopy and atomic force microscopy as both techniques offer 
nanoscale resolution (Barreto-Vieira and Barth, 2015; Ruozi et al., 2011; Ruozi et al., 2014; 
Tantra and Knight, 2011; Ye et al., 2015).  Scanning and transmission electron microscopes are 
most commonly used for the visualisation of individual nanoparticles to obtain information 
about size and shape (Reifarth et al., 2018). 
 
Scanning electron microscopy (SEM) is used for the investigation of shape and 
morphology of micro- and nanoparticles (Bootz et al., 2004; Dubes et al., 2003; Zhai et al., 
2015; Zhou et al., 2019).  In particular, the porosity of microparticles and morphological 
changes of microparticles during drug release (over a period of days to weeks) can be monitored 
using SEM (Gao et al., 2016; Zhai et al., 2015).  Before SEM analysis, the particle samples are 
dried and sputter coated with metals such as gold or palladium to generate contrast (Bootz et 
al., 2004; Gao et al., 2016; Zhai et al., 2015).  These two preparations steps are required, 
however also a major disadvantage as changes in the properties of the particles can occur (Bootz 
et al., 2004). 
 
TEM is used to generate information about the morphology of individual polymeric 
nanoparticles in a label-free manner (Augsten et al., 2008; Reifarth et al., 2018; Saarinen et al., 
2019).  Using TEM, the electron beam is focused onto the sample and unscattered electron 
waves undergo a change in their wave amplitude and phase after passing through the sample 
(Tantra and Knight, 2011; Winey et al., 2014).  The short wavelength electron beam originates 
from an electron source that is operated under vacuum (de Jonge and Ross, 2011; Miao et al., 
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1999) and due to the short wavelength of the electron beam, a high resolution below 20 nm and 
down to 1 nm can be achieved (Pauw, 2013; Winey et al., 2014). 
 
Sample preparation has an influence on the quality of the specimen and it is crucial to 
obtain high quality images with sufficient contrast between nanoparticles in the sample and the 
background (Ruozi et al., 2014).  Samples for TEM analysis are prepared by spotting a drop of 
nanoparticle suspension onto cooper grids (Bohrey et al., 2016; Winey et al., 2014).  Polymers 
are known to generate a low contrast and therefore, heavy metals like osmium tetroxide 
(Chelopo et al., 2016), phosphotungstic acid (Bohrey et al., 2016) or uranyl acetate (Chelopo 
et al., 2016; Ruozi et al., 2014) are used for negative staining of polymeric nanoparticles to 
enhance the contrast between nanoparticles and background to facilitate the observation of 
nanoparticle features. 
 
One of the main drawbacks of TEM is the presence of artefacts, which can be caused 
by drying of the nanoparticles during sample preparation (Franken et al., 2017) and damage of 
specimen through long exposure time to the electron beam (Tantra and Knight, 2011).  
Therefore, it is important to critically examine obtained TEM micrographs and incorporate 
other scattering techniques to complement the TEM data.  Further, investigation of 
nanoparticles with TEM is limited by the fact that not all nanoparticles in the sample are 
analysed and typically only representative images of the whole sample are reported (Li et al., 
2016). 
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 Functionalisation of polymeric nanoparticles using microfluidics 
As discussed earlier, functionalisation of nanoparticles with specific moieties for targeted 
and enhanced delivery of therapeutics to specific cells can be achieved using microfluidics 
(Kamaly et al., 2016; Kolishetti et al., 2010).  Conjugation of the polymer with a functional 
moiety can occur at different steps in the preparation process, namely before, during or after 
microfluidics preparation of polymeric nanoparticles (Figure 3.2).  The functionalisation of 
polymeric nanoparticles performed in a pre-microfluidics approach makes use of polymer-
ligand conjugates as a starting material (Figure 3.2A) (Kamaly et al., 2016; Liu et al., 2010; 
Valencia et al., 2013).  This approach has been used to achieve decoration of polymeric 
nanoparticles with targeted ligands including collagen IV (Kamaly et al., 2016), argininylglycyl 
aspartic acid (RGD) (Liu et al., 2010) and the LIG ligand (Valencia et al., 2013) for different 
therapeutic conditions including cancer and atherosclerosis.  Liu et al. (2010) formulated RGD-
targeted supramolecular nanoparticles for targeting the αvβ3 integrin receptor of tumour cells 
and an approximately 60% higher uptake was observed in αvβ3 receptor positive cells in 
comparison to αvβ3 receptor negative cells.  In addition, ligand density has been shown to 
influence cellular uptake of polymeric nanoparticles in prostate cancer cell lines that 
overexpress the prostate-specific membrane antigen (Valencia et al., 2013).  The use of 
increasing amounts of PLGA-PEG-LIG conjugates from 14 to 40 mol% of targeted polymeric 
nanoparticles increased cell uptake by approximately 35% in comparison to non-targeted 
polymeric nanoparticles (Valencia et al., 2013). 
 




Figure 3.2.  Functionalisation of polymeric nanoparticles using a pre-microfluidics (A) 
(Kamaly et al., 2016; Liu et al., 2010; Valencia et al., 2013), an in situ microfluidics (B) or a 
post-microfluidics (C) (Kolishetti et al., 2010) conjugation approach (Streck et al., 2019c). 
 
The modality for producing functionalised nanoparticles using microfluidics discussed in 
the literature involves mainly the formation of nanoparticles from functionalised polymer 
material during the mixing process.  An alternative strategy for the formulation of surface-
modified polymeric nanoparticles is to functionalise the nanoparticles after production in the 
microfluidic device in a post-microfluidics conjugation approach (Figure 3.2C).  In order to 
deliver anticancer drugs to prostate cancer cells, Kolishetti et al. (2010) functionalised the 
surface of PLGA-PEG nanoparticles with a targeting ligand (A10-Aptamer) and showed 
accumulation of the targeted nanoparticles in the endosomes of prostate cancer cells after 
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endocytosis.  The attachment of the targeting ligand was performed using a zero-length 
crosslinking reaction with a carbodiimide (Kolishetti et al., 2010).  Such zero-length 
crosslinking reactions are commonly used for the surface modification of polymeric 
nanoparticles (Yadav et al., 2011) and were described in Chapter 2, Section 2.1.4. 
 
The above mentioned studies illustrate that functionalised polymeric nanoparticles have 
the potential to achieve a targeted delivery approach for therapeutics.  The conjugation reaction 
is commonly performed in pre- and post-microfluidics conjugation approaches and the 
possibility of microfluidic devices to act as a reaction vessel for functionalisation of polymeric 
nanoparticles has not yet been fully exploited.  Theoretically, the conjugation reaction between 
the polymer and the moieties used for functionalisation of polymeric nanoparticles can be 
translated from a pre- or post-microfluidics reaction to an in situ microfluidics reaction (Figure 
3.2B).  For the translation of the conjugation reaction into the microfluidic channel, the 
conjugation reaction must be first evaluated for its suitability.  Performing the conjugation 
reaction in the microchannel relies on the formation of a covalent bond between the two 
components and that the formation of nanoparticles can occur simultaneously.  The conjugation 
needs to occur almost immediately since the mixing time in the microchannel is greatly reduced 
compared to a traditional bulk approach.  It is proposed here that with a successful conjugation, 
the functionalisation moiety will be present on the surface and free functionalisation moieties 
might be encapsulated in the polymeric matrix of the nanoparticles.  In this thesis, the in situ 
functionalisation approach is applied to the preparation of CPP-tagged PLGA nanoparticles for 
the first time.  The formulated CPP-tagged PLGA nanoparticles are evaluated with different 
advanced characterisation techniques including SAXS to get new insight on the influence of 
the preparation method on the physicochemical properties of the formulated nanoparticles. 
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 Chapter aims 
The aims of this study were to determine the utility of microfluidics for the production 
of CPP-tagged PLGA nanoparticles and the influence and distribution of CPP architecture on 
the nanoformulations after preparation.  PLGA nanoparticles were surface modified with CPPs 
of three different architectures (short, long linear and branched) using two different conjugation 
approaches, a post-microfluidics and an in situ microfluidics conjugation approach.  The 
influence of the different conjugation approaches on the distribution of CPPs was investigated 
using imaging techniques and X-ray scattering. 
  




Gold nanoparticles (5 nm Gold NanoSpheres, COOH-PEGylated) referred to as AuNPs 
were supplied by Nanohybrids (Austin, TX, USA).  The stock solution of AuNPs used in this 
work had the following characteristics as quoted by the manufacturer: diameter = 4.7 ± 0.8 nm; 
surface plasmon resonance peak = 514 nm; particle concentration = 5.3 × 1015 mL-1; Au mass 
concentration = 6.3 mg mL-1; pH = 7.0; particle surface = Carboxy-PEG 5 kDa, zeta potential 
= -6.5 mV. 
 
All other ingredients and peptides required for the preparation of the nanoformulations 
were used as listed in Chapter 2. 
 
 Methods 
 In situ microfluidics conjugation for the preparation of CPP-tagged PLGA 
nanoparticles and Au-labelled CPP-tagged nanoparticles 
For the in situ conjugation of CPPs to PLGA nanoparticles, a method was adapted from 
Karve et al. (2011).  The organic PLGA solution (10 mg/mL in ACN) was first activated by 
adding 250 µL of EDC solution (1.5 mM in ultra-pure water) and 250 µL of sulfo-NHS solution 
(2 mM in ultra-pure water) dropwise under gentle stirring, which was continued for 30 min at 
room temperature.  The mixture was precipitated by transfer into ultra-pure water and spun in 
a centrifuge at 3150 g for 20 min at 8°C.  The supernatant was removed and the pellet was 
dissolved at a concentration of 10 mg/mL in ACN.  100 µL of CPPs (containing either 75 mM 
RRH, 8.6 mM TAT or 4.5 mM bTAT) were mixed with 1 mL of 2% (w/v) PVA solution.  For 
the in situ microfluidics conjugation approach, a higher concentration of the CPP RRH was 
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selected due to a higher conjugation efficiency in comparison to the post-microfluidics 
conjugation approach. 
 
For the preparation of Au-labelled CPP-tagged PLGA nanoparticles, each CPP solution 
was incubated for 2 h with a 0.016 mM AuNPs solution (equals a 1-360 fold lower 
concentration than the expected conjugation efficiency of each CPP) prior to the microfluidics 
preparation.  The label-free CPP solutions and the Au-labelled CPP solutions were mixed with 
the activated organic solution of PLGA using the NanoAssemblr® Benchtop Device with a total 
flow rate of 10 mL/min and a flow rate ratio of 6:1. The Au-labelled CPP-tagged PLGA 
nanoparticles were kept in the fridge at 4°C until further required (Figure 3.3A, (ii)).  The label-
free CPP-tagged PLGA nanoparticles (Figure 3.3A, (i)) were separated by ultra-centrifugation 
at 42800 g for 15 min at 4°C to remove excess of ACN and unconjugated CPPs.  The 
supernatant was kept for RP-HPLC analysis and the nanoparticle pellet was re-suspended in 
100 µL of ultra-pure water and stored at 4°C until required. 
 




Figure 3.3.  Comparison of the in situ microfluidics (A) and the post-microfluidics (B) 
conjugation approaches for the formulation of Au-labelled CPP-tagged PLGA nanoparticles. 
Label-free CPP-tagged PLGA nanoparticles (i) and Au-labelled CPP-tagged PLGA 
nanoparticles (ii) were produced using the in situ microfluidics (A) conjugation approach.  The 
microchannel diagram, with the red box indicating the herringbone structure, was modified 
from Belliveau et al. (2012) (Streck et al., 2019b).  SHM = staggered herringbone mixer, ACN 
= acetonitrile. 
 
 Conjugation efficiency of CPPs after in situ microfluidics preparation of CPP-tagged 
PLGA nanoparticles 
The conjugation efficiency of the three CPPs (RRH, TAT and bTAT) to nanoparticles 
was obtained indirectly from the amount of CPP in the supernatant after preparation of CPP-
tagged PLGA nanoparticles using the in situ conjugation approach.  The supernatant was 
collected after in situ microfluidics preparation as described above for label-free CPP-tagged 
PLGA nanoparticles.  The RP-HPLC methods for the quantification of the CPP concentrations 
were described in Chapter 2, Section 2.3.9. 
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 Post-microfluidics conjugation for the preparation of CPP-tagged PLGA nanoparticles 
and Au-labelled CPP-tagged PLGA nanoparticles 
PLGA nanoparticles were prepared using the NanoAssemblr® Benchtop Device and 
surface modified with RRH (50 mM), TAT (8.6 mM) and bTAT (4.5 mM) as described in 
Chapter 2, Section 2.3.5 and 2.3.6, respectively.  After removal of free CPPs by ultra-
centrifugation, the nanoparticle pellet was re-suspended and diluted with 1 mL HEPES buffer 
(0.025 M, pH 6.11).  For the preparation of Au-labelled CPP-tagged PLGA nanoparticles, a 
suspension of the AuNPs was added to the CPP-tagged PLGA nanoparticles at a 1.5-2 fold 
lower concentration than the expected conjugation efficiency of each CPP (RRH: 1.6 mM 
AuNPs, TAT: 0.24 mM AuNPs and bTAT: 0.19 mM AuNPs) and incubated overnight with 
gentle stirring (Figure 3.3B). 
 
 Characterization of nanoformulations 
The Z-average diameter, PDI and zeta potential of the nanoformulations were measured 
using DLS and laser Doppler electrophoresis as described previously in Chapter 2, Section 
2.3.7. 
 
 Transmission electron microscopy  
TEM micrographs were recorded to investigate the morphology of the Au-labelled CPP-
tagged PLGA nanoparticles.  The Au-labelled CPP-tagged PLGA nanoparticles were prepared 
using either the post-microfluidics or the in situ microfluidics conjugation approach as 
described in Sections 3.3.1 and 3.3.3.  TEM grids (Electron Microscope Science, Hatfield, PA 
USA) were made hydrophilic by glow discharge in air for 1 min (Aebi and Pollard, 1987).  
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Solutions of the Au-labelled CPP-tagged PLGA nanoparticles (10 µL) were spotted onto a 300 
mesh copper grid and air-dried for 30-60 s before the excess solution was blotted with Whatman 
filter paper Number 1.  The samples were viewed with a Technai F30 (FEI, Eindhoven, The 
Netherlands) and a Philips CM 100 Bio TWIN TEM (Philips Electron Optics, Eindhoven, The 
Netherlands). 
 
 Small angle X-ray scattering 
The SAXS/WAXS beamline at the Australian Synchrotron (ANSTO, Clayton, 
Australia) was used to investigate the distribution of Au-labelled CPPs with different 
architectures conjugated to PLGA nanoparticles produced using either the post-microfluidics 
or in situ microfluidics conjugation approach.  The samples were measured in a quartz capillary 
mounted in the X-ray beam with a wavelength of the 0.954 Å (photon energy 13 keV).  Sample-
to-detector distances of 1.53 m and 7.33 m were used to cover a scattering vector q range of 
0.003 < q < 0.665 Å-1.  The scattering vector q is given by 𝑞 = (
4𝜋
𝜆
) sin 𝜃, where 𝜆 is the X-ray 
wavelength and 2θ is the scattering angle.  2D scattering profiles were acquired during X-ray 
exposures between 0.1-1 s using a Pilatus 1 M detector.  The obtained scattering patterns were 
radially integrated into plots of I (q) versus q using the in-house-developed software package 
ScatterBrain (Vithani et al., 2017). 
 
 Statistical analysis 
Students t-tests were performed to make a comparison between single groups and 
obtained p-values were statistically significant at p < 0.05. 
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 Results and Discussion 
 Conjugation approaches for preparation of CPP-tagged PLGA nanoparticles 
The main difference between the post-microfluidics and the in situ microfluidics 
conjugation approach to formulate CPP-tagged PLGA nanoparticles is the time point when the 
PLGA polymer was activated by EDC/sulfo-NHS to enable the conjugation reaction with the 
CPPs.  In the post-microfluidics conjugation approach, the free carboxyl groups of the PLGA 
polymer were activated after formation of the nanoparticles.  Using this approach, the 
conjugation reaction with the CPPs was limited to the surface available carboxyl groups. In the 
in situ microfluidics conjugation approach, the PLGA polymer was activated before formation 
of the nanoparticles.  The activated carboxyl groups react with the CPPs during mixing within 
the microchannel and consequently, the CPPs should have been distributed throughout the 
PLGA nanoparticles. 
 
 Characteristics of CPP-tagged PLGA nanoparticles depends on the CPP architecture 
The in situ microfluidics conjugation approach was used to formulate PLGA 
nanoparticles and CPP-tagged PLGA nanoparticles.  Unmodified PLGA nanoparticles were 
monodisperse and showed an average size of 130 nm and a negative surface charge of -18 mV 
(Figure 3.4).  In comparison to the unmodified PLGA nanoparticles prepared using 
microfluidics in Chapter 2 (Section 2.4.6), unmodified PLGA nanoparticles prepared using the 
in situ microfluidics conjugation approach showed a smaller size, which might be related to the 
use of the activated polymer for the preparation of PLGA nanoparticles.  A possible explanation 
is that the reactive sulfo-NHS ester intermediate on the activated PLGA polymer interferes with 
the nanoprecipitation process.  The unmodified PLGA nanoparticles were formulated for 
control purposes only as the reactive sulfo-NHS ester intermediate may lead to unwanted 
  Chapter Three 
130 
 
reactions.  CPP-tagged PLGA nanoparticles had a size between 159 and 174 nm, depending on 
the CPP used, and showed a monodisperse size distribution with a PDI < 0.155 after preparation 
with the in situ microfluidics conjugation approach (Figure 3.4A).  Both preparation methods 
resulted in CPP-tagged PLGA nanoparticles with a similar size and polydispersity (Chapter 2, 
Section 2.4.6).  The bTAT-tagged PLGA nanoparticles were only tested using one 
concentration of bTAT (4.5 mM) for the in situ microfluidics conjugation approach as the 
results from the post-microfluidics conjugation approach with 4.5 and 6 mM bTAT did not 
reveal a difference in size or zeta potential (Chapter 2, Figure 2.12). 
 
The zeta potential of RRH-tagged PLGA nanoparticles decreased from -18 to -8 mV 
with increasing concentrations of RRH (Figure 3.4B).  The conjugation of TAT resulted in 
slightly negatively charged PLGA nanoparticles with a surface charge between -4 to -2 mV 
(Figure 3.4B).  The CPP-tagged PLGA nanoparticles prepared with the branched CPP, bTAT, 
showed a positive zeta potential of +4 mV after preparation using the in situ microfluidics 
conjugation approach (Figure 3.4B).  A similar change in zeta potential after preparation of 
CPP-tagged PLGA nanoparticles was also observed using the post-microfluidics conjugation 
approach in Chapter 2, Section 2.4.6 and can be explained by the incorporation of more positive 
charges in the CPP sequence with a more complex architecture of the CPPs. 
 




Figure 3.4.  Size, polydispersity (A) and zeta potential (B) of PLGA nanoparticles and CPP-
tagged PLGA nanoparticles with different concentrations of the CPPs (RRH, TAT and bTAT), 
prepared using the in situ microfluidics conjugation approach.  Size is displayed as circles and 
triangles represent polydispersity.  Data are means  SD (n = 3 independent batches).  *p-value 
< 0.05 for the comparison of CPP-tagged PLGA nanoparticles with PLGA nanoparticles, ns = 
not significant. 
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 Conjugation efficiency of CPPs with different architecture on PLGA nanoparticles 
The conjugation efficiency of CPPs tagged to PLGA nanoparticles using the in situ 
microfluidics conjugation approach was dependent on the concentration of CPP added (Table 
3.1).  Conjugation efficiencies of RRH increased from 73% to 91% with higher amounts of 
RRH added.  For RRH-tagged PLGA nanoparticles, the amount of RRH associated to the 
nanoformulation was almost double using the in situ microfluidics conjugation approach in 
comparison to the post-microfluidics conjugation approach at a RRH concentration of 75 mM 
(Chapter 2, Section 2.4.8).  The bTAT-tagged PLGA nanoparticles showed a high conjugation 
efficiency (> 80%) using the in situ microfluidics conjugation approach.  The conjugation 
efficiency and the amount of bTAT conjugated to the PLGA nanoparticles using the in situ 
microfluidics approach were similar compared to the post-microfluidics conjugation (Chapter 
2, Section 2.4.8).  The higher conjugation efficiencies for RRH- and bTAT-tagged PLGA 
nanoparticles prepared using the in situ microfluidics conjugation approach compared to the 
post-microfluidics conjugation approach suggested encapsulation of RRH and bTAT within the 
formulated CPP-tagged PLGA nanoparticles.  Higher conjugation efficiencies were observed 
as RRH and bTAT were encapsulated as well as present on the surface of the PLGA 
nanoparticles.  The conjugation efficiency of TAT using the in situ microfluidics conjugation 
approach increased with higher amounts of TAT added, but was overall low and ranged 
between 15% to 29%.  The conjugation efficiency of TAT was lower, compared to the post-
microfluidics conjugation approach (Chapter 2, Section 2.4.8) and the other CPPs investigated.  
One possible reason for the low conjugation efficiency of TAT could be related to the amino 
acids present in the peptide sequence of the investigated CPPs.  RRH and bTAT both contain 
the amino acid histidine in their peptide sequence and histidine has been shown to bind to ethyl-
cyanoacrylate monomer units during preparation of PECA nanoparticles (Kafka et al., 2009).  
The lack of histidine in the TAT peptide sequence might be a reason for the lower conjugation 
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efficiency as fewer interactions with the PLGA polymer occur during the formulation of the 
nanoparticles in the microchannel. 
 
Table 3.1  Conjugation efficiencies and the equivalent concentration of the CPPs tagged to 
PLGA nanoparticles (NPs) using different concentrations of CPPs prepared with the in situ 
microfluidics conjugation approach.  Data are means  SD (n = 3 independent batches).  * p < 
0.05 in comparison to the CPP concentration of 10 and 50 mM RRH, *a p < 0.05 in comparison 
to the CPP concentration of 2.9 and 5.7 mM TAT, *b p < 0.05 in comparison to the CPP 




(%)  SD 
CPP concentration 
(µM)  SD 
RRH-tagged PLGA NPs  
10  73.2 ± 3.5 0.67 ± 0.03 
50  83.2 ± 1.1 3.78 ± 0.05 
75  91.0 ± < 0.1 6.20 ± < 0.01* 
TAT-tagged PLGA NPs  
2.9  14.7 ± 3.3 0.04 ± 0.01 
5.7  17.5 ± 1.6 0.09 ± 0.01 
8.6  28.7 ± 0.5 0.22 ± < 0.01*a 
bTAT-tagged PLGA NPs  
4.5  84.2 ± 0.3 0.35 ± < 0.01*b 
 
 Characterization of Au-labelled CPP-tagged PLGA nanoparticles 
CPP-tagged PLGA nanoparticles were labelled with gold nanoparticles (AuNPs) to 
facilitate subsequent structural analysis using TEM and SAXS.  The spherical AuNPs had a 
nominal diameter of 4.7 nm and had a zeta potential of -6.5 mV due to the surface decoration 
with PEG groups.  The Au-labelled CPP-tagged PLGA nanoparticles were produced using each 
of the different conjugation approaches previously described.  The addition of AuNPs to CPP-
tagged PLGA nanoparticles did not change the average size (Table 3.2) as it remained between 
140-180 nm, which was comparable with the size range of the Au label-free CPP-tagged PLGA 
nanoparticles prepared using post-microfluidics and in situ microfluidics conjugation approach 
(Figure 3.4 and Chapter 2, Figure 2.12).  The addition of AuNPs to CPP-tagged PLGA 
nanoparticles prepared using the post-microfluidics and the in situ microfluidics conjugation 
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approach resulted in an increase in polydispersity, which might be related to the presence of 
free AuNPs.  The zeta potential of the CPP-tagged PLGA nanoparticles was, however, 
influenced by the addition of AuNPs and resulted in a negative surface charge between -12 and 
0 mV (Table 3.1 and Table 3.2) indicating electrostatic interactions between the positively 
charged CPPs and the negatively charged AuNPs.  Using the in situ microfluidics conjugation 
approach, the surface charge of the Au-labelled CPP-tagged PLGA nanoparticles was less 
negative due to the encapsulation of the AuNPs within the polymeric nanoparticles, which 
cannot contribute to the overall surface charge. 
 
Table 3.2.  Characterization of Au-labelled CPP-tagged PLGA nanoparticles used for 
transmission electron microscopy and small angle X-ray scattering analysis prepared using the 
in situ microfluidics or post-microfluidics conjugation approach (Streck et al., 2019b).  Data 
are means ± SD (n = 3).  * p < 0.05 in comparison to bTAT-tagged PLGA NPs prepared with 
the in situ microfluidics conjugation approach. 
 
 
Sample Size ± SD (nm) PDI 
Zeta potential 
± SD (mV) 
In situ microfluidics conjugation approach for Au-labelled nanoformulations 
RRH-tagged PLGA NPs (75 mM) 140.6 ± 18.4 0.235 ± 0.034 0.2 ± 4.4 
TAT-tagged PLGA NPs (8.6 mM) 168.1 ± 14.3 0.224 ± 0.039 -2.4 ± 3.7 
bTAT-tagged PLGA NPs (4.5 mM) 142.4 ± 2.9 0.190 ± 0.043 -0.2 ± 6.3 
Post-microfluidics conjugation approach for Au-labelled nanoformulations 
RRH-tagged PLGA NPs (50 mM) 163.9 ± 3.2 0.225 ± 0.060 -12.3 ± 7.6 
TAT-tagged PLGA NPs (8.6 mM) 180.7 ± 19.6 0.187 ± 0.067 -5.2 ± 0.3 
bTAT-tagged PLGA NPs (4.5 mM) 156.9 ± 6.1* 0.162 ± 0.038 -4.6 ± 7.0 
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 TEM micrographs show the distribution of CPP on PLGA nanoparticles 
Visualisation of Au-labelled CPP-tagged PLGA nanoparticles prepared with both 
conjugation approaches showed individual nanoparticles with a regular spherical shape and a 
smooth surface of the CPP-tagged PLGA nanoparticles independent of the conjugation 
approach, (Figure 3.5 and Figure 3.7).  The AuNPs were attached to the RRH-tagged PLGA 
nanoparticles prepared using the post-microfluidics and in situ microfluidics conjugation 
approach (Figure 3.5).  The observed size of the polymeric nanoparticles after preparation on 
the TEM grids was smaller compared to DLS, which is related to the shrinkage of the polymer 
during the drying step during sample preparation (Luque-Michel et al., 2016). 
 
 
Figure 3.5.  Representative micrographs of Au-labelled RRH-tagged PLGA nanoparticles 
prepared using the post-microfluidics (A) and the in situ microfluidics conjugation approach 
(B) (Streck et al., 2019b). 
 
The AuNPs formed mono- and/or bi-layers around the RRH-tagged PLGA 
nanoparticles (Figure 3.5A) suggesting an interaction of the negatively charged AuNPs with 
the positively charged RRH on the PLGA nanoparticle surface.  Further, the RRH-tagged 
PLGA nanoparticles showed a surface saturation with AuNPs (Figure 3.5A).  It was also 
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possible to observe an apparent depletion zone around the Au-labelled RRH-tagged PLGA 
nanoparticles with free AuNPs also being observed (Figure 3.6A).  The interaction between the 
CPPs and AuNPs, as well as the behaviour of free AuNPs, is dependent on the surface charge 
of the respective particles.  The negatively charged AuNPs can electrostatically bind to the 
positive charges within the CPP sequence.  RRH contains positively charged guanidinium 
groups and here, the guanidinium groups are likely to act as binding sites for AuNPs.  An evenly 
spaced arrangement of free AuNPs was observed here, where the nanoparticles adopted a 
hexagonal lattice pattern (Figure 3.6, Insert 1) with an average distance of 27.6 ± 4.0 nm 
(n = 100, number of free AuNPs) between the AuNPs.  The free AuNPs are expected to repel 
each other because of their negative charge and the resulting electrostatic forces between the 
individual AuNPs.  Interestingly, it was observed that the average distance between AuNPs was 
significantly shorter when associated with the RRH-tagged PLGA nanoparticles (Figure 3.6, 
Insert 2) compared to the distance between free AuNPs.  The average distance between AuNPs 
surface-bound to RRH-tagged PLGA nanoparticles was 12.1 ± 2.5 nm (n = 6, number of Au-
labelled RRH-tagged PLGA nanoparticles).  The shorter distance can be explained by a 
reduction of electrostatic forces between AuNPs due to the binding to RRH. 
 




Figure 3.6.  Transmission electron micrograph of Au-labelled RRH-tagged PLGA 
nanoparticles (A) and inserts of free individual AuNPs (1) and a RRH-tagged PLGA 
nanoparticle with surface-bound AuNPs (2).  The hexagonal formation of the AuNPs is 
indicated by the red dashed line and the red arrows indicate how the distance between AuNPs 
was measured (Streck et al., 2019b). 
 
Au-labelled TAT-tagged PLGA nanoparticles prepared using the post-microfluidics 
conjugation approach showed an arrangement of AuNPs around individual TAT-tagged PLGA 
nanoparticles (Figure 3.7A).  The AuNPs did not cover the surface completely and showed a 
space between individual AuNPs, which might be due to steric hindrance introduced by the 
longer TAT sequence compared to the short CPP sequence of RRH.  Further, in Chapter 2 
(Section 2.4.8) the available binding sites for CPPs on a PLGA nanoparticle were estimated to 
be 16000 and it is possible that not all binding sites were occupied by TAT and therefore, no 
complete surface saturation with AuNPs was observed.  A similar observation was made for 
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Au-labelled bTAT-tagged PLGA nanoparticles, were the AuNPs arrange around bTAT-tagged 
PLGA nanoparticles with a regular distance between each other (Figure 3.7C).  
 
 
Figure 3.7.  Representative micrographs of Au-labelled TAT- and bTAT-tagged PLGA 
nanoparticles prepared using the post-microfluidics (A, C) and the in situ microfluidics 
conjugation approach (B, D). 
 
The TEM micrographs obtained for Au-labelled CPP-tagged PLGA nanoparticles 
prepared using the in situ microfluidics conjugation approach did not give conclusive results 
about the AuNPs distribution and therefore, the CPP distribution (Figure 3.5B and Figure 3.7B 
and D).  In comparison to the Au-labelled CPP-tagged PLGA nanoparticles prepared using the 
post-microfluidics conjugation approach, fewer AuNPs were observed in using TEM for the 
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Au-labelled CPP-tagged PLGA nanoparticles prepared with the in situ microfluidics 
conjugation approach and individual AuNPs seemed to generate less contrast and appeared grey 
in the TEM micrographs making the imaging more difficult to interpret. 
 
Since the aim of this study was to investigate the distribution of the CPPs on the PLGA 
nanoparticles another technique, namely SAXS, was used to examine how the CPPs were 
distributed after preparation of Au-labelled CPP-tagged PLGA nanoparticles using the post-
microfluidics and the in situ microfluidics conjugation approach. 
 
 Investigation of CPP distribution on PLGA nanoparticles using SAXS 
The distribution of CPPs conjugated to PLGA nanoparticles prepared using the two 
different conjugation approaches was investigated using SAXS.  The SAXS profiles were 
obtained by radial integration of 2D scattering patterns into plots of the scattered X-ray intensity 
I(q) versus the scattering vector q.  The scattering profiles of the three different Au-labelled 
CPP-tagged PLGA nanoparticles prepared using either the post-microfluidics or the in situ 
microfluidics conjugation approach are presented in Figure 3.8.  A suspension of AuNPs alone 
was used as a reference to determine the SAXS scattering pattern of the label used in this study 
(Appendix V and black data points in Figure 3.8A-F).  The manufacturer’s specifications for 
the AuNPs provided an average particle diameter of 4.7 ± 0.8 nm.  The high q portion of the 
scattering profile for the AuNPs above q = 0.10 Å-1 could be fitted with the sphere form factor 
for a sphere with a radius of 2.2 nm and a polydispersity of 0.17 
(Polydispersity =   
Standard deviation
Mean
) and was therefore consistent with the information 
supplied by the manufacturer.  However, the model did not account for some additional low q 
scattering intensity observed and this is suggestive of the presence of a small fraction of larger 
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AuNPs.  The full scattering profile was fitted by incorporating a second sphere form factor into 
the fitting model with a radius of 4.4 nm and a modelled volume fraction an order of magnitude 
lower than the AuNPs fitted with a sphere radius of 2.2 nm (Appendix V).  This suggested that 
the commercially obtained AuNPs contained a subpopulation of around 1% of AuNPs with 
diameters of 8.8 ± 1.5 nm in addition to those of the specified diameter of 4.4 ± 0.7 nm, 
consistent with the manufacturer’s specifications. 
 
The flat-plateau (Guinier region) below q = 0.02 Å-1 revealed that there were no 
structure factor perturbations to the form factor and indicated that the AuNPs were at a 
sufficiently low concentration in the dispersion not to be interacting with one another.  In 
addition, the scattering profiles of CPP-tagged PLGA nanoparticles prepared using the post-
microfluidics conjugation approach were obtained as a reference for both conjugation 
approaches since a similar size was measured with DLS.  These references account for the 
scattering caused by the Au-label free CPP-tagged PLGA nanoparticles themselves.  Given the 
large average diameter of the PLGA nanoparticles (> 150 nm), the Guinier plateau at low q was 
not observable within the measurable q-range of the instrument.  The lowest observable q value 
of 0.0026 Å-1 gave a maximum observable particle radius of ~ 500 Å (√5/3 × 1/qmin) and thereby 
a maximum observable diameter of ~100 nm.  However, scattering intensity indicated scattering 
length density (SLD) contrast between the nanoparticles and the dispersant and surface (Porod) 
scattering from the PLGA nanoparticles was observed at higher q that reached the incoherent 
background intensity at q ≈ 0.02 Å-1 (Figure 3.8, red data points). 
 




Figure 3.8.  Small angle X-ray scattering profiles of AuNPs (black data points) and PLGA 
nanoparticles tagged with CPPs of different architectures (RRH, TAT and bTAT) (red data 
points).  Panels A-C show Au-labelled CPP-tagged PLGA nanoparticles prepared with the post-
microfluidics conjugation approach (purple data points) and panels D-F were produced using 
the in situ microfluidics conjugation approach (green data points) (Streck et al., 2019b).  AuNPs 
= gold nanoparticles and MF = microfluidics. 
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The Au-labelled CPP-tagged PLGA nanoparticles prepared using the post-microfluidics 
conjugation approach had scattering profiles that showed features from the scattering profiles 
of the label-free CPP-tagged PLGA nanoparticles and the scattering profile of the AuNPs.  
Examining the Au-labelled CPP-tagged PLGA nanoparticles that were tagged in situ in the 
microfluidic channel, a low q scattering feature was observed (Figure 3.8D-F).  The scattering 
feature at low q was consistent with the scattering of the larger PLGA nanoparticles alongside 
a high q shoulder commensurate with the presence of a lower concentration of AuNPs than that 
used in the post-microfluidics conjugation approach.  The shape of the low q scattering feature 
of the Au-labelled CPP-tagged PLGA nanoparticles prepared with the in situ microfluidics 
conjugation approach was similar to the scattering profile of the label-free CPP-tagged PLGA 
nanoparticles in the cases of RRH and TAT, indicating PLGA nanoparticles with a similar size.  
The corresponding feature for the bTAT-tagged PLGA nanoparticles prepared with the in situ 
microfluidics conjugation approach was broader, extending to higher q scattering intensity than 
the corresponding nanoparticles not labelled with AuNPs.  This indicated that the Au-labelled 
bTAT-tagged PLGA particles were, in fact, smaller than their unlabelled counterparts.  The 
diameters of the Au-labelled CPP-tagged PLGA nanoparticles prepared using the in situ 
microfluidics conjugation approach measured by DLS were between 142 and 168 nm and 
similar to the label-free CPP-tagged PLGA nanoparticles (Table 3.2, Figure 3.4 and Chapter 2, 
Figure 2.10).  The primary difference between unmodified and CPP-tagged PLGA 
nanoparticles in the low q scattering feature was that for each CPP-tagged PLGA nanoparticle 
formulation there was an increase in the absolute scattering intensity by up to an order of 
magnitude when CPPs were pre-conjugated to AuNPs and incorporated into the polymerization 
mixture inside the microfluidic channel.  In contrast to the PLGA nanoparticles, the AuNPs are 
strong X-ray scatterers with higher SLDs because they have a greater electron density than the 
aqueous dispersant (Clara-Rahola et al., 2018).  These observations led to the conclusion that 
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the strongly scattering AuNPs were incorporated uniformly throughout the CPP-tagged PLGA 
nanoparticles when the in situ microfluidics conjugation approach was used.  With the 
incorporation of the AuNPs, the SLD contrast of the CPP-tagged PLGA nanoparticles increased 
without significantly changing their size as observed by the similar shapes and positions of the 
scattering profiles.  Similar binding behaviour has been shown previously for 
superparamagnetic iron oxide nanoparticles inside PLGA nanoparticles (Wassel et al., 2007). 
 
The scattering profiles obtained from the Au-labelled CPP-tagged PLGA nanoparticles 
prepared with the post-microfluidics conjugation approach (Figure 3.8A-C) were somewhat 
different to scattering profiles obtained with the in situ microfluidics conjugation approach, 
containing primarily the features of the AuNPs alone.  It is likely that the absence of prominent 
features from the PLGA nanoparticles at low q was obscured by the strong scattering from the 
AuNPs in this region.  For all three Au-labelled CPP-tagged PLGA nanoparticles, the scattering 
from the native PLGA nanoparticles was weaker than the scattering of the AuNPs at most 
observable q values.  It is also possible that binding of AuNPs to the surface of the PLGA 
nanoparticles, as observed by TEM (Figure 3.5A and Figure 3.7A and C), led to a measurable 
increase in the overall size of the PLGA nanoparticles, which would push the scattering feature 
to lower q values and outside of the observable range of the instrument.  However, a significant 
increase in the scattering intensity from the PLGA nanoparticles was not observed when AuNPs 
were bound to CPP-tagged PLGA nanoparticles after the post-microfluidics conjugation 
approach and this supports the hypothesis that the post-microfluidics conjugation approach did 
not lead to the conjugation of the PLGA polymer with CPPs inside the nanoparticles.  The only 
case where scattering from the CPP-tagged PLGA nanoparticles was observed with the post-
microfluidics conjugation approach was in the case of bTAT-tagged PLGA nanoparticles and 
in this case, the measured scattering intensity was the same as the sum of the scattering observed 
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from bTAT conjugated PLGA nanoparticles and the AuNPs used to label them (Figure 3.8C).  
As such, the location of any binding of the AuNPs by the CPPs could not be deduced directly 
from the SAXS data for the Au-labelled CPP-tagged PLGA nanoparticles prepared with the 
post-microfluidics conjugation approach.  Any feature that represents a polymer core and 
AuNPs-shell arrangement, which would typically appear as a side-maximum at higher q values, 
were obscured by the strong scattering from the AuNPs.  Lastly, it should be noted that SAXS 
experiments were performed using a bulk nanoparticle suspension and therefore the obtained 
data displays an average of the CPP distribution in the nanoparticle population. 
 
 Structural distribution of CPPs 
A model is proposed for the selective conjugation of CPPs to PLGA nanoparticles using 
different microfluidic approaches.  Based on the SAXS, DLS and TEM data the distribution of 
the CPPs depends on the conjugation approach.  The AuNPs were electrostatically bound to the 
positively charged CPPs and acted as a label to increase the scattering intensity of the PLGA 
nanoparticles.  TEM micrographs for the post-microfluidics conjugation approach indicated a 
core-shell like arrangement of the AuNPs around the PLGA nanoparticles.  Using the post-
microfluidics conjugation approach the CPPs were apparently initially conjugated to the 
available carboxyl groups on the surface of the PLGA nanoparticles (Figure 3.9A).  A potential 
movement of the CPPs towards the inside of the nanoparticles due to pores in the polymer 
matrix could not be observed with SAXS as the scattering contrast of the CPPs on their own is 
very low.  The presence of pores in PLGA nanoparticles is not clearly stated in the literature 
and a porous structure is mainly reported for larger PLGA microparticles prepared using a 
double emulsion solvent evaporation technique in the presence of ammonium bicarbonate 
(Chen et al., 2019b).  Even if pores are present in the PLGA nanoparticles, it is possible that 
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the AuNPs (with a size of approximately 4.4 nm) could not penetrate through those pores into 
the internal space of the nanoparticles. 
 
 
Figure 3.9.  Schematic overview of proposed CPP distribution of Au-labelled CPP-tagged 
PLGA nanoparticles and the corresponding distribution of label-free CPP-tagged PLGA 
nanoparticles prepared using a post-microfluidics conjugation (A) or an in situ microfluidics 
conjugation (B) approach (Streck et al., 2019b).  NP = nanoparticle. 
 
The scattering curves of the Au-labelled CPP-tagged PLGA nanoparticles prepared with 
the in situ microfluidics conjugation approach showed an enhanced scattering contrast between 
the nanoparticles and the dispersant and thereby a distribution of the strongly scattering Au-
labelled CPPs throughout the polymeric PLGA nanoparticles (Figure 3.9B).  When using the 
in situ microfluidics conjugation approach, the PLGA polymer was activated prior to the 
formulation of the nanoparticles and AuNPs/CPPs could bind to the PLGA polymer during the 
polymer matrix formation, both being encapsulated inside the PLGA nanoparticles and present 
on their surfaces (Figure 3.9B).  To further elucidate the dynamic distribution of CPPs during 
nanoparticle formation, future work could incorporate microfluidics coupled with SANS to 
study in situ scattering of soft matters over time (Adamo et al., 2018). 




The CPP-tagged PLGA nanoparticles prepared using the in situ microfluidics approach 
showed an influence of the CPP architecture on the physicochemical characteristics, in 
particular, the tuneability of the surface charge.  The amount of CPP tagged to PLGA 
nanoparticles was concentration dependent and increased with higher concentrations of CPPs 
added. Further, the distribution of ligands on and within nanoparticles is critical to their 
utilization in vivo but is not often understood.  Here, PLGA nanoparticles were tagged with 
variants of the cationic CPP, TAT, known to enhance cell uptake (Trehin et al., 2004) and 
prepared using different microfluidics-based conjugation approaches to probe the impact of 
architecture and preparation method on the structure of the resulting nanoparticles. TAT has 
been previously conjugated to polymer nanoparticles (Vasconcelos et al., 2015; Zhu et al., 
2016a), but the distribution of the ligand on and within the particles was not explored, nor was 
their preparation by microfluidic techniques.  In the present study, for the first time, the 
utilization of microfluidics to produce CPP-tagged PLGA nanoparticles has been demonstrated. 
It has also been shown that the distribution of the CPPs within the nanoparticle delivery system 
was influenced by the preparation method.  CPPs were distributed throughout the PLGA 
nanoparticles when prepared using the in situ microfluidics conjugation approach. In contrast, 
for CPP-tagged PLGA nanoparticles prepared using post-microfluidics conjugation, the results 
were consistent with the CPPs being distributed on the surface of the nanoparticles.  This 
finding has important implications for the use of such nanoparticles, where the density of CPPs 
on the surface is important in dictating biological interactions or alternatively when using an 
ion pairing strategy to localize labile drugs to the inside of the nanoparticles.  Future studies 
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Interactions of nanoparticles with cell membranes are widely investigated, but still not 
completely understood.  Different cell lines such as HeLa and Caco-2 cells have been utilized 
as in vitro cell culture models to study nanoparticle-cell interactions and cellular uptake of 
nanoparticles (Czuba et al., 2018; Morimoto et al., 2016; Nam et al., 2002; Sheng et al., 2015).  
The human cervical cancer cell line HeLa cells is a well-established cell line for uptake studies 
of CPPs (Masters, 2002; Ramaker et al., 2018), whereas Caco-2 cells are used as a cell culture 
model for the intestinal epithelium (Hidalgo et al., 1989).  In this Chapter, the focus is on the 
influences of surface modification of polymeric nanoparticles on nanoparticle-cell interactions 
in different in vitro cell culture models.  
 
 Interactions of nanoparticles at the nano-bio interface 
The nano-bio interface is described as the space between nanomaterials and biological 
systems, and processes occurring at the nano-bio interface determine the uptake of 
nanoparticles (Nel et al., 2009; Shang and Nienhaus, 2013).  Dynamic interactions at the nano-
bio interface include both long- and short-range forces (Nel et al., 2009; Shang and Nienhaus, 
2013).  Long-range forces include van der Waals and repulsive electrostatic interactions with 
the cell membrane, whereas short-range forces arise from surface charges or combine steric, 
depletion and solvent interactions (Nel et al., 2009; Shang and Nienhaus, 2013).  These forces 
influence the formation of a protein corona around nanoparticles, determine cellular contact 
and subsequent endocytosis and intracellular transport (Shang and Nienhaus, 2013).  A protein 
corona is formed around positively and negatively charged nanoparticles when they enter 
biological fluids, with albumin being the main protein component (Fleischer and Payne, 2014; 
Nel et al., 2009).  Adherence to the cell membrane involves either specific or non-specific 
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binding and CPPs are an example of surface modifications that can induce non-specific binding 
to cells (Nel et al., 2009).  Other factors that influence interactions at the nano-bio interface are 
hydrophobicity of the nanoparticles, the surface roughness of the cells and size and shape of 
the nanoparticles (Nel et al., 2009).  To better understand the time frame for particles to arrive 
at the nano-bio interface and their distribution within in vitro and in vivo systems, mathematical 
modelling is used to predict the kinetic behaviour of particles (Li et al., 2012; Thomas et al., 
2018). 
 
Kinetic studies of particle distribution can be either used for understanding the fate of 
nanoparticles in the human body (Li et al., 2010) or to estimate the delivered dose to the cell in 
an in vitro cell culture (Ahmad Khanbeigi et al., 2012).  The former is used for the evaluation 
of nanoparticles in the relevant compartments of the ADME (Absorption, Distribution, 
Metabolism and Excretion) system after administered to the human body (Li et al., 2017).  The 
latter is used for the improvement of in vitro cell culture systems and will be discussed further.  
The biological response of a system to an administered drug is dose dependent and 
particokinetics is used as a computational tool to estimate the behaviour of nanoparticles in in 
vitro cell culture systems (Price et al., 2019).  Knowledge of the delivered dose is important as 
there is a great difference between the administrated amount and the amount of nanoparticles 
that reached the cell surface (Faria et al., 2019).  Ahmad Khanbeigi et al. (2012) reported that 
only 0.03-0.33% of the administered dose of polystyrene microspheres reached the cell surface 
of macrophages in vitro and the findings were supported by particokinetic estimations. 
 
The biological effects between nanoparticles and the cell membrane occur primarily via 
interactions of the nanoparticles with the cell components (Thomas et al., 2018).  In in vitro 
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cell culture media or buffer, particles can sediment, diffuse and agglomerate according to their 
physicochemical characteristics including size, charge and density (Hinderliter et al., 2010).  
Hinderliter et al. (2010) used a computational model called the ISDD model (In vitro 
Sedimentation, Diffusion and Dosimetry model) to describe the dynamics of particles in liquids.  
The model can be used for the estimation of the amount of nanoparticles reaching the cell 
surface, but a weakness of the ISDD model is that it does not describe changes in size during 
degradation of the nanoparticles in the physiological environment (Hinderliter et al., 2010; 
Thomas et al., 2018).  The ISD3 model (In vitro Sedimentation, Diffusion, Dissolution, and 
Dosimetry model) developed by Thomas et al. (2018) includes dissolution and was tested with 
silver nanoparticles as model nanoparticles in buffer with 10% fetal bovine serum and 
macrophages as model cells.  Theoretically, the concept of the ISD3 model can also be applied 
to polymeric nanoparticles in in vitro cell culture system.  During incubation, the polymeric 
nanoparticles diffuse and sediment towards the cell surface.  At the same time, dissolution of 
the polymer is occurring and subsequent drug release is triggered by interactions with the cell 
culture media before and whilst the polymeric nanoparticles reach and interact with the cell 
surface (Figure 4.1). 
 




Figure 4.1.  Schematic representation of the in vitro Sedimentation, Diffusion, Dissolution, and 
Dosimetry model applied to polymeric nanoparticles including the sedimentation and diffusion 
of the drug-loaded polymeric nanoparticles (A), the dissolution of the polymer and drug release 
(B) and the interaction/uptake of drug/nanoparticles at the cell surface (C) (Thomas et al., 
2018). 
 
In addition to the delivered dose, the association of nanoparticles with cells can be 
included in mathematical modelling (Faria et al., 2019).  There are a number of different 
assumptions about nanoparticle-cell interactions that should be incorporated into these 
mathematical models.  These include assuming that all nanoparticles reach the cells and interact 
with the cells, cell association of nanoparticles is directly proportional to their concentration, 
cell association is directly proportional to concentration of nanoparticles at cell surface until 
saturation is reached, and cell association with nanoparticles occurs until association capacity 
is achieved (Faria et al., 2019).  Based on these assumptions Faria et al. (2019) proposed a 
dosimetric-kinetic model for nanoparticle-cell interactions and showed a good fit between 
theoretical and experimental data when the assumption of saturation of cells with nanoparticles 
was considered for the kinetic behaviour of the nanoparticles.  Using a dosimetric-kinetic model 
the comparison of data between cell lines is possible and it was found that the choice of cell 
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line mainly influences the cell-association rate of nanoparticles rather than nanoparticle size 
(Faria et al., 2019). 
 
 The intestinal epithelium as a barrier for nanoparticle uptake 
Specialized epithelial cells, such as the intestinal epithelium, separates the internal 
contents of the human body from the environment in the lumen of the gut (Peterson and Artis, 
2014).  Epithelial cells are highly polarized cells with an apical and basolateral side and the 
cells are connected to each other by tight junctions to increase tissue integrity and for protection 
from ingested pathogens (Cartiera et al., 2009).  The intestinal epithelium consists of different 
cell types including absorptive enterocytes, mucus-producing goblet cells and M cells as part 
of Peyer-patches that have been reported to play a crucial role in the uptake of polymeric 
nanoparticles through the epithelium (Beduneau et al., 2014; Boegh et al., 2014; Caldorera-
Moore et al., 2019; Rieux et al., 2005; Tariq et al., 2015).  Caco-2 cells are well-established as 
an in vitro cell culture model for the human intestinal epithelium since this human cancer 
adenocarcinoma cell line has similarities with normal intestinal cells (Gaumet et al., 2009).  
Hildago et al. (1989) reported morphological changes and endocytic differentiation of Caco-2 
cells cultured in permeable filter inserts in in vitro cultures after 16 days.  Caco-2 cell 
monolayers are morphologically similar to the columnar epithelium found in the small intestine 
and show the formation of domes, which are described as aggregations of transporting and 
polarized epithelial cells (Hidalgo et al., 1989).  Further, tight junctions are expressed and 
localized between cells in the Caco-2 cell monolayer, and metabolic enzymes like phosphatase 
and sucrase-isomaltase are produced at bio-relevant levels (Birch et al., 2018a; Pinto et al., 
1983).  A reason for Caco-2 cells being a popular in vitro cell culture model includes the 
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simplicity of the system and culturing of the cell line in a reproducible and rapid way (Beduneau 
et al., 2014; Lea, 2015). 
 
Despite the properties of Caco-2 cells that promote their suitability as an intestinal 
epithelium cell model, there are some limitations to the use of Caco-2 cells.  Variations in 
characteristics of Caco-2 cells occur with increasing passage numbers, due to the expression of 
differentiation markers, increase in transepithelial electrical resistance (TEER) and 
proliferation rate (Lea, 2015).  Therefore, making a direct comparison of Caco-2 cell results 
obtained with earlier or later passage numbers between laboratories is difficult (Lea, 2015).  
The main limitation of Caco-2 cells as a model for the intestinal epithelium is the differentiation 
into one particular cell type, namely enterocytes, and the absence of a mucus layer on top the 
cells (Beduneau et al., 2014; Birch et al., 2018a).  Mucus mainly consists of water (95%) but 
other components including mucin, proteins and lipids (Boegh et al., 2013) are responsible for 
the intestinal mucus being a rate-limiting step for the absorption of nanoparticles after oral 
delivery (Boegh et al., 2014).  In particular, mucin, which consists of glycosylated polymeric 
proteins that form a mesh on top of epithelial cells, represents a significant barrier for the uptake 
of nanoparticles across the epithelial lining. In vitro co-culture of Caco-2 cells with HT-29 cells 
(Beduneau et al., 2014) or the addition of biosimilar mucus on the Caco-2 cell monolayer (Birch 
et al., 2018a) are strategies to overcome the limitation of the Caco-2 cell culture model lacking 
mucus.  The co-culture of Caco-2 and HT-29 cells combines absorptive enterocyte-like cells 
and mucus-secreting cells to mimic the intestinal epithelium (Fan et al., 2014).  Intestinal mucus 
is a steric barrier for the interaction and uptake of compounds like small molecules, lipophilic 
drugs, biomacromolecules and nanoparticles by the epithelium (Birch et al., 2018a; Boegh et 
al., 2014).  Biosimilar mucus has similar rheological properties compared to mucus originating 
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from pig and can be used on Caco-2 cell monolayers or alone for the evaluation of particle 
movement and mucoadhesive formulations (Birch et al., 2018a; Boegh et al., 2014). 
 
Polymeric nanoparticles can be used as a controlled release drug delivery system to 
enhance oral absorption and protect the encapsulated drug against degradation in the GIT 
(Gaumet et al., 2009).  However, to achieve high drug absorption, the designed drug delivery 
system requires a controlled burst release of the drug at the surface of the epithelium and 
constant drug release while the nanoparticles are in close proximity to the cell surface.  It has 
been suggested that nanoparticles intended for oral drug delivery need to be (i) resistant to the 
GIT environment and (ii) penetrate mucus to localize at the cell surface (Du et al., 2018; He et 
al., 2013). 
 
The uptake mechanisms proposed for nanoparticles include endocytosis via clathrin-
dependent and caveolae-dependent pathways, and macropinocytosis (Dausend et al., 2008).  
The types of endocytic pathways were described in Chapter 1.  The uptake of PLGA 
nanoparticles into Caco-2 cells is reported to occur in a concentration- and time-dependent 
manner (Alqahtani et al., 2015; Cartiera et al., 2009; He et al., 2013; Tariq et al., 2015).  For 
identification of uptake mechanisms involved in the internalization of nanoparticles, in vitro 
cell experiments can be performed at a lower temperature to distinguish between active and 
passive uptake or inhibitors can be applied prior to the nanoparticle incubation of cells (Table 
4.1).  Endocytosis is an energy-dependent uptake pathway and a decrease in temperature to 4°C 
reduces the ATP synthesis and subsequently inhibits endocytosis due to low ATP levels, which 
can hinder endocytic uptake pathways (Cartiera et al., 2009; Morimoto et al., 2016).  In the 
literature, a reduction in nanoparticle uptake is reported of up to 50% at 4°C for PLGA, CPP-
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modified PLGA and PEG-PLA nanoparticles (Liu et al., 2013; Sheng et al., 2015; Siu et al., 
2018; Win and Feng, 2005).  These reports show that endocytosis is crucial for the uptake of 
nanoparticles in in vitro cell culture systems.  The application of specific endocytosis inhibitors 
shows that clathrin- and caveolae-dependent endocytosis are the main active uptake 
mechanisms (He et al., 2013; Siu et al., 2018; Tariq et al., 2015; Xu et al., 2013a).  Further, 
macropinocytosis is also involved in nanoparticle uptake depending on the properties of the 
nanoparticles, including their size (Elsner et al., 2015; Siu et al., 2018; Zhu et al., 2016b). 
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Table 4.1.  Chemical inhibitors of in vitro uptake pathways categorized based on their influence 
on polymeric nanoparticle internalization. +, ++, and +++ represent low, medium and high 
influence on nanoparticle internalization.  
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Caco-2 + to ++ 
(Sheng et al., 2015; 
Siu et al., 2018; Tariq 
et al., 2015; Xu et al., 




Macropinocytosis Caco-2 + to ++ 
(He et al., 2013; Siu et 
al., 2018; Zhu et al., 
2016b) 
Sodium azide Active transport Caco-2 ++ 
(Sheng et al., 2015; 
Tariq et al., 2015) 
 
Uptake of nanoparticles is also influenced by their size and surface chemistry. The size 
of nanoparticles is crucial for their interactions with and adhesion to cells (Win and Feng, 2005).  
With the increase in nanoparticle size from 50 to 1000 nm lower amounts of polystyrene 
nanoparticles, expressed as fluorophore concentration (≤ 0.05 µg/µg protein), were found to be 
taken up in Caco-2 cells (Banerjee et al., 2016).  Using confocal microscopy, PLGA 
nanoparticles with a size of > 300 nm were found to be located in the cell membrane of Caco-
2 cells after 4 h, whereas smaller PLGA nanoparticles with a size of 100 nm were found in the 
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intracellular space of the cells and in the cell nucleus (Gaumet et al., 2009).  Most studies 
reported in the literature have used PLGA nanoparticles with a size between 100 and 240 nm 
for uptake studies (Cartiera et al., 2009; Czuba et al., 2018; Guo et al., 2019; Joshi et al., 2016; 
Tariq et al., 2015).  The characteristics of the nanoparticle surface, including surface charge 
and hydrophilicity, are crucial for interactions of the nanoparticles with cells leading to potential 
cellular uptake (Gaumet et al., 2009).  The uptake of PLGA nanoparticles with a slightly 
negative surface charge between -9 to -2 mV was reported to be lower in comparison to surface-
modified PLGA nanoparticles with CPPs or chitosan and a surface charge above > +8 mV 
(Alqahtani et al., 2015; Czuba et al., 2018; Sheng et al., 2015; Zhu et al., 2016a).  
 
Uptake of nanoparticles is mostly stated qualitatively by fluorescence and confocal 
images (Alqahtani et al., 2015; Cartiera et al., 2009) and quantitatively by flow cytometry or 
measurement of drug and fluorophore concentration (Czuba et al., 2018; Guo et al., 2019).  
Methods for the quantitative measurement of drug or fluorophore concentration include the 
bicinchoninic acid (BCA) assay, fluorescence and HPLC analysis and results are reported as 
the concentration of drug in cells after cell lysis (Guo et al., 2019; Sheng et al., 2015; Siu et al., 
2018).  Flow cytometry is used to analyse fluorescence within individual cells, but results are 
often reported as the mean fluorescence intensity (Czuba et al., 2018) or as a peak shift (Tariq 
et al., 2015) making comparison with other studies difficult. In general, biological materials 
such as cells are prone to show a variation in their response and to ensure comparison between 
studies, more details of protocols should be shared within the research community.  A 
standardisation as suggested by Faria et al. (2018) can aid to overcome the limited 
comparability of in vitro cell culture data. MIRIBEL, minimum information reporting in bio-
nano experimental literature, combines information about the material characteristics, 
biological characteristics and experimental protocol that will promote the four principles of 
 Chapter Four 
158 
 
reusability, quantification, practically and quality to ensure the comparison of results (Faria et 
al., 2018). 
 
 Chapter aims 
The aim of the work presented in this Chapter is to investigate the interactions between 
CPP-tagged PLGA nanoparticles and cells at the nano-bio interface.  Therefore, a fluorophore-
labelled PLGA was used for the preparation of CPP-tagged PLGA-FPR nanoparticles to enable 
the detection of the vehicle using flow cytometry and confocal laser scanning microscopy 
(CLSM).  PLGA-FPR and CPP-tagged PLGA-FPR nanoparticles were prepared using the post-
microfluidics and the in situ microfluidics conjugation approach and characterised for their 
physicochemical properties.  Nanoparticle-cell interactions of the nanoformulations prepared 
with both preparation methods were tested in HeLa cells to investigate the influence of the 
preparation method and the architecture of the CPPs on the nano-bio interface.  In order to 
evaluate the potential of the CPP-tagged PLGA-FPR nanoparticles as an oral drug delivery 
system, cell interaction of the nanoformulations with Caco-2 cells was investigated. 
  




HeLa cells (human cervical cells) were purchased from American Type Culture 
Collection (ATCC, Manassas, VA, USA) and Caco-2 cells (carcinogenic human colonic cells) 
were provided by Prof. Ian Tucker as a kind gift. Poly(lactide-co-glycolide)-FPR648 (PLGA-
FPR, 50:50, FPR648 fluorescent end-capped, MW 23,240 Da) was supplied by PolySciTech 
(West Lafayette, IN, USA).  MEM non-essential amino acids solution (NEAA, 100×, cell 
culture grade), Hanks’ Balanced salts (powder, cell culture grade), bovine serum albumin (BSA, 
≥ 98%), propidium iodide (≥ 97%), phenazine methosulfate (PMS, ≥ 90%), 
ethylenediaminetetraacetic acid (EDTA, cell culture grade) and cell culture flasks were 
purchased from Sigma-Aldrich (St. Louis, MO, USA).  Penicillin-streptomycin (10,000 
units/mL penicillin, 10 mg/mL streptomycin, cell culture grade), Hoechst 33342 (purity ≥ 99%, 
final concentration 1 mg/mL) and CellMask™ Orange plasma membrane stain (5 mg/mL in 
DMSO, final concentration 5 µg/mL) were purchased from Thermo Fisher Scientific Australia 
Pty (Scoresby, Australia).  Dulbecco’s Modified Eagle Medium, (DMEM, 4.5 g/L glucose, L-
glutamine, phenol red, cell culture grade), Dulbecco’s Phosphate Buffered Saline powder 
(DPBS, cell culture grade), Trypan Blue Stain 0.4% and TrypLE Express (no phenol red) were 
supplied by Gibco® Life Technologies (Grand Island, NE, USA).  3-(4,5-Dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and CellTiter 
96®AQueous One Solution were purchased from Promega (Madison, WI, USA).  Cover glasses 
No. 1 (circular, 13 mm) were from Lab Supply (Dunedin, New Zealand). Ibidi µ-slides were 
obtained from Ibidi (Gräfelfing, Germany).  HyClone fetal bovine serum (FBS) was sourced 
from GE Healthcare Life Sciences (Tauranga, New Zealand).  Cell culture plates and Falcon® 
cell culture inserts (0.4 µm pore size) were sourced from BD Biosciences (San Jose, CA, USA). 
Nylon syringe filters (0.45 µm) were obtained from MicroAnalytix Pty Ltd (Auckland, New 
Zealand). 
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The cell culture buffer used in this study was HBSS supplemented with 10 mM HEPES 
and 0.05 % (w/v) BSA and is referred to below as hHBSS. 
 
All other ingredients and peptides required for the preparation of the nanoformulations 
used are listed in Chapter 2. 
 
 Methods 
 Preparation of CPP-tagged PLGA-FPR nanoparticles using microfluidics 
CPP-tagged PLGA-FPR nanoparticles were prepared using the post-microfluidics and 
in situ microfluidics conjugation approach as previously described in Chapters 2 and 3 with 
some modifications.  The PLGA polymer was exchanged with the PLGA-FPR polymer, which 
is a fluorophore-labelled PLGA polymer. Further, either the NanoAssemblr® Benchtop device 
(flow rate ratio 6:1, total flow rate 10 mL/min) or NanoAsssemblr® Cartridges were used in 
combination with a syringe pump (Pump 11 Elite (Harvard Apparatus, Cambridge, MA, USA), 
flow rate ratio 6:1 and total flow rate 2.5 mL/min). 
 
 Characterization of CPP-tagged PLGA-FPR nanoparticles 
The Z-average diameter, PDI and the zeta potential of the nanoformulations were 
measured using DLS and laser Doppler electrophoresis as described in Chapter 2.  The 
nanoformulations were prepared in hHBSS or in ultra-pure water and for size and zeta potential 
measurements further diluted with ultra-pure water. 
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The conjugation efficiencies of the three CPPs on CPP-tagged PLGA-FPR 
nanoparticles prepared using the post-microfluidics and in situ microfluidics conjugation 
approach were determined using RP-HPLC. The RP-HPLC methods were described in 
Chapter 2 and samples of supernatants were filtered through a 0.45 µm nylon membrane prior 
to RP-HPLC analysis. 
 
 Culturing of HeLa and Caco-2 cells 
HeLa cells were cultured in 75 cm2 cell culture flasks with Eagle's Minimal Essential 
Medium (EMEM) supplemented with 100 IU/mL penicillin, 100 μg/mL streptomycin, 2 mM 
L-glutamine, 0.01 mM non-essential amino acids, 1 mM sodium pyruvate and 10% (v/v) FBS 
at 37°C and 5% CO2.  At a confluence of 80-90% in the culturing flasks, HeLa cells were 
detached by trypsin-EDTA treatment (5 mg/mL trypsin and 2 mg/mL EDTA in DPBS, pH 7.4) 
and seeded for subsequent experiments.  HeLa cells were seeded at a density of 
1.5×104 cells/well in 96-well plates for cell viability assay, 1.5×105 cells/well in 12-well plates 
for flow cytometry, and 4.5×105 cells/well in ibidi µ-slides for CLSM, 24 or 48 h prior to the 
experiments using passages 2 to 9. 
 
Caco-2 cells were routinely cultured in 75 cm2 cell culture flask with Dulbecco’s 
Modified Eagle Medium (DMEM) containing 4 mM L-glutamine and supplemented with 
1% (v/v) penicillin-streptomycin, 1% (v/v) non-essential amino acids and 10% (v/v) FBS at 
37°C and 5% CO2.  Caco-2 cells were weekly sub-cultured in a 1:5 ratio at a confluence of 
around 50% and monitored using an Olympus CKX41 microscope (Auckland, New Zealand) 
with phase contrast to evaluate confluence. For the cell viability assay, Caco-2 cells were seeded 
in 96-well plate at a density of 5×103 cells/well for 7-12 days until they reached confluence.  
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Caco-2 cells were seeded at a density of 1×105 cells/cm2 in Falcon® cell culture inserts 
(diameter, 0.4 µm pores) and grown for 22 days for the cell integrity study.  Caco-2 cells were 
seeded for 21 days in 12-well plates at a density of 3×104 cells/well or on cover glasses in 12-
well plates at a density of 5×103 cells/well for flow cytometry and CLSM analysis, respectively.  
The medium was replaced every two to three days and passage 59 to 73 were used for 
experiments. 
 
 Toxicity of nanoformulations in HeLa and Caco-2 cells 
HeLa cells were washed with hHBSS (pH 7.4) and incubated with 100 µL PLGA-FPR 
or CPP-tagged PLGA-FPR nanoparticles (0.09-0.90 mg/mL) and CPP solutions (1-100 µM) 
for 1 h before the test solutions were removed and HeLa cells were washed twice with hHBSS 
(pH 7.4).  Subsequently, HeLa cells were incubated with a MTS/PMS solution containing 
240 µg/mL MTS and 2.4 µg/mL PMS in hHBSS (pH 7.4) for 4 h at 37°C and 5% CO2.  
Absorbance was measured at 490 nm using microplate reader POLARstar OPTIMA (BMG 
Labtech, Ortenberg, Germany). 
 
Caco-2 cells were washed with hHBSS (pH 7.4) and incubated with 100 µL PLGA-FPR 
or CPP-tagged PLGA-FPR nanoparticles (0.07-0.72 mg/mL) and CPP solutions (0.05-20 µM) 
for 2 h.  Afterwards, the test solutions were removed and Caco-2 cells were washed twice with 
hHBSS (pH 7.4) before incubation with the CellTiter96® AQueous One Solution Reagent 
containing 90 µg/mL MTS and 4.8 µg/mL µM phenazine ethosulfate (PES) for 1 h at 37°C and 
5% CO2.  Absorbance was measured at 490 nm using the POLARstar OMEGA microplate 
reader (BMG Labtech, Ortenberg, Germany). 
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Both cell lines were treated with hHBSS (pH 7.4) only and 0.2 % (w/v) SDS in HBSS 
as negative and positive controls, respectively.  Cell viability for both cell lines was calculated 
with the absorbance of the test solutions and positive and negative controls as described in 
Equation (4-1). 
 
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =  
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒(𝑡𝑒𝑠𝑡 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛𝑠)−𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒(𝑝𝑜𝑠.  𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒(𝑛𝑒𝑔.  𝑐𝑜𝑛𝑡𝑟𝑜𝑙)−𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒(𝑝𝑜𝑠.  𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
 × 100 (4-1) 
 
 Cell integrity of Caco-2 cell monolayer 
Caco-2 cells were washed and equilibrated with hHBSS (pH 7.4) for 20 min at 37°C 
and 5% CO2 before TEER was measured using Millicell
® ERS Voltohmmeter (EMD Millipore, 
Billerica, MA, USA) with a chopstick electrode.  The reported TEER values (TEERCaco-2 cell 
monolayer) were obtained from the resistance of the tissue (Equation 4-2) and multiplication with 
the semipermeable membrane area (Equation 4-3). 
 
𝑅𝑇𝑖𝑠𝑠𝑢𝑒(Ω) =  𝑅𝐶𝑎𝑐𝑜−2 𝑚𝑜𝑛𝑜𝑙𝑎𝑦𝑒𝑟 −  𝑅𝑏𝑙𝑎𝑛𝑘 𝑖𝑛𝑠𝑒𝑟𝑡    (4-2) 
𝑇𝐸𝐸𝑅𝐶𝑎𝑐𝑜−2 cell monolayer(Ω × 𝑐𝑚
2) =  𝑅𝑇𝑖𝑠𝑠𝑢𝑒 −  𝑀𝐴𝑟𝑒𝑎    (4-3) 
 
 Uptake of nanoparticles using flow cytometry for HeLa and Caco-2 cells 
HeLa cells were washed with hHBSS (pH 7.4) and incubated with 500 µL of PLGA-
FPR or CPP-tagged PLGA-FPR nanoparticles (0.09-0.90 mg/mL) for 1 h at 37°C and 5% CO2.  
The nanoformulations were removed and the HeLa cells were washed with ice-cold DPBS (pH 
7.4).  For the trypsinization of HeLa cells, 500 µL of trypsin (0.05% (v/v) in DPBS, pH 7.4) 
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was added to the HeLa cells and incubated for 5 min at 37°C and 5% CO2.  The plate was 
slightly agitated before 800 µL complete medium (hHBSS (pH 7.4) with 10% (v/v) FBS) was 
added to terminate the trypsinization process.  HeLa cells were collected and separated by 
centrifugation at 270 g for 3 min, prior to a second wash with 400 µL ice-cold heparin (20 
µg/mL in DPBS, pH 7.4) and again separated by centrifugation as above.  Finally, HeLa cells 
were re-suspended in 500 µL complete medium and 10,000 viable cells were analysed and 
gated for forward/sideways light scattering using a Gallios Flow Cytometer (Beckman Coulter, 
Brea, CA, USA) and obtained data were analysed using FlowJo V10 analysis software (BD, 
Franklin Lakes, NJ, USA). 
 
Caco-2 cells were washed once with hHBSS (pH 7.4) and incubated with 500 µL 
PLGA-FPR or CPP-tagged PLGA-FPR nanoparticles (0.07-0.72 mg/mL) at 37°C and 5% CO2 
for 0.5, 2 and 6 h.  The nanoformulations were discarded and Caco-2 cells were washed twice 
with DPBS (pH 7.4) at room temperature.  For the trypsinization of Caco-2 cells, 400 µL 
TrypLE Express was added and incubated at 37°C and 5% CO2 for 10 min. To stop the 
trypsinization process, 1 mL of complete medium (hHBSS (pH 7.4) with 1% (v/v) FBS) was 
added.  Caco-2 cells were separated by centrifugation at 330 g for 5 min, re-suspended and 
washed with 400 µL of ice-cold DPBS (pH 7.4) containing heparin (20 µg/mL).  For the 
quantification of internalized and surface-bound nanoparticles, no heparin treatment was 
applied and Caco-2 cells were washed with of ice-cold DPBS (pH 7.4) only.  Caco-2 cells were 
separated by centrifugation as above and re-suspend with 500 µL of DPBS (pH 7.4).  Cell 
viability was evaluated by adding 5 µL of propidium iodide (0.025 mg/mL) before analysis.  
30,000 viable cells were analysed with FACS Canto™ II flow cytometry (BD Biosciences, San 
Jose, CA, USA), gated for forward/sideways light scattering and obtained data were analysed 
using FlowJo V10 analysis software. 
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 Qualitative cell uptake study using confocal laser scanning microscopy for HeLa and 
Caco-2 cells 
HeLa cells were washed with hHBSS (pH 7.4) before incubation with 200 µL of PLGA-
FPR or CPP-tagged PLGA-FPR nanoparticles (0.90 mg/mL) for 1 h.  After the incubation, 
HeLa cells were washed with hHBSS (pH 7.4) and first incubated with 2 µL of Hoechst 33342 
(1 mg/mL) in 200 µL hHBSS (pH 7.4) for 15 to 30 min at 37°C and 5% CO2 to stain the cell 
nucleus.  HeLa cells were washed with hHBSS (pH 7.4) and incubated with 1 µL of CellMask 
orange (5 µg/mL) in 200 µL hHBSS (pH 7.4) for another 15 to 30 min at 37°C and 5% CO2.  
Finally, the cells were washed again with hHBSS (pH 7.4) and live cell images were taken 
using the LSM 780 Zeiss inverted confocal microscope equipped with a 63 ×/1.4 numerical 
aperture oil medium DIC III objective (Carl Zeiss, Oberkochen, Germany). 
 
Similarly, Caco-2 cells were washed with hHBSS (pH 7.4) and incubated with 400 µL 
of PLGA-FPR or CPP-tagged PLGA-FPR (0.72 mg/mL) nanoparticles for 2 h at 37°C and 5% 
CO2.  After the incubation Caco-2 cells were washed twice with hHBSS (pH 7.4) and further 
incubated with 2 µL of Hoechst 33342 (1 mg/mL) in 500 µL hHBSS (pH 7.4) for 10 min at 
37°C and 5% CO2 to stain the cell nucleus.  Caco-2 cells were washed with hHBSS (pH 7.4) 
and incubated with 1 µL of CellMask orange (5 µg/mL) in 500 µL hHBSS (pH 7.4) for another 
10 min at 37°C and 5% CO2.  Finally, the cells were washed again with hHBSS (pH 7.4) before 
the cover glass was removed from the well with tweezers and carefully placed onto a drop of 
Fluoromount-G™ to reduce fluorescence bleaching.  Caco-2 cells were investigated using the 
Nikon A1+ Inverted Confocal Scanning Microscope equipped with a 60 ×/1.4 numerical 
aperture PlanApo oil objective (Nikon Instruments, Melville, NY, USA). 
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 Statistical analysis 
Experiments for the characterisation of the PLGA-FPR and CPP-tagged PLGA-FPR 
nanoparticles were performed at least in triplicate of independent batches and results are 
presented as mean ± SD.  In vitro cell culture experiments were performed as biological 
replicates with at least three repeats and results are presented as mean ± standard error of the 
mean (SEM).  Student’s t-test was performed to make a comparison between single groups and 
obtained p-values were considered statistically significant at p < 0.05. 
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 Results and Discussion 
 Characterization of CPP-tagged PLGA-FPR nanoparticles 
For the in vitro investigation of CPP-tagged PLGA nanoparticles, the PLGA polymer 
was replaced by a fluorescent PLGA labelled with the fluorophore FPR 648, which emits red 
fluorescence (ʎex wavelength = 648 nm, ʎem wavelength = 672 nm).  The fluorescent PLGA 
polymer is hereafter referred to as PLGA-FPR. The CPP-tagged PLGA-FPR nanoparticles were 
characterized for their physicochemical properties and conjugation efficiencies of CPPs were 
determined before investigating in vitro interactions with HeLa and Caco-2 cells. 
 
4.4.1.1 Physicochemical properties of nanoparticles in ultra-pure water 
PLGA-FPR and CPP-tagged PLGA-FPR nanoparticles were characterized in ultra-pure 
water to obtain their native size and charge.  The nanoformulations were monodisperse and 
showed a size between 140 and 180 nm for PLGA-FPR and CPP-tagged PLGA-FPR 
nanoparticles produced using the post-microfluidics or the in situ microfluidics conjugation 
approach (Table 4.2).  The surface charge of the CPP-tagged PLGA-FPR nanoparticles 
prepared with both conjugation approaches changed from a negative zeta potential of -16 mV 
to a positive zeta potential of +8 mV depending on the conjugated CPP (Table 4.2).  The 
influence of the CPP architecture on the surface charge was discussed earlier in Chapters 2 
and 3.  Fluorophore-labelled PLGA and CPP-tagged PLGA nanoparticles prepared using the 
post-microfluidics and in situ microfluidics conjugation approach had a size below 200 nm, a 
similar size distribution, and a similar zeta potential in comparison to PLGA and CPP-tagged 
PLGA nanoparticles prepared with the non-labelled PLGA polymer as a precursor material 
(Table 4.2 and Chapter 3, Figure 3.4 and Chapter 2, Figure 2.12). 
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Table 4.2.  Characterization of PLGA-FPR and CPP-tagged PLGA-FPR nanoparticles in ultra-
pure water prepared using the post-microfluidics or the in situ microfluidics conjugation 
approach.  Data are mean ± SD (n = 3). 
Nanoparticles Size ± SD (nm) PDI ± SD 
Zeta potential ± 
SD (mV) 
Post-microfluidics conjugation approach 
PLGA-FPR 176.9 ± 4.5 0.131 ± 0.013 -22.9 ± 0.9 
RRH-tagged PLGA-FPR 178.1 ± 1.2 0.130 ± 0.008 -16.3 ± 0.4 
TAT-tagged PLGA-FPR 182.5 ± 5.2 0.137 ± 0.017 -2.3 ± 1.2 
bTAT-tagged PLGA-FPR 185.1 ± 6.1 0.164 ± 0.017 8.8 ± 0.6 
In situ microfluidics conjugation approach 
PLGA-FPR 137.4 ± 16.0 0.150 ± 0.021 -13.2 ± 3.1 
RRH-tagged PLGA-FPR 139.7 ± 4.6 0.177 ± 0.032 -5.7 ± 3.2 
TAT-tagged PLGA-FPR 139.3 ± 1.2 0.172 ± 0.023 -3.1 ± 0.4 
bTAT-tagged PLGA-FPR 142.1 ± 7.2 0.161 ± 0.017 1.5 ± 0.3 
 
Further, the conjugation efficiency of each CPP was determined to estimate the amount 
of CPP covalently bound to PLGA-FPR nanoparticles formulated with the post-microfluidics 
or the in situ microfluidic conjugation approach.  Details of the conjugation reaction and 
theoretical considerations were discussed earlier in Chapters 2 and 3.  Using the fluorophore-
labelled PLGA polymer, the CPP conjugation efficiency was lower compared to the non-
labelled PLGA polymer (Table 4.3).  The conjugation efficiencies were 74%, 56% and 80% for 
the post-microfluidics conjugation approach and 91%, 29% and 85% for the in situ 
microfluidics conjugation approach using RRH, TAT and bTAT, respectively (Chapter 3, Table 
3.1 and Chapter 2, Table 2.9).  The lower conjugation efficiencies of the three CPPs can be 
attributed to the presence of the fluorescent FPR molecules, which were conjugated to the 
PLGA polymer to obtain the fluorophore-labelled PLGA polymer.  For the conjugation of the 
fluorescent dye and the CPPs, the carboxyl groups of the PLGA polymer were utilized and 
therefore a lower number of carboxyl groups remained available for conjugation of CPPs.  One 
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exception was the conjugation efficiency of TAT-tagged PLGA-FPR nanoparticles prepared 
using the in situ microfluidics conjugation approach, which showed a higher conjugation 
efficiency with the fluorophore-labelled PLGA polymer in comparison to the non-labelled 
PLGA polymer (Table 4.3 and Chapter 3, Table 3.1).  This might be related to a higher 
encapsulation of TAT, since a distinction between the encapsulated amount and the amount on 
the surface of the PLGA-FPR nanoparticles cannot be made using the RP-HPLC method to 
determine the amount of CPP. 
 
Table 4.3.  Conjugation efficiencies and the equivalent concentration of CPPs tagged to PLGA-
FPR nanoparticles using the post-microfluidics and the in situ microfluidics conjugation 
approach.  Data are mean ± SD (n = 3). 
Nanoparticles 
Conjugation efficiency ± 
SD (%) 
CPP concentration 
± SD (µM) 
Post-microfluidics conjugation approach 
RRH-tagged PLGA-FPR 8.9 ± 4.3 0.32 ± 0.15 
TAT-tagged PLGA-FPR 19.4 ± 12.4 0.14 ± 0.08 
bTAT-tagged PLGA-FPR 5.5 ± 5.1 0.02 ± 0.02 
In situ microfluidics conjugation approach 
RRH-tagged PLGA-FPR 9.4 ± 4.8 0.62 ± 0.31 
TAT-tagged PLGA-FPR 47.3 ± 7.0 0.36 ± 0.05 
bTAT-tagged PLGA-FPR 11.7 ± 6.9 0.05 ± 0.03 
 
 
4.4.1.2 Physicochemical properties of nanoparticles in cell culture buffer 
For the in vitro investigation of PLGA-FPR and CPP-tagged PLGA-FPR nanoparticles 
in cell culture systems, nanoformulations formulated with both preparation methods were re-
suspended in cell culture buffer to maintain physiological conditions for the cells during 
incubation.  The size of PLGA-FPR and CPP-tagged PLGA-FPR nanoparticles in cell culture 
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buffer was found to be between 175 and 245 nm with a PDI below 0.250 indicating that the 
nanoformulations were monodisperse (Table 4.4 and Table 4.5).  Similarly, the size and surface 
charge of OVA-loaded chitosan nanoparticles was influenced by their suspension in HBSS in 
comparison to ultra-pure water with a size increase from 126 to 196 nm and a decrease in the 
surface charge from +38 to +10 mV when HBSS was the suspending media (Cole et al., 2018).  
Here, the surface charge of the nanoformulations was between -8 and -2 mV, which showed the 
influence of the cell culture buffer (hHBBS) (Table 4.4 and Table 4.5).  Due to the presence of 
salts and proteins in the cell culture buffer, it is likely that an electrostatic reaction between the 
positively charged CPPs and negatively charged ions leads to the formation of a salt/protein 
corona around the nanoparticles and an increase in the hydrodynamic diameter.  In addition, it 
is likely that the salts and proteins present in the cell culture buffer also influenced the surface 
charge of the CPP-tagged PLGA-FPR nanoparticles and therefore positive charged induced by 
CPP architecture were shielded and did not contribute to the overall surface charge.  Since the 
zeta potential for all formulations was similar, the surface charge as a factor for enhancing 
cellular uptake of nanoparticles could be excluded and any difference in cellular uptake can be 
related to the CPP architecture used for the conjugation with PLGA-FPR nanoparticles. 
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Table 4.4.  Characterization of PLGA-FPR and CPP-tagged PLGA-FPR nanoparticles in cell 
culture buffer for in vitro studies in HeLa cells prepared using the post-microfluidics and the in 
situ microfluidics conjugation approach.  Data are mean ± SD (n = 6). 
Nanoparticles Size ± SD (nm) PDI ± SD 
Zeta potential ± 
SD (mV) 
Post-microfluidics conjugation approach 
PLGA-FPR 204.3 ± 10.6 0.165 ± 0.032 -8.2 ± 0.7 
RRH-tagged PLGA-FPR 210.2 ± 5.8 0.176 ± 0.037 -8.1 ± 0.6 
TAT-tagged PLGA-FPR 213.6 ± 3.0 0.151 ± 0.044 -3.5 ± 0.5 
bTAT-tagged PLGA-FPR 210.7 ± 12.4 0.169 ± 0.006 -3.2 ± 1.2 
In situ microfluidics conjugation approach 
PLGA-FPR 216.9 ± 15.2 0.194 ± 0.073 -5.3 ± 2.2 
RRH-tagged PLGA-FPR 241.8 ± 15.3 0.253 ± 0.028 -6.6 ± 1.9 
TAT-tagged PLGA-FPR 245.4 ± 6.7 0.238 ± 0.018 -5.0 ± 0.4 
bTAT-tagged PLGA-FPR 240.5 ± 30.8 0.236 ± 0.064 -4.6 ± 1.2 
 
 
Table 4.5.  Characterization of PLGA-FPR and CPP-tagged PLGA-FPR nanoparticles in cell 
culture buffer for in vitro studies in Caco-2 cells prepared using the post-microfluidics 
conjugation approach.  Data are mean ± SD (n = 6). 
Nanoparticles Size ± SD (nm) PDI ± SD 
Zeta potential ± 
SD (mV) 
Post-microfluidics conjugation approach 
PLGA-FPR 175.4 ± 7.2 0.165 ± 0.037 -4.0 ± 1.0 
RRH-tagged PLGA-FPR 176.6 ± 4.6 0.164 ± 0.022 -3.8 ± 2.2 
TAT-tagged PLGA-FPR 185.1 ± 10.1 0.199 ± 0.054 -2.0 ± 1.2 
bTAT-tagged PLGA-FPR 194.4 ± 14.1 0.234 ± 0.065 -4.1 ± 2.8 
 
 
 Chapter Four 
172 
 
 Interaction of nanoformulations with HeLa cells 
The interactions between CPP-tagged PLGA-FPR nanoparticles and the nano-bio 
interface of cells were first investigated with HeLa cells. For the in vitro cell experiments with 
HeLa cells, PLGA-FPR and CPP-tagged PLGA-FPR nanoparticles were prepared using the 
post-microfluidics or the in situ microfluidics conjugation approach.  The CPPs used in the 
study are described by their distinct architecture including a short (RRH), a long linear (TAT) 
and a branched peptide sequence (bTAT) (Chapter 2, Figure 2.5). 
 
4.4.2.1 Cell viability of HeLa cells 
The effect of nanoformulations on the cell viability of HeLa cells was investigated using 
the MTS assay.  The MTS assay is an end-point assay for the determination of viable cells and 
utilizes an electron transfer reaction from the electron coupling reagent (PMS or PES) to the 
tetrazolium salt (MTS) (Jacobsen et al., 1996).  The electron transfer can only occur if viable 
cells are present and the absorbance of the resulting coloured formazan product can be directly 
related to the viability of the cells (Cory et al., 1991).  Cell viability of HeLa cells was 
investigated after incubation with PLGA-FPR and CPP-tagged PLGA-FPR nanoparticles for 
1 h (Figure 4.2A and B).  The nanoformulations were tested at three different concentrations 
and the negative control was set to 100% as indicated by the black line in the cell viability 
graphs (Figure 4.2).  HeLa cells were viable after incubation with PLGA-FPR and CPP-tagged 
PLGA-FPR nanoparticles, indicating that the nanoformulations in different concentrations had 
no toxic effect on the cells.  As reported in the literature, unmodified PLGA nanoparticles with 
concentrations between 0.625 and 2.5 mg/mL were non-toxic to HeLa cells after 48 h of 
incubation (Egusquiaguirre et al., 2015).  In contrast, a decrease in cell viability of HeLa cells 
incubated with PLGA nanoparticles for 48 h to below 70% was reported at a concentration 
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of ≥ 0.2 mg/mL (Chen et al., 2017a).  In the present study, the nanoparticle concentrations 
ranged between 0.09 and 0.9 mg/mL for PLGA-FPR nanoparticles and did not show a negative 
influence on cell viability.  An influence on the cell viability was not expected since the PLGA 
polymer is biocompatible and no toxicity was induced by the fluorescent label of the PLGA 
polymer.  RRH-tagged PLGA-FPR nanoparticles formulated with both preparation methods 
showed a decrease in cell viability to 84%, which was lower, compared to other CPP-tagged 
PLGA-FPR nanoparticles, but the cell viability was acceptable for using a concentration of 0.90 
mg/mL in further in vitro experiments.  CPP-modified PLGA nanoparticles (0.625-2.5 mg/mL) 
were reported to maintain moderate viability levels in HeLa cells and cell viability decreased 
with higher concentrations of nanoparticles administered (Egusquiaguirre et al., 2015).  Feiner-
Gracia et al. (2018) found a reduction in cell viability to about 60% when TAT-modified 
nanoparticles were used in a concentration of 3 mg/mL in comparison to 0.3 mg/mL after 24 h 
incubation in HeLa cells and the toxicity was attributed to the positive charges of TAT-modified 
PLGA nanoparticles.  Further, HeLa cells were incubated with five different concentrations of 
the three CPPs, RRH, TAT and bTAT, ranging from 1 to 100 µM. For all concentrations, HeLa 
cells showed a cell viability of above 91% indicating that the CPPs were non-toxic (Figure 
4.2C).  This is in alignment with a study by Trehin et al. (2004) that showed that TAT (47-57) 
was non-toxic to lung cancer (Calu-3 cells) and buccal mucosa cells (TR146) at concentrations 
between 10 and 100 µM. 
 




Figure 4.2.  Cell viability of HeLa cells after 1 h incubation with PLGA-FPR and CPP-tagged 
PLGA-FPR nanoparticles prepared using the post-microfluidics (A) or in situ microfluidics (B) 
conjugation approach and CPP solutions with different concentrations (C).  The black line 
indicates 100% as negative control.  Data are means ± SEM (n = 3). NPs = nanoparticles. 
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4.4.2.2 Quantification of cellular uptake of nanoparticles in HeLa cells 
Flow cytometry was used to quantify the cellular uptake of PLGA-FPR and CPP-tagged 
PLGA-FPR nanoparticles prepared using the post-microfluidics and the in situ microfluidics 
conjugation approach in HeLa cells (Figure 4.3).  By using flow cytometry analysis, individual 
cells are analysed for their fluorescence intensity using forward/sideward light scattering.  Flow 
cytometry analysis revealed that the mean fluorescence intensity of HeLa cells incubated with 
PLGA-FPR and CPP-tagged PLGA-FPR nanoparticles was similar to the control, HeLa cells 
incubated with cell culture buffer, or approximately up to 1.7-fold higher.  The low increase in 
fluorescence intensity between control cells and HeLa cells treated with nanoformulations 
indicates a low internalization efficiency of the nanoformulations (Figure 4.3).  PLGA-FPR and 
CPP-tagged PLGA-FPR nanoparticles were applied to HeLa cells in different concentrations 
ranging between 0.05 and 0.90 mg/mL, but a concentration-dependent uptake of the 
nanoformulations was not observed.  Further, higher cellular uptake was expected for the 
branched CPP bTAT, but this was not observed. Arginine-rich dendrimers based on TAT 
showed 10-15 times higher fluorescence after incubation with HeLa cells for 1 h in comparison 
to the linear TAT (Eggimann et al., 2014).  The addition of the branched CPP to a polymeric 
carrier might influence the penetration abilities of the branched CPP as in the literature, uptake 
of sequence-modified CPPs were reported for the CPPs only (Brock et al., 2018; Hoyer et al., 
2012; Zhao et al., 2014a).  One exception was the TAT-tagged PLGA-FPR nanoparticles 
prepared with the post-microfluidics conjugation approach, which showed a 1.8 and 1.6-fold 
higher uptake in comparison to PLGA-FPR nanoparticles when a concentration of 0.90 mg/mL 
or the 1:2 dilution of that concentration was used, respectively (Figure 4.3A).  The increase in 
uptake was significant for the 1:2 dilution in comparison to the PLGA-FPR nanoparticles. HeLa 
cells were washed with heparin to remove membrane-associated nanoformulations (Iwasa et 
al., 2006; Patel et al., 2019) and therefore a contribution of membrane-associated nanoparticles 
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to the fluorescence intensity was unlikely.  Spider silk protein nanoparticles modified with TAT 
or R8 and with a size below 300 nm showed that after incubation for 24 or 48 h up to 60% of 
cultured HeLa cells contained nanoparticles (Elsner et al., 2015).  Cellular uptake of 
lyophilisomes, hollow micro- or nano-meter capsules made of albumin, with a size below 1 µm 
was investigated with flow cytometry and trypan blue was used to quench the fluorescence of 
membrane-associated lyophilisomes (van Bracht et al., 2014).  Double the amount of 
lyophilisome positive cells in the HeLa cell population were observed over 4 h for TAT-
conjugated lyophilisomes in comparison to unmodified lyophilisomes (van Bracht et al., 2014).  
These two studies claim that HeLa cells were able to take up nanoparticles with a size > 200 
nm as fluorescence was tested with flow cytometry after trypan blue treatment (Elsner et al., 
2015; van Bracht et al., 2014).  The main difference to the present study was the time selected 
for the incubation with HeLa cells.  The literature reports suggest that longer incubation times 
between 4 to 48 h may be required for the efficient internalization of CPP-tagged PLGA-FPR 
nanoparticles in HeLa cells.  In the present study, a shorter incubation time of 1 h was selected 
to investigate the likelihood of the initial contact between the CPPs with different architectures 
and the cells.  Further, the internalization of CPP solutions including penetratin and branched 
peptides is reported in the literature after 1 h in HeLa cells (Birch et al., 2017; Monreal et al., 
2015; Saleh et al., 2010) indicating that cell interactions occur within a short time. 
 




Figure 4.3.  Fluorescence intensity measured in HeLa cells after 1 h incubation with different 
dilutions of PLGA-FPR and CPP-tagged PLGA-FPR nanoparticles prepared using the post-
microfluidics (A) or the in situ microfluidics (B) conjugation approach.  Control cells were 
incubated with cell culture buffer.  Data are means ± SEM (n = 3).  * p-value < 0.05 for 
comparison between PLGA-FPR and TAT-tagged PLGA-FPR nanoparticles. NPs = 
nanoparticles. 
 
4.4.2.3 Qualification of cellular uptake of nanoparticles in HeLa cells 
For qualitative microscopic analysis, HeLa cells were incubated with PLGA-FPR and 
CPP-tagged PLGA-FPR nanoparticles prepared using the post-microfluidics or the in situ 
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microfluidics conjugation approach.  In order to observe the HeLa cells under the microscope, 
the cell nucleus was stained with Hoechst 33342 and the cell membrane was stained with 
CellMask™ Orange plasma membrane stain appearing in blue and green, respectively. 
 
Confocal images showed association of the PLGA-FPR and CPP-tagged PLGA-FPR 
nanoparticles to the cell membrane of HeLa cells after incubation for 1 h.  This observation was 
made for nanoparticles prepared using the post-microfluidics (Figure 4.4) and the in situ 
microfluidics conjugation approach (Figure 4.5).  A study by Chen et al. (2017a) showed 
overlapping fluorescence of doxorubicin-loaded PLGA-PEG-folic acid nanoparticles with the 
nucleus after 4 and 24 h of incubation indicating that a longer incubation time was needed for 
the uptake of polymeric nanoparticles in HeLa cells.  No difference in cellular interactions of 
PLGA-FPR nanoparticles tagged with the three CPPs: RRH, TAT and bTAT nor a difference 
between preparation methods was observed.  For example, confocal images of TAT-tagged 
PLGA-FPR nanoparticles prepared using the post-microfluidics and the in situ microfluidics 
conjugation approach showed a similar even distribution of the nanoparticles and association 
of the nanoparticles with the cell membrane of HeLa cells (Figure 4.4C and Figure 4.5C).  The 
larger cluster of TAT-tagged PLGA-FPR nanoparticles prepared using the in situ microfluidics 
conjugation can be related to aggregation of the nanoparticles (Figure 4.4C).  Improvement of 
internalization was reported in the literature for PLGA nanoparticles modified with 
fluorophore-labelled CPPs at a concentration of 5 mg/mL after incubation in HeLa cells for 4 
to 72 h, whereas no efficient internalization of PLGA nanoparticles on their own was observed 
(Egusquiaguirre et al., 2015).  Another study also observed uptake after incubation in HeLa 
cells for 4 h with TAT-modified lyophilisomes in comparison to unmodified lyophilisomes (van 
Bracht et al., 2014).  As for PLGA-FPR nanoparticles, the incubation time is crucial for CPP-
modified nanoparticles to show efficient uptake into HeLa cells. 
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Figure 4.4.  Confocal images of HeLa cells incubated for 1 h with PLGA-FPR (A), RRH- (B), 
TAT- (C) and bTAT-tagged PLGA-FPR nanoparticles (D) prepared using the post-
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Figure 4.5.  Confocal images of HeLa cells incubated for 1 h with PLGA-FPR (A), RRH- (B), 
TAT- (C) and bTAT-tagged PLGA-FPR nanoparticles (D) prepared using the in situ 
microfluidics conjugation approach. 
 
As observed from the confocal images for PLGA-FPR and CPP-tagged PLGA-FPR 
nanoparticles, the cell membrane appeared intact after incubation with the nanoformulations.  
Further, as red fluorescence can be observed between the HeLa cells, an interaction of PLGA-
FPR or CPP-tagged PLGA-FPR nanoparticles with the coating of the cell culture µ-slides 
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cannot be excluded.  The µ-slides were coated with collagen IV displaying a neutral charge at 
physiological pH and HeLa cells were not confluent leaving space between them and the 
possibility of interactions between the nanoformulations and the coating. 
 
 Interaction of nanoformulations with Caco-2 cells 
Caco-2 cell monolayers are frequently used as a model for the intestinal epithelium and 
the cell line was selected to evaluate the potential of CPP-tagged PLGA-FPR nanoparticles as 
an oral drug delivery system.  Based on the similar results obtained with HeLa cells for PLGA-
FPR and CPP-tagged PLGA-FPR nanoparticles prepared using both conjugation approaches, 
further experiments were performed with CPP-tagged PLGA-FPR nanoparticles prepared using 
the post-microfluidics conjugation approach only.  The CPPs are present on the surface of 
PLGA-FPR nanoparticles after post-microfluidics conjugation (Streck et al., 2019b) and 
therefore interactions between CPPs and the cell surface are more likely.  The in situ 
microfluidics conjugation approach also encapsulates the CPPs, which cannot contribute to cell 
interactions.  In this thesis, Caco-2 cells were grown as cell monolayers and for analysis of cell 
viability and uptake of nanoparticles with CLSM an intact cell monolayer was used, whereas 
for analysis of uptake using flow cytometry the cell monolayer was suspended into single cells. 
 
4.4.3.1 Cell viability and cell integrity of Caco-2 cells 
The influence of PLGA-FPR and CPP-tagged PLGA-FPR nanoparticles on the viability 
of Caco-2 cells was evaluated after incubation for 2 h (Figure 4.6).  The PLGA-FPR and CPP-
tagged PLGA nanoparticles were non-toxic to Caco-2 cells and the cell viability was above 
90%.  Previous studies reported that surface-modified and drug-loaded PLGA nanoparticles 
were non-toxic to Caco-2 cells at concentrations between 2 mg/mL to 5 mg/well after 
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incubation for 2-4 h (Czuba et al., 2018; Sheng et al., 2016).  TAT- and R8-modified PLGA 
and R8-modified PLGA-PEG nanoparticles showed cell viability above 80% after 2-6 h 
incubation in Caco-2 cells (Liu et al., 2013; Zhu et al., 2016a).  Further, CPP solutions with 
concentrations ranging between 0.05 and 20 µM were non-toxic to Caco-2 cells and showed a 
cell viability of around 100% (Figure 4.6B).  In the present study, no toxicity of the CPPs was 
found and the concentrations used were lower compared to the concentration used in HeLa cells 
(Section 4.4.2.1) and in other cell lines as described in the literature (Section 4.4.2.1). 
 




Figure 4.6.  Cell viability graphs of Caco-2 cells after 2 h incubation with PLGA-FPR and 
CPP-tagged PLGA-FPR nanoparticles prepared using the post-microfluidics conjugation 
approach (A) and CPP solutions with different concentrations (B).  The black line indicates 
100% as negative control.  Data are means ± SEM (n = 3).  NPs = nanoparticles. 
 
The TEER value is the main measurement of epithelial integrity and primarily reflects 
the tightness of the tight junctions between cells (Mukherjee et al., 2004).  During the culturing 
of Caco-2 cells on permeable filter inserts, the TEER value increases as the cells grow into a 
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monolayer (Mukherjee et al., 2004).  The TEER value of the Caco-2 cell monolayer was 
monitored between day 17 and day 22 after seeding the Caco-2 cells on cell culture inserts with 
a permeable membrane and a TEERCaco-2 cell monolayer value of 352 Ω×cm
2 was reached by day 
20 showing the presence of a tight cell monolayer (Appendix VI).  Minimum TEER values 
between 200 and 450 Ω×cm2 have been reported in the literature as a threshold for a Caco-2 
cell monolayer to be used as a model for intestinal epithelium (Banerjee et al., 2016; Beduneau 
et al., 2014; Birch et al., 2018a; Faralli et al., 2019; Mu et al., 2019). 
 
4.4.3.2 Quantification of cellular uptake of nanoparticles in Caco-2 cells 
The cellular uptake of PLGA-FPR and CPP-tagged PLGA-FPR nanoparticles was 
measured at different time points to investigate the time-dependent behaviour of the 
nanoformulations with Caco-2 cells.  Before flow cytometry analysis, the Caco-2 cells were 
washed with heparin to remove any membrane-associated nanoformulations (Iwasa et al., 2006; 
Patel et al., 2019).  The cellular uptake of the nanoformulations was expressed as percentage 
fluorescence and was found to be between 2.5 to 5% after 2 h incubation (Figure 4.7A).  PLGA-
FPR nanoparticles showed the highest uptake into Caco-2 cells, but without being significantly 
different from the uptake of the CPP-tagged PLGA nanoparticles.  After 6 h incubation, there 
was no increase in cellular uptake, indicating that a longer incubation time was not necessarily 
beneficial for the uptake of nanoformulations into Caco-2 cells (Figure 4.7A).  Overall, the 
findings showed very low uptake of the PLGA-FPR and CPP-tagged PLGA-FPR nanoparticles 
in Caco-2 cells.  Reports from the literature showed internalisation due to the increase or shift 
of mean fluorescence intensity of PLGA nanoparticles in Caco-2 cells in comparison to control 
formulations or dye solutions after incubation times between 1 and 4 h (Czuba et al., 2018; 
Joshi et al., 2016).  CPP-modified proliposomes, reconstituted from dry liposomal formulations 
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before use, showed an initial higher uptake at 2 h, but at a time point of 4 h the mean 
fluorescence intensity for different proliposome formulations, with and without CPPs showed 
similar levels (Tunsirikongkon et al., 2019).  The study was performed with individual Caco-2 
cells that were allowed to adhere overnight and mean fluorescence intensity of control cells 
without treatment for comparison was not reported. 
 
The cell viability of Caco-2 cells was assessed over the time of the kinetic experiment 
using propidium iodide.  The Caco-2 cells were viable and no toxicity was induced by the 
nanoformulations over the incubation period of 6 h (Figure 4.7B).  Propidium iodide is taken 
up by dead cells and intercalates with DNA resulting in a red fluorescence and detection of 
propidium iodide-positive cell with flow cytometry indicates toxicity (Totterman et al., 1997). 
 




Figure 4.7.  Uptake of PLGA-FPR and CPP-tagged PLGA-FPR nanoparticles prepared using 
the post-microfluidics conjugation approach in Caco-2 cells after incubation for different time 
points (0.5, 2 and 6 h) (A) and cell viability assessed with propidium iodide staining (B).  Data 
are means ± SEM (n = 3).  NPs = nanoparticles. 
 
Possible reasons for the low uptake found in the present study can be related to the Caco-
2 cells and to the used nanoformulations.  The Caco-2 cells were grown as a monolayer for 21 
days before the quantitative and qualitative uptake experiments to generate cells that represent 
similar characteristics to the intestinal epithelium.  With longer culturing times (> 14 days) the 
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Caco-2 cell monolayer represents a tight barrier due to fully developed tight junctions and 
internalisation of nanoparticles less favourable.  Further, the conjugation efficiencies of the 
CPPs using the post-microfluidics conjugation approach were below 20% and therefore, the 
amount of CPP present might have been too low to enhance interactions with the cell surface. 
 
In the literature, evidence of cellular uptake is found for unmodified and surface-
modified nanoparticles including polymeric nanoparticles and liposomal formulations (Czuba 
et al., 2018; Joshi et al., 2016; Tunsirikongkon et al., 2019), but transport across epithelia is 
often reported to be low.  Reasons for low transport include possible exocytosis of nanoparticles 
towards the apical and basolateral side of the Caco-2 cell monolayer after internalization and 
during incubation for longer time points (Zhuang et al., 2018).  Also, the culturing times for 
Caco-2 cells used for uptake studies vary greatly between 24 h (Joshi et al., 2016; 
Tunsirikongkon et al., 2019) and 14 and 21 days (Czuba et al., 2018; Zhuang et al., 2018) of 
culturing, making the comparison of results difficult. 
 
Since the ability of CPP-tagged PLGA-FPR nanoparticles to penetrate into Caco-2 cell 
monolayers was low, an association of the CPP-tagged PLGA-FPR nanoparticles was 
investigated.  Flow cytometry data presented in Figure 4.8 shows the percent uptake of 
nanoformulations into Caco-2 cells after the cells were treated with heparin during sample 
preparation for the removal of membrane-associated nanoparticles.  In order to discriminate 
between uptake and membrane-associated nanoparticles, a heparin treatment can be applied to 
cells (Iwasa et al., 2006; Patel et al., 2019).  For evaluating the relative amount of membrane-
associated nanoformulations, Caco-2 cells were incubated for 2 h with PLGA-FPR and CPP-
tagged PLGA-FPR nanoparticles and analysed without heparin treatment.  The comparison 
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between heparin treatment and no heparin treatment indicated that the amount of membrane-
associated nanoformulation was low since the uptake, including membrane-associated 
nanoformulations, remained below 10% without heparin treatment (Figure 4.8).  There was a 
2 and 2.5-fold increase in percent uptake for PLGA-FPR and bTAT-tagged PLGA-FPR 
nanoparticles, respectively, when no heparin treatment was applied.  The percent uptake for 
RRH- and TAT-tagged PLGA-FPR nanoparticles showed no difference between heparin 
treatment and no heparin treatment.  Overall, this indicates that the increase in apparent uptake 
is related to the membrane-associated nanoparticles, which could be taken up into cells with 
longer incubation times. 
 
 
Figure 4.8.  Comparison of uptake of PLGA-FPR and CPP-tagged PLGA-FPR nanoparticles 
after heparin treatment and no heparin treatment in Caco-2 cells after incubation for 2 h. Cells 
were either washed with heparin (20 µg/mL in DPBS, pH 7.4) or washed with DPBS (pH 7.4) 
without heparin. Data are means ± SEM (n = 3).  * p-value < 0.05 for comparison between 
samples prepared with or without heparin treatment.  NPs = nanoparticles. 
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4.4.3.3 Qualification of cellular uptake in Caco-2 cells 
CLSM was applied for the qualitative assessment of the cellular uptake of PLGA-FPR 
and CPP-tagged PLGA-FPR nanoparticles in Caco-2 cells.  In order to observe the Caco-2 cell 
monolayer under the microscope, the cell nucleus and the cell membrane were stained as 
described for HeLa cells.  After incubation of the Caco-2 cell monolayer with PLGA-FPR 
nanoparticles, a red fluorescence of PLGA-FPR nanoparticles was observed within the 
monolayer (Figure 4.9A).  TAT-tagged PLGA-FPR nanoparticles showed some red 
fluorescence in the Caco-2 cell monolayer indicating little uptake of the nanoparticles (Figure 
4.9C).  Uptake studies of nanoparticles containing PLGA are well-reported in the literature. A 
study by Cartiera et al. (2009) found that uptake of rhodamine-loaded PLGA nanoparticles with 
a size below 100 nm was low and after 24 h of incubation, an association to the Caco-2 cell 
monolayer with an age between 14 to 21 days was observed.  Further, PLGA nanoparticles 
were found to accumulate in the cell cytoplasm and nucleus of Caco-2 cells (Win and Feng, 
2005) and the observed fluorescence intensity was time- and concentration-dependent (He et 
al., 2013; Joshi et al., 2016; Katsikari et al., 2009).  Other studies using confocal microscopy 
showed that positively charged, lipid-modified PLA-PEG nanoparticles had a better uptake 
after 0.5 h incubation in Caco-2 cells compared to neutral and negatively charged lipid-modified 
PLA-PEG nanoparticles (Du et al., 2018).  Also, chitosan-coated PLGA nanoparticles with a 
positive surface charge showed stronger fluorescence than uncoated nanoparticles after 2 h 
incubation in Caco-2 cell monolayer (Sheng et al., 2015).  Uptake studies with CPP-modified 
nanoparticles showed stronger fluorescence of TAT- and R8-modified nanoparticles in 
comparison to unmodified nanoparticles after incubation with Caco-2 cells for 1 h to 4 h (Chen 
et al., 2017b; Koch et al., 2005; Tunsirikongkon et al., 2019; Zhu et al., 2016a).  In contrast to 
the literature, in this study very little evidence was found that PLGA-FPR and TAT-tagged 
PLGA-FPR nanoparticles are taken up by Caco-2 cells.  
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Figure 4.9.  Representative confocal images of Caco-2 cell monolayer incubated for 2 h with 
PLGA-FPR (A), RRH- (B), TAT- (C) and bTAT-tagged PLGA-FPR nanoparticles (D) 
prepared using the post-microfluidics conjugation approach.  The white arrow is pointing 
towards red fluorescence of PLGA-FPR nanoparticles or CPP-tagged PLGA-FPR 
nanoparticles. 
 
In contrast to TAT-tagged PLGA-FPR nanoparticles, no uptake of RRH- and bTAT-
tagged PLGA-FPR nanoparticles was observed within the Caco-2 cell monolayer (Figure 4.9B 
and D).  To further evaluate the localization of the CPP-tagged PLGA-FPR nanoparticles z-
stack images of Caco-2 cells were taken. The red fluorescence related to the CPP-tagged PLGA-
FPR nanoparticles was observed towards the top layer of the Caco-2 cell monolayer indicating 
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an association with the cell membrane (Appendix VII).  This association might be rather weak 
since little red fluorescence was seen. A difference in the behaviour of the CPP-tagged PLGA-
FPR nanoparticles depending on the CPP architecture was not observed (Figure 4.9B, C and 
D).  The confocal images of the Caco-2 cell monolayer showed the integrity of the cell 
membrane after incubation with the nanoformulations. 
 
As discussed earlier, a comparison between the results published in the literature and 
results presented in this thesis is difficult as culturing times and analysis protocols vary greatly.  
In the literature, Caco-2 cells were of different ages (Cartiera et al., 2009; Katsikari et al., 2009; 
Sheng et al., 2015; Tunsirikongkon et al., 2019; Win and Feng, 2005), had a confluence of 70-
85% (Cartiera et al., 2009; Chen et al., 2017b; Du et al., 2018; He et al., 2013; Joshi et al., 
2016), were fixed during sample preparation and either cell nucleus or cell membrane were 
stained (Cartiera et al., 2009; Joshi et al., 2016; Katsikari et al., 2009; Koch et al., 2005; Sheng 
et al., 2015).  In the present study, Caco-2 cells were cultured for 21 days to obtain a tight 
monolayer comparable with the small intestine.  Culturing times of Caco-2 cells in literature 
are often less than 21 days and therefore no tight Caco-2 cell monolayer has developed and 
nanoparticles can penetrate easier into cells.  In addition, the Caco-2 cells in the present study 
were not fixed to avoid artefacts introduced by the fixation process and cell compartments such 
as cell nucleus and membrane were stained to distinguish between the compartments.  In 
particular, the age of Caco-2 cells has an influence on cellular uptake and the observation of no 
uptake might be related to the tight monolayer formed after 21 days. 
 
The observation of no uptake for CPP-tagged PLGA nanoparticles in Caco-2 cells can 
also be related to little interaction between the CPPs and cells and a low concentration of CPP-
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tagged PLGA-FPR nanoparticles reaching the cell surface.  As discussed earlier, the amount of 
CPPs on PLGA-FPR nanoparticles was below 20% and in order to increase the amount of CPP, 
the fluorophore-labelled PLGA polymer can be spiked with non-labelled PLGA polymer.  The 
addition of non-labelled PLGA will increase the amount of available carboxyl groups used for 
the conjugation of CPPs and thus the concentration of CPPs on the polymeric nanoparticles can 
be increased.  Further, calculations to estimate the delivered dose can be applied to optimise the 
amount of nanoparticles that are actually reaching the cell surface. Increasing the nanoparticle 




The physiochemical characteristics of CPP-tagged PLGA-FPR nanoparticles were 
controlled by the CPP architecture as previously observed for non-fluorescent PLGA.  
Changing the media from ultra-pure water to cell culture buffer resulted in larger PLGA-FPR 
and CPP-tagged PLGA-FPR nanoparticles (up to 250 nm) with a slightly negative surface 
charge.  Further, the conjugation efficiency of CPPs to the fluorophore-labelled PLGA was low 
as binding sites for CPP conjugation were partly occupied by the fluorophore.  The PLGA-FPR 
and CPP-tagged PLGA-FPR were non-toxic to HeLa and Caco-2 cells and showed low uptake 
in both HeLa cells and Caco-2 cells.  An influence of CPP architecture on the uptake of CPP-
tagged PLGA-FPR nanoparticles was not found, but CPP-tagged PLGA-FPR nanoparticles 
prepared using the post-microfluidics conjugation approach showed a slightly higher uptake in 
HeLa in comparison to CPP-tagged PLGA-FPR nanoparticles prepared using the in situ 
microfluidics conjugation approach.  There was a trend for increased uptake in Caco-2 cells 
with longer incubations time of the nanoformulations.  The low cellular uptake observed with 
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flow cytometry was supported by the confocal images for the nanoformulations in both cell 
lines.  In addition, the confocal images indicated an association rather than uptake of the PLGA-
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 Introduction and general summary 
Nanoparticulate drug delivery systems are of great interest to assist in the treatment of 
a range of different diseases that require biomacromolecules, such as proteins and peptides, as 
the therapeutic agent.  Efficient delivery of drugs in nanoparticles after oral administration 
depends on the ability of the nanoparticles to shield and deliver the drug to the site of action.  
Encapsulation of biomacromolecules in nanoparticles protects the fragile drug against the harsh 
environment in the GIT following oral ingestion.  One strategy to enhance nanoparticle-cell 
interactions after oral administration is the surface modification of polymeric nanoparticles with 
cell-penetrating peptides (CPPs) to increase interaction of the delivery system with the intestinal 
epithelium.  Cellular internalisation of nanoparticles decorated with CPPs, such as TAT, is 
reported in the literature (Feiner-Gracia et al., 2018; van Bracht et al., 2014), however the 
surface modification of polymeric nanoparticles with CPPs of different architectures has not 
yet been explored.  In this thesis, the hypothesis is that the CPP architecture influences 
nanoparticle-cell interactions and therefore novel surface-modified polymeric nanoparticles 
were designed as an oral drug delivery system to test this hypothesis.  PLGA nanoparticles were 
surface-modified with CPPs of different architectures and the physicochemical properties of 
CPP-tagged PLGA nanoparticles were tuned by using CPPs of different architectures (Chapters 
2 and 3).  The distribution of CPPs on PLGA nanoparticles depends on the conjugation 
approach used for the preparation of CPP-tagged PLGA nanoparticles (Chapter 3).  Association 
instead of uptake was found as between CPP-tagged PLGA nanoparticles and two different cell 
lines in in vitro cell culture studies (Chapter 4).  The in vitro study with Caco-2 cells was used 
to evaluate the nanoparticle-cell interactions using a cell culture model representing the human 
intestinal epithelium.  The in vitro study indicated association of the CPP-tagged PLGA 
nanoparticles with the cell membrane, in particular of nanoparticles surface-modified with the 
branched CPP.  The observed nanoparticle-cell interactions represent the initial step before 
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internalisation of nanoparticles into Caco-2 cells.  The presented results are valuable for a better 
understanding of nanoparticle-cell interactions of CPP-tagged PLGA nanoparticles utilizing the 
oral route of administration.  Therefore, the title displays the crucial parts of the thesis including 
CPPs, the use of nanoformulations and the aim of oral administration in a broad context.  The 
present Chapter firstly discusses the relevance of the results obtained in each Chapter in a 
broader context and then gives future direction for the further development of the 
nanoformulations. 
 
 Application of research in the wider research area 
Surface modification of nanoparticles is a prudent approach to increase interactions 
between nanoparticles and the epithelium in the small intestine.  Generally, nanoparticles are 
surface-modified to increase blood circulation time and avoid opsonisation by macrophages 
(Partikel et al., 2019), for the targeting of specific cell-receptors on the cell surface 
(Bartheldyova et al., 2018) and to introduce positive charges on the nanoparticle surface 
(Feiner-Gracia et al., 2018).  For these purposes, specific groups such as PEG, receptor-specific 
ligands and CPPs can be used, respectively. In this thesis, three CPPs with a distinct architecture 
were used namely the short RRH, the long linear TAT and the branched TAT (Chapter 2).  The 
results presented in Chapter 2 show that after surface modification with CPPs, the surface of 
PLGA nanoparticles was tuned from slightly negative to slightly positive values depending on 
the CPP architecture.  Of particular interest was the suitability of the branched CPP for surface 
modification of polymeric nanoparticles.  To the best of my knowledge branched CPPs has not 
yet been conjugated to polymeric nanoparticles before.  Further, modifications of the CPP 
sequence have been of great interest and an increase in positive charges in the CPP sequence 
was reported to enhance cellular uptake (Brock et al., 2018).  In this thesis, the novel branched 
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CPP, bTAT, was designed based on the known peptides TAT and RRH.  As demonstrated in 
Chapter 2, the branched CPP can be conjugated to polymeric nanoparticles, demonstrating that 
surface decoration of nanoparticles with ligands of complex shape and architecture is feasible.  
Surface-modification of nanoparticles with complex ligands might be beneficial to increase cell 
interactions and improve the efficiency of drug delivery systems.  In addition, the branched 
architecture of the CPP sequence is considered to cover more surface area of the cell as the 
amino acids in the branches can reach over a wider area and can potentially enhance interactions 
between CPP-tagged PLGA nanoparticles and cells. 
 
The use of CPPs for the surface modification of polymeric nanoparticles results in a 
tuneability of the surface charge of polymeric nanoparticles.  Further, the use of covalent bonds 
between the polymeric nanoparticles and the CPPs leads to well-defined systems in comparison 
to non-covalent bound CPPs as the amount of CPPs on covalent modified nanoparticles can be 
quantified and optimised.  Pre- and post-conjugation approaches are well-described in the 
literature and require either the synthesis of polymer-ligand conjugates before formulation of 
nanoparticles or the performance of a conjugation reaction after formulation of nanoparticles 
(Kamaly et al., 2016; Valencia et al., 2013).  In this thesis, the preparation of surface-modified 
polymeric nanoparticles using the in situ microfluidics conjugation approach was described for 
the first time.  The in situ conjugation approach aims to utilize the benefits of microfluidics 
such as a rapid and controlled mixing of precursor materials for the formulation of surface-
modified nanoparticles.  The preparation time of the CPP-tagged PLGA nanoparticles was 
greatly reduced, as the post-microfluidics conjugation approach takes 2 days due to an overnight 
incubation, whereas the in situ microfluidics conjugation approach takes only 3 to 4 hours 
(Chapter 3).  The innovative approach of gold labelling and the application of small angle X-
ray scattering in this thesis proofed evidence that the CPP distribution depended on the 
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preparation method.  Therefore, the in situ microfluidic conjugation approach is a time efficient 
and well-characterised approach that can be applied to the surface-modification of other 
nanoparticulate systems e.g. liposomes. 
 
Following formulation, in vitro cell culture studies can elucidate nanoparticle-cell 
interactions to collect information about toxicity, cell response and efficacy of drug delivery.  
The testing of nanoparticles in different cell lines allows the identification of cell-specific 
interactions.  HeLa cells are a well-known cell line for the investigation of cell interactions and 
uptake of CPPs, whereas Caco-2 cells are an in vitro model for the intestinal barrier offering 
the possibility to evaluate the suitability of nanoparticles as oral drug delivery systems.  The 
initial contact between CPP-tagged PLGA nanoparticles and HeLa cells did not result in an 
efficient internalization of nanoformulations, which might be related to the limited incubation 
time of 1 h (Chapter 4).  The analysis of CPP-tagged PLGA nanoparticles exposed to Caco-2 
cells for different time points showed an association to the epithelial cells rather than 
localisation of the nanoformulations within cells in the Caco-2 cell monolayer (Chapter 4).  A 
slight advantage of the nanoformulations prepared with the branched CPP was observed in 
Caco-2 cells indicating the potential of the branched CPP to be further investigated for oral drug 
delivery systems. 
 
The minimal observed interactions observed between the CPP-tagged PLGA 
nanoparticles and HeLa or Caco-2 cells might be due to method-related limitations.  As with 
most in vitro cell culture studies described in the literature, the in vitro cell culture studies in 
this thesis were performed in multiwell plates and this set up might not sufficiently represent 
the environment of the human GIT.  As an example, a lack of similarity between the small 
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intestine and in vitro cell culture model relates to a difference in cell structure and 
differentiation, cell organisation, exposed surface area and flow conditions (Beduneau et al., 
2014; Guo et al., 2000; Wang et al., 2018).  Further, when using multiwell plates, washing steps 
are compulsory for analysis and detachment of cells from the wells is thus possible. The forces 
used in these washing steps might be stronger compared to the flow of fluids in vivo resulting 
in the removal of non-tightly bound nanoparticles, which could have taken up by the cells 
eventually in an in vivo situation. 
 
Formulation related-limitations identified in in vitro cell culture studies performed in 
this thesis were associated with the influence of the cell culture buffer on the measured surface 
charge of the CPP-tagged PLGA nanoparticles.  Independent of the surface modification with 
CPPs of different architecture or no surface modification, the nanoformulations displayed net 
zeta potentials close to neutral.  To achieve cellular uptake, negatively charged nanoparticles 
have to overcome an electrostatic repulsion barrier due to the same charge of nanoparticles and 
cells.  This repulsion barrier is less difficult to overcome for slightly negatively charged 
nanoparticles (Reix et al., 2012) and net neutral nanoparticles.  Thus, the low interaction of the 
overall net neutral CPP-tagged PLGA nanoparticles presented in Chapter 4 might arise from 
formulation- and method-related limitations. 
 
 Future direction: Defining the surface of nanoparticles 
Future direction should be aimed at specific improvements for the formulation of 
nanoparticles and analytical methods to overcome the described formulation- and method-
related limitations.  In order to improve the functionality of the CPP-tagged PLGA 
nanoparticles presented in this study, the surface coverage of the PLGA nanoparticles with 
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CPPs and the CPP orientation can be optimised.  The used CPPs, in particular, the long linear 
TAT and the branched TAT, have multiple primary amines in their sequence and binding to the 
surface of PLGA nanoparticles can occur in multiple directions.  Without controlling the 
orientation of the CPPs on the nanoparticle surface, the surface coverage is non-uniform and 
this results in variation of how individual CPP molecules are present on the PLGA nanoparticle 
surface.  To achieve uniform coverage of the surface of PLGA nanoparticles with CPPs, 
protective groups could be added to the CPPs prior to the conjugation reaction.  The addition 
of protective groups limits the amount of available primary amines in the CPP sequence and 
facilitates the arrangement of the CPPs in a defined orientation on the surface of PLGA 
nanoparticles.  It should be noted that the protection groups have to be removed before the 
nanoformulations can be used for further studies.  Application of this approach results in 
specific amino acid sequences pointing towards the cell membrane to trigger nanoparticle-cell 
interaction.  The targeting-specificity of modified nanoparticles is increased with the 
conjugation of the sdAb protein to the nanoparticle surface if the protein remains in its native 
structure and the orientation of the protein favours interaction with the targeted receptors (Yong 
et al., 2019). 
 
A recent advance in the area of surface modification for nanoparticles is the use of 
crystal structure to identify protein binding sites and the binding of proteins to the surface of 
nanoparticles utilizing chemical modification and reactions to achieve a desired surface 
orientation (Yong et al., 2019).  An example of innovative surface modifications is molecular 
imprinting for the design of polymeric nanoparticles with receptor specific ligands.  The 
principle behind molecular imprinting is that functionalized monomers polymerize with cross-
linkers around a template molecule e.g. a cell ligand (Chen et al., 2016).  After removing the 
template, the formulated nanoparticles include the shape and size of the ligands, which are 
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embedded in the rigid polymer (Gagliardi et al., 2017).  An example for molecular imprinting 
of polymeric nanoparticles was shown by Gagliardi et al. (2017).  They imprinted PLGA 
nanoparticles towards the biotin-receptor, which is overexpressed on cancer cells.  The analysis 
of HeLa cells showed an increase in fluorescence for molecular imprinted PLGA nanoparticles 
in comparison to control nanoparticles over 30 min indicating the receptor-mediated uptake of 
the biotin imprinted PLGA nanoparticles (Gagliardi et al., 2017). 
 
Work extending from this thesis can aim to optimise the conjugation reaction between 
polymer and ligand within the microfluidics channel for the formulation of surface-modified 
nanoparticles.  This could be investigated using techniques such as microfluidic-small angle 
neutron scattering.  To enable real time neutron scattering, the microfluidic device needs to 
fulfil certain requirements including high transmission for neutrons, low background scattering 
and little neutron-induced radioactivity (Adamo et al., 2018; Lopez et al., 2015).  With the 
introduction of the microchannel into the scattering beam, the kinetics of in situ microfluidic 
conjugation reactions can be followed and used for an optimisation of the process-related 
parameters.  Further, the in situ microfluidics conjugation approach is of interest for the 
potential encapsulation of protein drugs, as surface modification should be avoided after protein 
encapsulation to prevent unwanted release (Zhu et al., 2016b).  Generally, a bulk surface 
modification approach after preparation of nanoparticles is a time-intensive process and 
nanoparticles are exposed to buffered solutions.  A possible issue is that degradation of the 
nanoparticles and unwanted release of encapsulated drug can occur due to the exposure of the 
nanoparticles to a buffer with reagents and pH necessary to maintain ideal conditions for the 
conjugation reaction, but not ideal for the storage of nanoparticles.  Thus, for drug-loaded 
nanoparticles, simultaneous drug-loading and surface modification is advantageous to ensure 
the retention of the drug within the nanoparticles until use. 
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 Future direction: Elucidating nanoparticle-cell interactions 
Future experiments to improve current cell culture methods can be facilitated by both, 
microscopic techniques and microfluidic-based cell experiments.  Static and dynamic changes 
in the membrane of live cells can be monitored with scanning ion conductance microscopy 
(Chen et al., 2019a).  Topographical changes in the cell membrane can be recorded after 
incubation with nanoparticles (Chen et al., 2019a) to elucidate interactions between 
nanoparticles and cells.  To explore details of interactions between individual nanoparticles and 
cells, the technique of single particle tracking can be utilized.  The mobility of fluorophore-
labelled nanoparticles is tracked using an optical microscope to generate a trajectory of the 
nanoparticle mobility as a function of time and space (Manzo and Garcia-Parajo, 2015).  
Tracking individual nanoparticles aids in understanding the physical behaviour of nanoparticles 
including sedimentation and diffusion during incubation with cells. Luo et al. (2019a) showed 
that internalisation of CPP-modified semiconductive polymer dots in HeLa cells occurred in 
three stages, namely the movement of nanoparticles towards the cell membrane, crossing of 
cell membrane and movement of the nanoparticles within the cytosol.  Single particle tracking 
is a promising technique and can be exploited in future studies to gain more insight into how 
the architecture of CPPs influences interactions with cells.  The main advantage of single 
particle tracking over other methods such as confocal laser scanning microscopy is that the 
dynamics of the interactions between nanoparticles and cells are captured.  Traditional static 
images of nanoparticles and cells are not able to visualise the movement of nanoparticles during 
incubation, which generates useful information about the timeframe and kind of interactions.  
Lastly, microfluidic devices can be fabricated to accommodate a membrane within the 
microchannel to accommodate a Caco-2 cell monolayer, which is surrounded by media flowing 
on the apical and basolateral side (Tan et al., 2018).  In this modified microfluidic device, drug 
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transport studies can be tested under flow conditions with similar fluid shear stresses found in 
the human gut (Tan et al., 2018) making the results more biologically-relevant. 
 
Future in vitro experiments looking at the kinetics of interaction over a longer time 
period may profit from taking the delivered dose of nanoparticles into consideration to ensure 
that nanoparticles reach the cell surface and interactions between surface ligands such as CPPs 
and cells can occur.  The design of future experiments is recommended to follow the guidelines 
for minimum information reporting in bio-nano experimental literature (MIRIBEL) to obtain 
results that are based on standardised protocols and easily comparable with other studies 
following the guidelines.  Further, an underestimation of interactions between CPP-tagged 
PLGA nanoparticles and cells due to the analytical methods is possible and therefore, the 
utilization of microfluidics for uptake studies and visualization of nanoparticle-cell interactions 
with single particle tracking in future studies has the potential to add crucial information. 
 
In conclusion, this thesis demonstrates that polymeric nanoparticles can be modified 
with CPPs of different architecture to tune the surface characteristics of PLGA nanoparticles.  
Microfluidics has been shown for the first time to be suitable for the conjugation of CPPs to the 
PLGA polymer and the formation of surface-modified polymeric nanoparticles.  The well-
characterised nanoformulations presented in this thesis can be further exploited to elucidate 
interactions at the nano-bio interface that govern cellular interactions and therefore the efficacy 






Abouelmagd, S.A., Ku, Y.J., Yeo, Y., 2015. Low molecular weight chitosan-coated polymeric 
nanoparticles for sustained and pH-sensitive delivery of paclitaxel. Journal of Drug 
Targeting, 23 (7-8), 725-35. 
Adamo, M., Poulos, A.S., G. Lopez, C., Martel, A., Porcar, L., Cabral, J.T., 2018. Droplet 
microfluidic SANS. Soft Matter, 14 (10), 1759-70. 
Aebi, U., Pollard, T.D., 1987. A glow discharge unit to render electron microscope grids and 
other surfaces hydrophilic. Journal of Electron Microscopy Technique, 7 (1), 29-33. 
Ahmad Khanbeigi, R., Kumar, A., Sadouki, F., Lorenz, C., Forbes, B., Dailey, L.A., Collins, 
H., 2012. The delivered dose: Applying particokinetics to in vitro investigations of 
nanoparticle internalization by macrophages. Journal of Controlled Release, 162 (2), 
259-66. 
Alexander-Bryant, A.A., Vanden Berg-Foels, W.S., Wen, X., 2013. Bioengineering strategies 
for designing targeted cancer therapies. Advances in Cancer Research, 118, 1-59. 
Allemann, E., Leroux, J.C., Gurny, R., Doelker, E., 1993. In vitro extended-release properties 
of drug-loaded poly(DL-lactic acid) nanoparticles produced by a salting-out procedure. 
Pharmaceutical Research, 10 (12), 1732-7. 
Alqahtani, S., Simon, L., Astete, C.E., Alayoubi, A., Sylvester, P.W., Nazzal, S., Shen, Y., Xu, 
Z., Kaddoumi, A., Sabliov, C.M., 2015. Cellular uptake, antioxidant and 
antiproliferative activity of entrapped alpha-tocopherol and gamma-tocotrienol in poly 
(lactic-co-glycolic) acid (PLGA) and chitosan covered PLGA nanoparticles (PLGA-
Chi). Journal of Colloid and Interface Science, 445, 243-51. 
Alves, I.D., Goasdoue, N., Correia, I., Aubry, S., Galanth, C., Sagan, S., Lavielle, S., Chassaing, 
G., 2008. Membrane interaction and perturbation mechanisms induced by two cationic 
cell penetrating peptides with distinct charge distribution. Biochimica et Biophysica 
Acta, 1780 (7-8), 948-59. 
Amoura, M., Illien, F., Joliot, A., Guitot, K., Offer, J., Sagan, S., Burlina, F., 2019. Head to tail 
cyclisation of cell-penetrating peptides: Impact on GAG-dependent internalisation and 
direct translocation. Chemical Communications, 55 (31), 4566-69. 
Amoyav, B., Benny, O., 2018. Controlled and tunable polymer particles’ production using a 
single microfluidic device. Applied Nanoscience, 8 (4), 905-14. 
Angeles-Boza, A.M., Erazo-Oliveras, A., Lee, Y.J., Pellois, J.P., 2010. Generation of 
endosomolytic reagents by branching of cell-penetrating peptides: Tools for the delivery 
of bioactive compounds to live cells in cis or trans. Bioconjugate Chemistry, 21 (12), 
2164-7. 
Arshad, A., Yang, B., Bienemann, A.S., Barua, N.U., Wyatt, M.J., Woolley, M., Johnson, D.E., 
Edler, K.J., Gill, S.S., 2015. Convection-enhanced delivery of carboplatin PLGA 
nanoparticles for the treatment of glioblastoma. PLoS One, 10 (7), e0132266. 
Augsten, C., Kiselev, M.A., Gehrke, R., Hause, G., Mäder, K., 2008. A detailed analysis of 
biodegradable nanospheres by different techniques--a combined approach to detect 
particle sizes and size distributions. Journal of Pharmaceutical and Biomedical 
Analysis, 47 (1), 95-102. 
Avgoustakis, K., 2008. Poly lactide-co-glycolic acid (PLGA), in: Mishra, M. (Ed.), 
Encyclopedia of Biomaterials and Biomedical Engineering, 1st ed. Taylor & Francis pp. 
2259-69. 
Babos, G., Biró, E., Meiczinger, M., Feczkó, T., 2018. Dual drug delivery of sorafenib and 





Baby, T., Liu, Y., Middelberg, A.P.J., Zhao, C.-X., 2017. Fundamental studies on throughput 
capacities of hydrodynamic flow-focusing microfluidics for producing monodisperse 
polymer nanoparticles. Chemical Engineering Science, 169, 128-39. 
Bahnsen, J.S., Franzyk, H., Sandberg-Schaal, A., Nielsen, H.M., 2013. Antimicrobial and cell-
penetrating properties of penetratin analogs: Effect of sequence and secondary structure. 
Biochimica et Biophysica Acta, 1828 (2), 223-32. 
Bailey, B.A., Desai, K.H., Ochyl, L.J., Ciotti, S.M., Moon, J.J., Schwendeman, S.P., 2017. Self-
encapsulating poly(lactic-co-glycolic acid) (PLGA) microspheres for intranasal vaccine 
delivery. Molecular Pharmaceutics, 14 (9), 3228-37. 
Bairagi, U., Mittal, P., Singh, J., Mishra, B., 2018. Preparation, characterization, and in vivo 
evaluation of nano formulations of ferulic acid in diabetic wound healing. Drug 
Development and Industrial Pharmacy, 44 (11), 1783-96. 
Banerjee, A., Qi, J., Gogoi, R., Wong, J., Mitragotri, S., 2016. Role of nanoparticle size, shape 
and surface chemistry in oral drug delivery. Journal of Controlled Release, 238, 176-85. 
Banik, B.L., Fattahi, P., Brown, J.L., 2016. Polymeric nanoparticles: The future of 
nanomedicine. Wiley Interdisciplinary Reviews: Nanomedicine and 
Nanobiotechnology, 8 (2), 271-99. 
Barreto-Vieira, D.F., Barth, O.M., 2015. Negative and positive staining in transmission electron 
microscopy for virus diagnosis, in: Maitama, Y. (Ed.), Microbiology in Agriculture and 
Human Health, 1st ed. Intech, pp. 45-56. 
Bartczak, D., Kanaras, A.G., 2011. Preparation of peptide-functionalized gold nanoparticles 
using one pot EDC/sulfo-NHS coupling. Langmuir, 27 (16), 10119-23. 
Bartheldyova, E., Effenberg, R., Masek, J., Prochazka, L., Knotigova, P.T., Kulich, P., 
Hubatka, F., Velinska, K., Zelnickova, J., Zouharova, D., Fojtikova, M., Hrebik, D., 
Plevka, P., Mikulik, R., Miller, A.D., Macaulay, S., Zyka, D., Droz, L., Raska, M., 
Ledvina, M., Turanek, J., 2018. Hyaluronic acid surface modified liposomes prepared 
via orthogonal aminoxy coupling: Synthesis of nontoxic aminoxylipids based on 
symmetrically alpha-branched fatty acids, preparation of liposomes by microfluidic 
mixing, and targeting to cancer cells expressing CD44. Bioconjugate Chemistry, 29 (7), 
2343-56. 
Beduneau, A., Tempesta, C., Fimbel, S., Pellequer, Y., Jannin, V., Demarne, F., Lamprecht, A., 
2014. A tunable Caco-2/HT29-MTX co-culture model mimicking variable 
permeabilities of the human intestine obtained by an original seeding procedure. 
European Journal of Pharmaceutics and Biopharmaceutics, 87 (2), 290-8. 
Belliveau, N.M., Huft, J., Lin, P.J., Chen, S., Leung, A.K., Leaver, T.J., Wild, A.W., Lee, J.B., 
Taylor, R.J., Tam, Y.K., Hansen, C.L., Cullis, P.R., 2012. Microfluidic synthesis of 
highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Molecular 
Therapy Nucleic Acids, 1, e37. 
Bilati, U., Pasquarello, C., Corthals, G.L., Hochstrasser, D.F., Allemann, E., Doelker, E., 2005. 
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for 
quantitation and molecular stability assessment of insulin entrapped within PLGA 
nanoparticles. Journal of Pharmaceutical Sciences, 94 (3), 688-94. 
Binder, H., Lindblom, G., 2003. Charge-dependent translocation of the Trojan peptide 
penetratin across lipid membranes. Biophysical Journal, 85 (2), 982-95. 
Birch, D., Christensen, M.V., Staerk, D., Franzyk, H., Nielsen, H.M., 2017. Fluorophore 
labeling of a cell-penetrating peptide induces differential effects on its cellular 
distribution and affects cell viability. Biochimica et Biophysica Acta (BBA) - 




Birch, D., Diedrichsen, R.G., Christophersen, P.C., Mu, H., Nielsen, H.M., 2018a. Evaluation 
of drug permeation under fed state conditions using mucus-covered Caco-2 cell 
epithelium. European Journal of Pharmaceutical Sciences, 118, 144-53. 
Birch, D., Christensen, M.V., Staerk, D., Franzyk, H., Nielsen, H.M., 2018b. Stereochemistry 
as a determining factor for the effect of a cell-penetrating peptide on cellular viability 
and epithelial integrity. Biochemical Journal, 475 (10), 1773-88. 
Bobo, D., Robinson, K.J., Islam, J., Thurecht, K.J., Corrie, S.R., 2016. Nanoparticle-based 
medicines: A review of FDA-approved materials and clinical trials to date. 
Pharmaceutical Research, 33 (10), 2373-87. 
Boegh, M., Foged, C., Müllertz, A., Nielsen, H.M., 2013. Mucosal drug delivery: Barriers, in 
vitro models and formulation strategies. Journal of Drug Delivery Science and 
Technology, 23 (4), 383-91. 
Boegh, M., Baldursdottir, S.G., Müllertz, A., Nielsen, H.M., 2014. Property profiling of 
biosimilar mucus in a novel mucus-containing in vitro model for assessment of 
intestinal drug absorption. European Journal of Pharmaceutics and Biopharmaceutics, 
87 (2), 227-35. 
Bohrey, S., Chourasiya, V., Pandey, A., 2016. Factorial design based preparation, optimization, 
characterization and in vitro drug release studies of olanzapine loaded PLGA 
nanoparticles. Materials Research Express, 3 (12), 125403. 
Bootz, A., Vogel, V., Schubert, D., Kreuter, J., 2004. Comparison of scanning electron 
microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing of 
poly(butyl cyanoacrylate) nanoparticles. European Journal of Pharmaceutics and 
Biopharmaceutics, 57 (2), 369-75. 
Borrelli, A., Tornesello, A.L., Tornesello, M.L., Buonaguro, F.M., 2018. Cell penetrating 
peptides as molecular carriers for anti-cancer agents. Molecules, 23 (2). 
Bourganis, V., Karamanidou, T., Kammona, O., Kiparissides, C., 2017. Polyelectrolyte 
complexes as prospective carriers for the oral delivery of protein therapeutics. European 
Journal of Pharmaceutics and Biopharmaceutics, 111, 44-60. 
Boyd, B.J., Rades, T., 2016. Applications of small angle X-ray scattering in pharmaceutical 
science, in: Müllertz, A., Perrie, Y., Rades, T. (Eds.), Analytical techniques in the 
pharmaceutical sciences. Springer, pp. 339-60. 
Bozkir, A., Saka, O.M., 2005. Formulation and investigation of 5-FU nanoparticles with 
factorial design-based studies. Il Farmaco, 60 (10), 840-46. 
Bramosanti, M., Chronopoulou, L., Grillo, F., Valletta, A., Palocci, C., 2017. Microfluidic-
assisted nanoprecipitation of antiviral-loaded polymeric nanoparticles. Colloids and 
Surfaces A: Physicochemical and Engineering Aspects, 532, 369-76. 
Brar, S.K., Verma, M., 2011. Measurement of nanoparticles by light-scattering techniques. 
TrAC Trends in Analytical Chemistry, 30 (1), 4-17. 
Brock, D.J., Kustigian, L., Jiang, M., Graham, K., Wang, T.Y., Erazo-Oliveras, A., Najjar, K., 
Zhang, J., Rye, H., Pellois, J.P., 2018. Efficient cell delivery mediated by lipid-specific 
endosomal escape of supercharged branched peptides. Traffic, 19 (6), 421-35. 
Brock, R., 2014. The uptake of arginine-rich cell-penetrating peptides: Putting the puzzle 
together. Bioconjugate Chemistry, 25 (5), 863-8. 
Bu, X., Zhu, T., Ma, Y., Shen, Q., 2015. Co-administration with cell penetrating peptide 
enhances the oral bioavailability of docetaxel-loaded nanoparticles. Drug Development 
and Industrial Pharmacy, 41 (5), 764-71. 
Cai, H., Liang, Z., Huang, W., Wen, L., Chen, G., 2017. Engineering PLGA nano-based 
systems through understanding the influence of nanoparticle properties and cell-
penetrating peptides for cochlear drug delivery. International Journal of Pharmaceutics, 




Caldero, G., Garcia-Celma, M.J., Solans, C., 2011. Formation of polymeric nano-emulsions by 
a low-energy method and their use for nanoparticle preparation. Journal of Colloid and 
Interface Science, 353 (2), 406-11. 
Caldorera-Moore, M., Vela Ramirez, J.E., Peppas, N.A., 2019. Transport and delivery of 
interferon-alpha through epithelial tight junctions via pH-responsive poly(methacrylic 
acid-grafted-ethylene glycol) nanoparticles. Journal of Drug Targeting, 27 (5-6), 582-
89. 
Capretto, L., Mazzitelli, S., Brognara, E., Lampronti, I., Carugo, D., Hill, M., Zhang, X., 
Gambari, R., Nastruzzi, C., 2012. Mithramycin encapsulated in polymeric micelles by 
microfluidic technology as novel therapeutic protocol for beta-thalassemia. 
International Journal of Nanomedicine, 7, 307-24. 
Capretto, L., Carugo, D., Mazzitelli, S., Nastruzzi, C., Zhang, X., 2013. Microfluidic and lab-
on-a-chip preparation routes for organic nanoparticles and vesicular systems for 
nanomedicine applications. Advanced Drug Delivery Reviews, 65 (11), 1496-532. 
Cardoso, A.M.S., Trabulo, S., Cardoso, A.L., Lorents, A., Morais, C.M., Gomes, P., Nunes, C., 
Lúcio, M., Reis, S., Padari, K., Pooga, M., Pedroso de Lima, M.C., Jurado, A.S., 2012. 
S4(13)-PV cell-penetrating peptide induces physical and morphological changes in 
membrane-mimetic lipid systems and cell membranes: Implications for cell 
internalization. Biochimica et Biophysica Acta, 1818 (3), 877-88. 
Cartiera, M.S., Johnson, K.M., Rajendran, V., Caplan, M.J., Saltzman, W.M., 2009. The uptake 
and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials, 30 (14), 
2790-8. 
Chelopo, M.P., Kalombo, L., Wesley-Smith, J., Grobler, A., Hayeshi, R., 2016. The fabrication 
and characterization of a PLGA nanoparticle–Pheroid® combined drug delivery 
system. Journal of Materials Science, 52 (6), 3133-45. 
Chen, F., Manandhar, P., Ahmed, M.S., Chang, S., Panday, N., Zhang, H., Moon, J.H., He, J., 
2019a. Extracellular surface potential mapping by scanning ion conductance 
microscopy revealed transient transmembrane pore formation induced by conjugated 
polymer nanoparticles. Macromolecular Bioscience, 19 (2), e1800271. 
Chen, J., Wu, Q., Luo, L., Wang, Y., Zhong, Y., Dai, H.B., Sun, D., Luo, M.L., Wu, W., Wang, 
G.X., 2017a. Dual tumor-targeted poly(lactic-co-glycolic acid)-polyethylene glycol-
folic acid nanoparticles: A novel biodegradable nanocarrier for secure and efficient 
antitumor drug delivery. International Journal of Nanomedicine, 12, 5745-60. 
Chen, L., Wang, X., Lu, W., Wu, X., Li, J., 2016. Molecular imprinting: Perspectives and 
applications. Chemical Society Reviews, 45 (8), 2137-211. 
Chen, Q., Gou, S., Ma, P., Song, H., Zhou, X., Huang, Y., Kwon Han, M., Wan, Y., Kang, Y., 
Xiao, B., 2019b. Oral administration of colitis tissue-accumulating porous nanoparticles 
for ulcerative colitis therapy. International Journal of Pharmaceutics, 557, 135-44. 
Chen, S., Guo, F., Deng, T., Zhu, S., Liu, W., Zhong, H., Yu, H., Luo, R., Deng, Z., 2017b. 
Eudragit S100-coated chitosan nanoparticles co-loading Tat for enhanced oral colon 
absorption of insulin. AAPS PharmSciTech, 18 (4), 1277-87. 
Chiesa, E., Dorati, R., Modena, T., Conti, B., Genta, I., 2018. Multivariate analysis for the 
optimization of microfluidics-assisted nanoprecipitation method intended for the 
loading of small hydrophilic drugs into PLGA nanoparticles. International Journal of 
Pharmaceutics, 536 (1), 165-77. 
Chiu, J.Z., Tucker, I.G., McLeod, B.J., McDowell, A., 2015. Arginine-tagging of polymeric 
nanoparticles via histidine to improve cellular uptake. European Journal of 
Pharmaceutics and Biopharmaceutics, 89, 48-55. 
Clara-Rahola, J., Moscoso, A., Belén Ruiz-Muelle, A., Laurenti, M., Formanek, P., Lopez-




R., 2018. Au@p4VP core@shell pH-sensitive nanocomposites suitable for drug 
entrapment. Journal of Colloid and Interface Science, 514, 704-14. 
Clayton, A.H.A., Atcliffe, B.W., Howlett, G.J., Sawyer, W.H., 2006. Conformation and 
orientation of penetratin in phospholipid membranes. Journal of Peptide Science, 12 (3), 
233-38. 
Clulow, A.J., Salim, M., Hawley, A., Boyd, B.J., 2018. A closer look at the behaviour of milk 
lipids during digestion. Chemistry and Physics of Lipids, 211, 107-16. 
Cole, H., Bryan, D., Lancaster, L., Mawas, F., Vllasaliu, D., 2018. Chitosan nanoparticle 
antigen uptake in epithelial monolayers can predict mucosal but not systemic in vivo 
immune response by oral delivery. Carbohydrate Polymers, 190, 248-54. 
Connolly, M., 1983. Solvent-accessible surfaces of proteins and nucleic acids. Science, 221 
(4612), 709-13. 
Coolen, A.L., Lacroix, C., Mercier-Gouy, P., Delaune, E., Monge, C., Exposito, J.Y., Verrier, 
B., 2019. Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-
based vaccine expression in dendritic cells triggering their activation. Biomaterials, 195, 
23-37. 
Cory, A.H., Owen, T.C., Barltrop, J.A., Cory, J.G., 1991. Use of an aqueous soluble 
tetrazolium/formazan assay for cell growth assays in culture. Cancer Communications, 
3 (7), 207-12. 
Cox, A., Vinciguerra, D., Re, F., Magro, R.D., Mura, S., Masserini, M., Couvreur, P., Nicolas, 
J., 2019. Protein-functionalized nanoparticles derived from end-functional polymers 
and polymer prodrugs for crossing the blood-brain barrier. European Journal of 
Pharmaceutics and Biopharmaceutics, 142, 70-82. 
Crucho, C.I.C., Barros, M.T., 2017. Polymeric nanoparticles: A study on the preparation 
variables and characterization methods. Materials Science and Engineering: C Materials 
for Biological Applications, 80, 771-84. 
Czuba, E., Diop, M., Mura, C., Schaschkow, A., Langlois, A., Bietiger, W., Neidl, R., Virciglio, 
A., Auberval, N., Julien-David, D., Maillard, E., Frere, Y., Marchioni, E., Pinget, M., 
Sigrist, S., 2018. Oral insulin delivery, the challenge to increase insulin bioavailability: 
Influence of surface charge in nanoparticle system. International Journal of 
Pharmaceutics, 542 (1-2), 47-55. 
Danhier, F., Ansorena, E., Silva, J.M., Coco, R., Le Breton, A., Preat, V., 2012. PLGA-based 
nanoparticles: An overview of biomedical applications. Journal of Controlled Release, 
161 (2), 505-22. 
Date, A.A., Hanes, J., Ensign, L.M., 2016. Nanoparticles for oral delivery: Design, evaluation 
and state-of-the-art. Journal of Controlled Release, 240, 504-26. 
Dausend, J., Musyanovych, A., Dass, M., Walther, P., Schrezenmeier, H., Landfester, K., 
Mailander, V., 2008. Uptake mechanism of oppositely charged fluorescent 
nanoparticles in HeLa cells. Macromolecular Bioscience, 8 (12), 1135-43. 
de Jonge, N., Ross, F.M., 2011. Electron microscopy of specimens in liquid. Nature 
Nanotechnology, 6, 695-704. 
Derakhshandeh, K., Erfan, M., Dadashzadeh, S., 2007. Encapsulation of 9-nitrocamptothecin, 
a novel anticancer drug, in biodegradable nanoparticles: Factorial design, 
characterization and release kinetics. European Journal of Pharmaceutics and 
Biopharmaceutics, 66 (1), 34-41. 
Derossi, D., Calvet, S., Trembleau, A., Brunissen, A., Chassaing, G., Prochiantz, A., 1996. Cell 
internalization of the third helix of the Antennapedia homeodomain is receptor-




Desgouilles, S., Vauthier, C., Bazile, D., Vacus, J., Grossiord, J.-L., Veillard, M., Couvreur, P., 
2003. The design of nanoparticles obtained by solvent evaporation:  A comprehensive 
study. Langmuir, 19 (22), 9504-10. 
Di Cola, E., Grillo, I., Ristori, S., 2016. Small angle X-ray and neutron scattering: Powerful 
tools for studying the structure of drug-loaded liposomes. Pharmaceutics, 8 (2). 
Dong, Y.D., Tchung, E., Nowell, C., Kaga, S., Leong, N., Mehta, D., Kaminskas, L.M., Boyd, 
B.J., 2019. Microfluidic preparation of drug-loaded PEGylated liposomes, and the 
impact of liposome size on tumour retention and penetration. Journal of Liposome 
Research, 29 (1), 1-9. 
Donno, R., Gennari, A., Lallana, E., De La Rosa, J.M.R., d’Arcy, R., Treacher, K., Hill, K., 
Ashford, M., Tirelli, N., 2017. Nanomanufacturing through microfluidic-assisted 
nanoprecipitation: Advanced analytics and structure-activity relationships. International 
Journal of Pharmaceutics, 534 (1), 97-107. 
Draheim, C., de Crecy, F., Hansen, S., Collnot, E.M., Lehr, C.M., 2015. A design of experiment 
study of nanoprecipitation and nano spray drying as processes to prepare PLGA nano- 
and microparticles with defined sizes and size distributions. Pharmaceutical Research, 
32 (8), 2609-24. 
Du, X.J., Wang, J.L., Iqbal, S., Li, H.J., Cao, Z.T., Wang, Y.C., Du, J.Z., Wang, J., 2018. The 
effect of surface charge on oral absorption of polymeric nanoparticles. Biomaterials 
Science, 6 (3), 642-50. 
Du, Y., Zhang, Z., Yim, C., Lin, M., Cao, X., 2010. A simplified design of the staggered 
herringbone micromixer for practical applications. Biomicrofluidics, 4 (2), 024105. 
Dubes, A., Parrot-Lopez, H., Abdelwahed, W., Degobert, G., Fessi, H., Shahgaldian, P., 
Coleman, A.W., 2003. Scanning electron microscopy and atomic force microscopy 
imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins. European 
Journal of Pharmaceutics and Biopharmaceutics, 55 (3), 279-82. 
Eggimann, G.A., Blattes, E., Buschor, S., Biswas, R., Kammer, S.M., Darbre, T., Reymond, J.-
L., 2014. Designed cell penetrating peptide dendrimers efficiently internalize cargo into 
cells. Chemical Communications, 50 (55), 7254-57. 
Egusquiaguirre, S.P., Manguan-Garcia, C., Pintado-Berninches, L., Iarriccio, L., Carbajo, D., 
Albericio, F., Royo, M., Pedraz, J.L., Hernandez, R.M., Perona, R., Igartua, M., 2015. 
Development of surface modified biodegradable polymeric nanoparticles to deliver 
GSE24.2 peptide to cells: A promising approach for the treatment of defective 
telomerase disorders. European Journal of Pharmaceutics and Biopharmaceutics, 91, 
91-102. 
Elsner, M.B., Herold, H.M., Muller-Herrmann, S., Bargel, H., Scheibel, T., 2015. Enhanced 
cellular uptake of engineered spider silk particles. Biomaterials Science, 3 (3), 543-51. 
Erazo-Oliveras, A., Najjar, K., Dayani, L., Wang, T.Y., Johnson, G.A., Pellois, J.P., 2014. 
Protein delivery into live cells by incubation with an endosomolytic agent. Nature 
Methods, 11 (8), 861-7. 
Fan, T., Chen, C., Guo, H., Xu, J., Zhang, J., Zhu, X., Yang, Y., Zhou, Z., Li, L., Huang, Y., 
2014. Design and evaluation of solid lipid nanoparticles modified with peptide ligand 
for oral delivery of protein drugs. European Journal of Pharmaceutics and 
Biopharmaceutics, 88 (2), 518-28. 
Faralli, A., Shekarforoush, E., Mendes, A.C., Chronakis, I.S., 2019. Enhanced transepithelial 
permeation of gallic acid and (-)-epigallocatechin gallate across human intestinal Caco-
2 cells using electrospun xanthan nanofibers. Pharmaceutics, 11 (4). 
Faria, M., Bjornmalm, M., Thurecht, K.J., Kent, S.J., Parton, R.G., Kavallaris, M., Johnston, 
A.P.R., Gooding, J.J., Corrie, S.R., Boyd, B.J., Thordarson, P., Whittaker, A.K., 




Caruso, F., 2018. Minimum information reporting in bio-nano experimental literature. 
Nature Nanotechnology, 13 (9), 777-85. 
Faria, M., Noi, K.F., Dai, Q., Björnmalm, M., Johnston, S.T., Kempe, K., Caruso, F., Crampin, 
E.J., 2019. Revisiting cell–particle association in vitro: A quantitative method to 
compare particle performance. Journal of Controlled Release, 307, 355-67. 
Farkhani, S.M., Valizadeh, A., Karami, H., Mohammadi, S., Sohrabi, N., Badrzadeh, F., 2014. 
Cell penetrating peptides: Efficient vectors for delivery of nanoparticles, nanocarriers, 
therapeutic and diagnostic molecules. Peptides, 57, 78-94. 
Farokhzad, O.C., Langer, R., 2009. Impact of nanotechnology on drug delivery. ACS Nano, 3 
(1), 16-20. 
FDA, 1997. Guidance for industry: Q2B validation of analytical procedures: Methology. Food 
and Drug Administration, Center for Drug Evaluation and Research and Center for 
Veterinary Medicine. 
FDA, 2001. Guidance for Industry: Bioanalytical Method Validation. Food and Drug 
Administration, Center for Drug Evaluation and Research and Center for Veterinary 
Medicine. 
Feiner-Gracia, N., Dols-Perez, A., Royo, M., Solans, C., Garcia-Celma, M.J., Fornaguera, C., 
2018. Cell penetrating peptide grafting of PLGA nanoparticles to enhance cell uptake. 
European Polymer Journal, 108, 429-38. 
Feng, Q., Liu, J., Li, X., Chen, Q., Sun, J., Shi, X., Ding, B., Yu, H., Li, Y., Jiang, X., 2017. 
One-step microfluidic synthesis of nanocomplex with tunable rigidity and acid-
switchable surface charge for overcoming drug resistance. Small, 13 (9), 1603109. 
Fenton, O.S., Olafson, K.N., Pillai, P.S., Mitchell, M.J., Langer, R., 2018. Advances in 
biomaterials for drug delivery. Advanced Materials, e1705328. 
Fessi, H., Puisieux, F., Devissaguet, J.P., Ammoury, N., Benita, S., 1989. Nanocapsule 
formation by interfacial polymer deposition following solvent displacement. 
International Journal of Pharmaceutics, 55 (1), R1-R4. 
Fischer, R., Kohler, K., Fotin-Mleczek, M., Brock, R., 2004. A stepwise dissection of the 
intracellular fate of cationic cell-penetrating peptides. The Journal of Biological 
Chemistry, 279 (13), 12625-35. 
Fleischer, C.C., Payne, C.K., 2014. Nanoparticle-cell interactions: Molecular structure of the 
protein corona and cellular outcomes. Accounts of Chemical Research, 47 (8), 2651-9. 
Foerg, C., Ziegler, U., Fernandez-Carneado, J., Giralt, E., Merkle, H.P., 2007. Differentiation 
restricted endocytosis of cell penetrating peptides in MDCK cells corresponds with 
activities of Rho-GTPases. Pharmaceutical Research, 24 (4), 628-42. 
Fornaguera, C., Dols-Perez, A., Caldero, G., Garcia-Celma, M.J., Camarasa, J., Solans, C., 
2015. PLGA nanoparticles prepared by nano-emulsion templating using low-energy 
methods as efficient nanocarriers for drug delivery across the blood-brain barrier. 
Journal of Controlled Release, 211, 134-43. 
Franke, D., Kikhney, A.G., Svergun, D.I., 2012. Automated acquisition and analysis of small 
angle X-ray scattering data. Nuclear Instruments and Methods in Physics Research 
Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 689, 52-
59. 
Frankel, A.D., Pabo, C.O., 1988. Cellular uptake of the tat protein from human 
immunodeficiency virus. Cell, 55 (6), 1189-93. 
Franken, L.E., Boekema, E.J., Stuart, M.C.A., 2017. Transmission electron microscopy as a 
tool for the characterization of soft materials: Application and interpretation. Advanced 
Science, 4 (5), 1600476. 
Frohlich, E., 2016. Cellular elimination of nanoparticles. Environmental Toxicology and 




Futaki, S., Suzuki, T., Ohashi, W., Yagami, T., Tanaka, S., Ueda, K., Sugiura, Y., 2001. 
Arginine-rich peptides. An abundant source of membrane-permeable peptides having 
potential as carriers for intracellular protein delivery. The Journal of Biological 
Chemistry, 276 (8), 5836-40. 
Gagliardi, M., Bertero, A., Bifone, A., 2017. Molecularly imprinted biodegradable 
nanoparticles. Scientific Reports, 7, 40046. 
Galindo-Rodríguez, S.A., Puel, F., Briançon, S., Allémann, E., Doelker, E., Fessi, H., 2005. 
Comparative scale-up of three methods for producing ibuprofen-loaded nanoparticles. 
European Journal of Pharmaceutical Sciences, 25 (4), 357-67. 
Gao, X., Hong, S., Liu, Z., Yue, T., Dobnikar, J., Zhang, X., 2019. Membrane potential drives 
direct translocation of cell-penetrating peptides. Nanoscale, 11 (4), 1949-58. 
Gao, Y., Zhao, D., Chang, M.-W., Ahmad, Z., Li, J.-S., 2016. Optimising the shell thickness-
to-radius ratio for the fabrication of oil-encapsulated polymeric microspheres. Chemical 
Engineering Journal, 284, 963-71. 
Gartziandia, O., Egusquiaguirre, S.P., Bianco, J., Pedraz, J.L., Igartua, M., Hernandez, R.M., 
Préat, V., Beloqui, A., 2016. Nanoparticle transport across in vitro olfactory cell 
monolayers. International Journal of Pharmaceutics, 499 (1), 81-89. 
Gaumet, M., Gurny, R., Delie, F., 2009. Localization and quantification of biodegradable 
particles in an intestinal cell model: The influence of particle size. European Journal of 
Pharmaceutical Sciences, 36 (4), 465-73. 
Ghazal, A., Gontsarik, M., Kutter, J.P., Lafleur, J.P., Ahmadvand, D., Labrador, A., Salentinig, 
S., Yaghmur, A., 2017. Microfluidic platform for the continuous production and 
characterization of multilamellar vesicles: A synchrotron small-angle X-ray scattering 
(SAXS) study. The Journal of Physical Chemistry Letters, 8 (1), 73-79. 
Green, M., Loewenstein, P.M., 1988. Autonomous functional domains of chemically 
synthesized human immunodeficiency virus tat trans-activator protein. Cell, 55 (6), 
1179-88. 
Griffin, B.T., Guo, J., Presas, E., Donovan, M.D., Alonso, M.J., O'Driscoll, C.M., 2016. 
Pharmacokinetic, pharmacodynamic and biodistribution following oral administration 
of nanocarriers containing peptide and protein drugs. Advanced Drug Delivery 
Reviews, 106, 367-80. 
Grillo, I., 2008. Small-angle neutron scattering and applications in soft condensed matter,  
Springer, pp. 723-82. 
Guidotti, G., Brambilla, L., Rossi, D., 2017. Cell-penetrating peptides: From basic research to 
clinics. Trends in Pharmacological Sciences, 38 (4), 406-24. 
Gullotti, E., Yeo, Y., 2012. Beyond the imaging: Limitations of cellular uptake study in the 
evaluation of nanoparticles. Journal of Controlled Release, 164 (2), 170-76. 
Gump, J.M., June, R.K., Dowdy, S.F., 2010. Revised role of glycosaminoglycans in TAT 
protein transduction domain-mediated cellular transduction. The Journal of Biological 
Chemistry, 285 (2), 1500-7. 
Guo, F., Ouyang, T., Peng, T., Zhang, X., Xie, B., Yang, X., Liang, D., Zhong, H., 2019. 
Enhanced oral absorption of insulin using colon-specific nanoparticles co-modified with 
amphiphilic chitosan derivatives and cell-penetrating peptides. Biomaterials Science, 7 
(4), 1493-506. 
Guo, P., Weinstein, A.M., Weinbaum, S., 2000. A hydrodynamic mechanosensory hypothesis 
for brush border microvilli. American Journal of Physiology-Renal Physiology, 279 (4), 
F698-F712. 
Habault, J., Poyet, J.L., 2019. Recent advances in cell penetrating peptide-based anticancer 




Haggag, Y.A., Faheem, A.M., Tambuwala, M.M., Osman, M.A., El-Gizawy, S.A., O'Hagan, 
B., Irwin, N., McCarron, P.A., 2018. Effect of poly(ethylene glycol) content and 
formulation parameters on particulate properties and intraperitoneal delivery of insulin 
from PLGA nanoparticles prepared using the double-emulsion evaporation procedure. 
Pharmaceutical Development and Technology, 23 (4), 370-81. 
Hanrahan, G., Lu, K., 2006. Application of factorial and response surface methodology in 
modern experimental design and optimization. Critical Reviews in Analytical 
Chemistry, 36 (3-4), 141-51. 
Haque, S., Boyd, B.J., McIntosh, M.P., Pouton, C.W., Kaminskas, L.M., Whittaker, M., 2018. 
Suggested procedures for the reproducible synthesis of poly(d,l-lactide-co-glycolide) 
nanoparticles using the emulsification solvent diffusion platform. Current Nanoscience, 
14 (5), 448-53. 
Haris, P.I., Severcan, F., 1999. FTIR spectroscopic characterization of protein structure in 
aqueous and non-aqueous media. Journal of Molecular Catalysis B: Enzymatic, 7 (1), 
207-21. 
He, B., Lin, P., Jia, Z., Du, W., Qu, W., Yuan, L., Dai, W., Zhang, H., Wang, X., Wang, J., 
Zhang, X., Zhang, Q., 2013. The transport mechanisms of polymer nanoparticles in 
Caco-2 epithelial cells. Biomaterials, 34 (25), 6082-98. 
He, C., Hu, Y., Yin, L., Tang, C., Yin, C., 2010. Effects of particle size and surface charge on 
cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials, 31 (13), 
3657-66. 
He, C., Yin, L., Tang, C., Yin, C., 2012. Size-dependent absorption mechanism of polymeric 
nanoparticles for oral delivery of protein drugs. Biomaterials, 33 (33), 8569-78. 
Herce, H.D., Garcia, A.E., Cardoso, M.C., 2014. Fundamental molecular mechanism for the 
cellular uptake of guanidinium-rich molecules. Journal of the American Chemical 
Society, 136 (50), 17459-67. 
Hermanson, G.T., 2013a. Introduction to bioconjugation, in: Audet, J., Preap, M. (Eds.), 
Bioconjugate Techniques, 3rd ed. Academic Press, pp. 1-125. 
Hermanson, G.T., 2013b. (Strept)avidin–biotin systems, in: Audet, J., Preap, M. (Eds.), 
Bioconjugate Techniques, 3rd ed. Academic Press, pp. 465-505. 
Hermanson, G.T., 2013c. Zero-length crosslinkers, in: Audet, J., Preap, M. (Eds.), Bioconjugate 
Techniques, 3rd ed. Academic Press, pp. 259-73. 
Hidalgo, I.J., Raub, T.J., Borchardt, R.T., 1989. Characterization of the human colon carcinoma 
cell line (Caco-2) as a model system for intestinal epithelial permeability. 
Gastroenterology, 96 (3), 736-49. 
Hinderliter, P.M., Minard, K.R., Orr, G., Chrisler, W.B., Thrall, B.D., Pounds, J.G., 
Teeguarden, J.G., 2010. ISDD: A computational model of particle sedimentation, 
diffusion and target cell dosimetry for in vitro toxicity studies. Particle and Fibre 
Toxicology, 7 (1), 36. 
Hofmann, A.M., Wurm, F., Hühn, E., Nawroth, T., Langguth, P., Frey, H., 2010. 
Hyperbranched polyglycerol-based lipids via oxyanionic polymerization: Toward 
multifunctional stealth liposomes. Biomacromolecules, 11 (3), 568-74. 
Homs, M., Calderó, G., Monge, M., Morales, D., Solans, C., 2018. Influence of polymer 
concentration on the properties of nano-emulsions and nanoparticles obtained by a low-
energy method. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 
536, 204-12. 
Hong, L., Salentinig, S., Hawley, A., Boyd, B.J., 2015. Understanding the mechanism of 





Hoyer, J., Schatzschneider, U., Schulz-Siegmund, M., Neundorf, I., 2012. Dimerization of a 
cell-penetrating peptide leads to enhanced cellular uptake and drug delivery. Beilstein 
Journal of Organic Chemistry, 8, 1788-97. 
Hu, J., Lou, Y., Wu, F., 2019. Improved intracellular delivery of polyarginine peptides with 
cargoes. The Journal of Physical Chemistry B, 123 (12), 2636-44. 
Huang, Y., Jiang, Y., Wang, H., Wang, J., Shin, M.C., Byun, Y., He, H., Liang, Y., Yang, V.C., 
2013. Curb challenges of the "Trojan Horse" approach: Smart strategies in achieving 
effective yet safe cell-penetrating peptide-based drug delivery. Advanced Drug 
Delivery Reviews, 65 (10), 1299-315. 
Huang, Y.W., Lee, H.J., Tolliver, L.M., Aronstam, R.S., 2015. Delivery of nucleic acids and 
nanomaterials by cell-penetrating peptides: Opportunities and challenges. BioMed 
Research International, 2015, 834079. 
Hyrup Møller, L., Bahnsen, J.S., Nielsen, H.M., Ostergaard, J., Sturup, S., Gammelgaard, B., 
2015. Selenium as an alternative peptide label - comparison to fluorophore-labelled 
penetratin. European Journal of Pharmaceutical Sciences, 67, 76-84. 
Iwasa, A., Akita, H., Khalil, I., Kogure, K., Futaki, S., Harashima, H., 2006. Cellular uptake 
and subsequent intracellular trafficking of R8-liposomes introduced at low temperature. 
Biochimica et Biophysica Acta, 1758 (6), 713-20. 
Jacobsen, J., Pedersen, M., Rassing, M.R., 1996. TR146 cells as a model for human buccal 
epithelium: II. Optimisation and use of a cellular sensitivity MTS/PMS assay. 
International Journal of Pharmaceutics, 141 (1), 217-25. 
Jafari, S., Maleki Dizaj, S., Adibkia, K., 2015. Cell-penetrating peptides and their analogues as 
novel nanocarriers for drug delivery. BioImpacts, 5 (2), 103-11. 
Jafarifar, E., Hajialyani, M., Akbari, M., Rahimi, M., Shokoohinia, Y., Fattahi, A., 2017. 
Preparation of a reproducible long-acting formulation of risperidone-loaded PLGA 
microspheres using microfluidic method. Pharmaceutical Development and 
Technology, 22 (6), 836-43. 
Jäger, A., Jäger, E., Giacomelli, F.C., Nallet, F., Steinhart, M., Putaux, J.-L., Konefał, R., 
Spěváček, J., Ulbrich, K., Štěpánek, P., 2018. Structural changes on polymeric 
nanoparticles induced by hydrophobic drug entrapment. Colloids and Surfaces A: 
Physicochemical and Engineering Aspects, 538, 238-49. 
Jahn, A., Vreeland, W.N., Gaitan, M., Locascio, L.E., 2004. Controlled vesicle self-assembly 
in microfluidic channels with hydrodynamic focusing. Journal of the American 
Chemical Society, 126 (9), 2674-5. 
Jaimes-Aguirre, L., Morales-Avila, E., Ocampo-Garcia, B.E., Medina, L.A., Lopez-Tellez, G., 
Gibbens-Bandala, B.V., Izquierdo-Sanchez, V., 2017. Biodegradable poly(D,L-lactide-
co-glycolide)/poly(L-gamma-glutamic acid) nanoparticles conjugated to folic acid for 
targeted delivery of doxorubicin. Materials Science and Engineering: C Materials for 
Biological Applications, 76, 743-51. 
Jain, A., Jain, S.K., 2015. L-Valine appended PLGA nanoparticles for oral insulin delivery. 
Acta Diabetologica, 52 (4), 663-76. 
Jara, M.O., Catalan-Figueroa, J., Landin, M., Morales, J.O., 2018. Finding key 
nanoprecipitation variables for achieving uniform polymeric nanoparticles using 
neurofuzzy logic technology. Drug Delivery and Translational Research, 8 (6), 1797-
806. 
Jeevanandam, J., Chan, Y.S., Danquah, M.K., 2016. Nano-formulations of drugs: Recent 
developments, impact and challenges. Biochimie, 128-129, 99-112. 
Jeffries, C.M., Graewert, M.A., Svergun, D.I., Blanchet, C.E., 2015. Limiting radiation damage 
for high-brilliance biological solution scattering: Practical experience at the EMBL P12 




Jeong, C., Yoo, J., Lee, D., Kim, Y.C., 2016. A branched TAT cell-penetrating peptide as a 
novel delivery carrier for the efficient gene transfection. Biomaterials Research, 20 (1), 
28. 
Jones, A.T., 2007. Macropinocytosis: Searching for an endocytic identity and role in the uptake 
of cell penetrating peptides. Journal of Cellular and Molecular Medicine, 11 (4), 670-
84. 
Jones, S.W., Christison, R., Bundell, K., Voyce, C.J., Brockbank, S.M.V., Newham, P., 
Lindsay, M.A., 2005. Characterisation of cell-penetrating peptide-mediated peptide 
delivery. British Journal of Pharmacology, 145 (8), 1093-102. 
Joshi, G., Kumar, A., Sawant, K., 2016. Bioavailability enhancement, Caco-2 cells uptake and 
intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles. Drug 
Delivery, 23 (9), 3492-504. 
Kafka, A.P., Kleffmann, T., Rades, T., McDowell, A., 2009. Histidine residues in the peptide 
D-Lys6-GnRH: Potential for copolymerization in polymeric nanoparticles. Molecular 
Pharmaceutics, 6 (5), 1483-91. 
Kafka, A.P., Kleffmann, T., Rades, T., McDowell, A., 2011. The application of MALDI TOF 
MS in biopharmaceutical research. International Journal of Pharmaceutics, 417 (1-2), 
70-82. 
Kalani, M., Yunus, R., 2012. Effect of supercritical fluid density on nanoencapsulated drug 
particle size using the supercritical antisolvent method. International Journal of 
Nanomedicine, 7, 2165-72. 
Kamaly, N., Fredman, G., Fojas, J.J., Subramanian, M., Choi, W.I., Zepeda, K., Vilos, C., Yu, 
M., Gadde, S., Wu, J., Milton, J., Carvalho Leitao, R., Rosa Fernandes, L., Hasan, M., 
Gao, H., Nguyen, V., Harris, J., Tabas, I., Farokhzad, O.C., 2016. Targeted interleukin-
10 nanotherapeutics developed with a microfluidic chip enhance resolution of 
inflammation in advanced atherosclerosis. ACS Nano, 10 (5), 5280-92. 
Kamei, N., Morishita, M., Takayama, K., 2009. Importance of intermolecular interaction on the 
improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating 
peptides. Journal of Controlled Release, 136 (3), 179-86. 
Kaneko, K., McDowell, A., Ishii, Y., Hook, S., 2018. Characterization and evaluation of 
stabilized particulate formulations as therapeutic oral vaccines for allergy. Journal of 
Liposome Research, 28 (4), 296-304. 
Kang, H., DeLong, R., Fisher, M.H., Juliano, R.L., 2005. Tat-conjugated PAMAM dendrimers 
as delivery agents for antisense and siRNA oligonucleotides. Pharmaceutical Research, 
22 (12), 2099-106. 
Kang, X., Luo, C., Wei, Q., Xiong, C., Chen, Q., Chen, Y., Ouyang, Q., 2013. Mass production 
of highly monodisperse polymeric nanoparticles by parallel flow focusing system. 
Microfluidics and Nanofluidics, 15 (3), 337-45. 
Karnik, R., Gu, F., Basto, P., Cannizzaro, C., Dean, L., Kyei-Manu, W., Langer, R., Farokhzad, 
O.C., 2008. Microfluidic platform for controlled synthesis of polymeric nanoparticles. 
Nano Letters, 8 (9), 2906-12. 
Karve, S., Werner, M.E., Cummings, N.D., Sukumar, R., Wang, E.C., Zhang, Y.-A., Wang, 
A.Z., 2011. Formulation of diblock polymeric nanoparticles through nanoprecipitation 
technique. Journal of Visualized Experiments (55), e3398. 
Kastner, E., Kaur, R., Lowry, D., Moghaddam, B., Wilkinson, A., Perrie, Y., 2014. High-
throughput manufacturing of size-tuned liposomes by a new microfluidics method using 
enhanced statistical tools for characterization. International Journal of Pharmaceutics, 




Kastner, E., Verma, V., Lowry, D., Perrie, Y., 2015. Microfluidic-controlled manufacture of 
liposomes for the solubilisation of a poorly water soluble drug. International Journal of 
Pharmaceutics, 485 (1-2), 122-30. 
Katsikari, A., Patronidou, C., Kiparissides, C., Arsenakis, M., 2009. Uptake and cytotoxicity of 
poly(d,l-lactide-co-glycolide) nanoparticles in human colon adenocarcinoma cells. 
Materials Science and Engineering: B, 165 (3), 160-64. 
Khan, I.U., Serra, C.A., Anton, N., Vandamme, T.F., 2015. Production of nanoparticle drug 
delivery systems with microfluidics tools. Expert Opinion on Drug Delivery, 12 (4), 
547-62. 
Kikhney, A.G., Svergun, D.I., 2015. A practical guide to small angle X-ray scattering (SAXS) 
of flexible and intrinsically disordered proteins. FEBS Letters, 589 (19), 2570-7. 
Kim, Y., Lee Chung, B., Ma, M., Mulder, W.J., Fayad, Z.A., Farokhzad, O.C., Langer, R., 
2012. Mass production and size control of lipid-polymer hybrid nanoparticles through 
controlled microvortices. Nano Letters, 12 (7), 3587-91. 
Klein, M.J., Schmidt, S., Wadhwani, P., Burck, J., Reichert, J., Afonin, S., Berditsch, M., 
Schober, T., Brock, R., Kansy, M., Ulrich, A.S., 2017. Lactam-stapled cell-penetrating 
peptides: Cell uptake and membrane binding properties. Journal of Medicinal 
Chemistry, 60 (19), 8071-82. 
Koch, A.M., Reynolds, F., Merkle, H.P., Weissleder, R., Josephson, L., 2005. Transport of 
surface-modified nanoparticles through cell monolayers. ChemBioChem, 6 (2), 337-45. 
Koh, M.L., FitzGerald, P.A., Warr, G.G., Jolliffe, K.A., Perrier, S., 2016. Study of (cyclic 
peptide)-polymer conjugate assemblies by small-angle neutron scattering. Chemistry, 
22 (51), 18419-28. 
Kolishetti, N., Dhar, S., Valencia, P.M., Lin, L.Q., Karnik, R., Lippard, S.J., Langer, R., 
Farokhzad, O.C., 2010. Engineering of self-assembled nanoparticle platform for 
precisely controlled combination drug therapy. Proceedings of the National Academy 
of Sciences of the United States of America, 107 (42), 17939-44. 
Kong, J., Yu, S., 2007. Fourier transform infrared spectroscopic analysis of protein secondary 
structures. Acta Biochimica et Biophysica Sinica, 39 (8), 549-59. 
Koren, E., Torchilin, V.P., 2012. Cell-penetrating peptides: Breaking through to the other side. 
Trends in Molecular Medicine, 18 (7), 385-93. 
Kostag, M., Köhler, S., Liebert, T., Heinze, T., 2010. Pure cellulose nanoparticles from 
trimethylsilyl cellulose. Macromolecular Symposia, 294 (2), 96-106. 
Kristensen, M., de Groot, A.M., Berthelsen, J., Franzyk, H., Sijts, A., Nielsen, H.M., 2015. 
Conjugation of cell-penetrating peptides to parathyroid hormone affects its structure, 
potency, and transepithelial permeation. Bioconjugate Chemistry, 26 (3), 477-88. 
Kristensen, M., Nielsen, H.M., 2016. Cell-penetrating peptides as carriers for oral delivery of 
biopharmaceuticals. Basic & Clinical Pharmacology & Toxicology, 118 (2), 99-106. 
Künnapuu, K., Veiman, K.-L., Porosk, L., Rammul, E., Kiisholts, K., Langel, Ü., Kurrikoff, K., 
2019. Tumor gene therapy by systemic delivery of plasmid DNA with cell-penetrating 
peptides. FASEB BioAdvances, 1 (2), 105-14. 
Laulicht, B., Cheifetz, P., Mathiowitz, E., Tripathi, A., 2008. Evaluation of continuous flow 
nanosphere formation by controlled microfluidic transport. Langmuir, 24 (17), 9717-
26. 
Lea, T., 2015. Caco-2 cell line, in: Verhoeckx, K., Cotter, P., Lopez-Exposito, I., Kleiveland, 
C., Lea, T., Mackie, A., Requena, T., Swiatecka, D., Wichers, H. (Eds.), The Impact of 
Food Bioactives on Health: In vitro and ex vivo models, ed. Springer, pp. 103-11. 
Lee, S.Y., Jung, E., Park, J.H., Park, J.W., Shim, C.K., Kim, D.D., Yoon, I.S., Cho, H.J., 2016. 




nanoparticles in the blood stream and improved lung targeting efficiency. Journal of 
Colloid and Interface Science, 480, 102-08. 
Lepeltier, E., Bourgaux, C., Couvreur, P., 2014. Nanoprecipitation and the "Ouzo effect": 
Application to drug delivery devices. Advanced Drug Delivery Reviews, 71, 86-97. 
Leung, M.H.M., Shen, A.Q., 2018. Microfluidic assisted nanoprecipitation of PLGA 
nanoparticles for curcumin delivery to leukemia Jurkat cells. Langmuir, 34 (13), 3961-
70. 
Li, M., Al-Jamal, K.T., Kostarelos, K., Reineke, J., 2010. Physiologically based 
pharmacokinetic modeling of nanoparticles. ACS Nano, 4 (11), 6303-17. 
Li, M., Panagi, Z., Avgoustakis, K., Reineke, J., 2012. Physiologically based pharmacokinetic 
modeling of PLGA nanoparticles with varied mPEG content. International Journal of 
Nanomedicine, 7, 1345-56. 
Li, M., Zou, P., Tyner, K., Lee, S., 2017. Physiologically based pharmacokinetic (PBPK) 
modeling of pharmaceutical nanoparticles. The AAPS Journal, 19 (1), 26-42. 
Li, T., Senesi, A.J., Lee, B., 2016. Small angle X-ray scattering for nanoparticle research. 
Chemical Reviews, 116 (18), 11128-80. 
Lim, J.M., Bertrand, N., Valencia, P.M., Rhee, M., Langer, R., Jon, S., Farokhzad, O.C., 
Karnik, R., 2014a. Parallel microfluidic synthesis of size-tunable polymeric 
nanoparticles using 3D flow focusing towards in vivo study. Nanomedicine, 10 (2), 401-
9. 
Lim, J.M., Swami, A., Gilson, L.M., Chopra, S., Choi, S., Wu, J., Langer, R., Karnik, R., 
Farokhzad, O.C., 2014b. Ultra-high throughput synthesis of nanoparticles with 
homogeneous size distribution using a coaxial turbulent jet mixer. ACS Nano, 8 (6), 
6056-65. 
Lince, F., Marchisio, D.L., Barresi, A.A., 2008. Strategies to control the particle size 
distribution of poly-ε-caprolactone nanoparticles for pharmaceutical applications. 
Journal of Colloid and Interface Science, 322 (2), 505-15. 
Liu, K., Wang, H., Chen, K.J., Guo, F., Lin, W.Y., Chen, Y.C., Phung, D.L., Tseng, H.R., Shen, 
C.K., 2010. A digital microfluidic droplet generator produces self-assembled 
supramolecular nanoparticles for targeted cell imaging. Nanotechnology, 21 (44), 
445603. 
Liu, K., Zhu, Z., Wang, X., Gonçalves, D., Zhang, B., Hierlemann, A., Hunziker, P., 2015. 
Microfluidics-based single-step preparation of injection-ready polymeric nanosystems 
for medical imaging and drug delivery. Nanoscale, 7 (40), 16983-93. 
Liu, X., Liu, C., Zhang, W., Xie, C., Wei, G., Lu, W., 2013. Oligoarginine-modified 
biodegradable nanoparticles improve the intestinal absorption of insulin. International 
Journal of Pharmaceutics, 448 (1), 159-67. 
Lonn, P., Dowdy, S.F., 2015. Cationic PTD/CPP-mediated macromolecular delivery: Charging 
into the cell. Expert Opinion on Drug Delivery, 12 (10), 1627-36. 
Lopes, M., Shrestha, N., Correia, A., Shahbazi, M.A., Sarmento, B., Hirvonen, J., Veiga, F., 
Seica, R., Ribeiro, A., Santos, H.A., 2016. Dual chitosan/albumin-coated 
alginate/dextran sulfate nanoparticles for enhanced oral delivery of insulin. Journal of 
Controlled Release, 232, 29-41. 
Lopez, C.G., Watanabe, T., Martel, A., Porcar, L., Cabral, J.T., 2015. Microfluidic-SANS: 
Flow processing of complex fluids. Scientific Reports, 5, 7727. 
Lopez, C.G., Watanabe, T., Adamo, M., Martel, A., Porcar, L., Cabral, J.T., 2018. Microfluidic 
devices for small-angle neutron scattering. Journal of Applied Crystallography, 51, 570-
83. 
Lukanowska, M., Howl, J., Jones, S., 2013. Bioportides: Bioactive cell-penetrating peptides 




Lundquist, P., Artursson, P., 2016. Oral absorption of peptides and nanoparticles across the 
human intestine: Opportunities, limitations and studies in human tissues. Advanced 
Drug Delivery Reviews, 106, 256-76. 
Luo, Y., Han, Y., Hu, X., Yin, M., Wu, C., Li, Q., Chen, N., Zhao, Y., 2019a. Live-cell imaging 
of octaarginine-modified polymer dots via single particle tracking. Cell Proliferation, 
52 (2), e12556. 
Luo, Z., Yang, Y., Radulescu, A., Kohlbrecher, J., Darwish, T.A., Ong, Q.K., Guldin, S., 
Stellacci, F., 2019b. Multidimensional characterization of mixed ligand nanoparticles 
using small angle neutron scattering. Chemistry of Materials. 
Luque-Michel, E., Larrea, A., Lahuerta, C., Sebastian, V., Imbuluzqueta, E., Arruebo, M., 
Blanco-Prieto, M.J., Santamaria, J., 2016. A simple approach to obtain hybrid Au-
loaded polymeric nanoparticles with a tunable metal load. Nanoscale, 8 (12), 6495-506. 
Makadia, H.K., Siegel, S.J., 2011. Poly lactic-co-glycolic acid (PLGA) as biodegradable 
controlled drug delivery carrier. Polymers, 3 (3), 1377-97. 
Malhaire, H., Gimel, J.C., Roger, E., Benoit, J.P., Lagarce, F., 2016. How to design the surface 
of peptide-loaded nanoparticles for efficient oral bioavailability? Advanced Drug 
Delivery Reviews, 106, 320-36. 
Mandenius, C.F., Brundin, A., 2008. Bioprocess optimization using design-of-experiments 
methodology. Biotechnology Progress, 24 (6), 1191-203. 
Manet, S., Lecchi, A., Imperor-Clerc, M., Zholobenko, V., Durand, D., Oliveira, C.L., 
Pedersen, J.S., Grillo, I., Meneau, F., Rochas, C., 2011. Structure of micelles of a 
nonionic block copolymer determined by SANS and SAXS. The Journal of Physical 
Chemistry B, 115 (39), 11318-29. 
Mante, A., Heider, M., Zlomke, C., Mader, K., 2016. PLGA nanoparticles for peroral delivery: 
How important is pancreatic digestion and can we control it? European Journal of 
Pharmaceutics and Biopharmaceutics, 108, 32-40. 
Manzo, C., Garcia-Parajo, M.F., 2015. A review of progress in single particle tracking: From 
methods to biophysical insights. Reports on Progress in Physics, 78 (12), 124601. 
Masood, F., 2016. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. 
Materials Science and Engineering: C Materials for Biological Applications, 60, 569-
78. 
Masters, J.R., 2002. HeLa cells 50 years on: The good, the bad and the ugly. Nature Reviews 
Cancer, 2 (4), 315-19. 
Miao, J., Charalambous, P., Kirz, J., Sayre, D., 1999. Extending the methodology of X-ray 
crystallography to allow imaging of micrometre-sized non-crystalline specimens. 
Nature, 400 (6742), 342-44. 
Min, K.I., Im, D.J., Lee, H.J., Kim, D.P., 2014. Three-dimensional flash flow microreactor for 
scale-up production of monodisperse PEG-PLGA nanoparticles. Lab on a Chip, 14 (20), 
3987-92. 
Mitchell, D.J., Kim, D.T., Steinman, L., Fathman, C.G., Rothbard, J.B., 2000. Polyarginine 
enters cells more efficiently than other polycationic homopolymers. The Journal of 
Peptide Research, 56 (5), 318-25. 
Moku, G., Layek, B., Trautman, L., Putnam, S., Panyam, J., Prabha, S., 2019. Improving 
payload capacity and anti-tumor efficacy of mesenchymal stem cells using TAT peptide 
functionalized polymeric nanoparticles. Cancers, 11 (4). 
Monreal, I.A., Liu, Q., Tyson, K., Bland, T., Dalisay, D.S., Adams, E.V., Wayman, G.A., 
Aguilar, H.C., Saludes, J.P., 2015. Branched dimerization of Tat peptide improves 





Montrose, K., Yang, Y., Krissansen, G.W., 2014a. The tetrapeptide core of the carrier peptide 
Xentry is cell-penetrating: Novel activatable forms of Xentry. Scientific Reports, 4, 
4900. 
Montrose, K., Yang, Y., Krissansen, G.W., 2014b. X-pep, a novel cell-penetrating peptide 
motif derived from the hepatitis B virus. Biochemical and Biophysical Research 
Communications, 453 (1), 64-8. 
Morikawa, Y., Tagami, T., Hoshikawa, A., Ozeki, T., 2018. The use of an efficient microfluidic 
mixing system for generating stabilized polymeric nanoparticles for controlled drug 
release. Biological and Pharmaceutical Bulletin, 41 (6), 899-907. 
Morimoto, N., Wakamura, M., Muramatsu, K., Toita, S., Nakayama, M., Shoji, W., Suzuki, 
M., Winnik, F.M., 2016. Membrane translocation and organelle-selective delivery 
steered by polymeric zwitterionic nanospheres. Biomacromolecules, 17 (4), 1523-35. 
Mu, Y., Fu, Y., Li, J., Yu, X., Li, Y., Wang, Y., Wu, X., Zhang, K., Kong, M., Feng, C., Chen, 
X., 2019. Multifunctional quercetin conjugated chitosan nano-micelles with P-gp 
inhibition and permeation enhancement of anticancer drug. Carbohydrate Polymers, 
203, 10-18. 
Mukherjee, T., Squillantea, E., Gillespieb, M., Shao, J., 2004. Transepithelial electrical 
resistance is not a reliable measurement of the Caco-2 monolayer integrity in Transwell. 
Drug Delivery, 11 (1), 11-8. 
Nam, Y.S., Park, J.Y., Han, S.-H., Chang, I.-S., 2002. Intracellular drug delivery using poly(d,l-
lactide-co-glycolide) nano- particles derivatized with a peptide from a transcriptional 
activator protein of HIV-1. Biotechnology Letters, 24 (24), 2093-98. 
Nel, A.E., Mädler, L., Velegol, D., Xia, T., Hoek, E.M.V., Somasundaran, P., Klaessig, F., 
Castranova, V., Thompson, M., 2009. Understanding biophysicochemical interactions 
at the nano–bio interface. Nature Materials, 8, 543. 
Ortiz de Solorzano, I., Uson, L., Larrea, A., Miana, M., Sebastian, V., Arruebo, M., 2016. 
Continuous synthesis of drug-loaded nanoparticles using microchannel emulsification 
and numerical modeling: Effect of passive mixing. International Journal of 
Nanomedicine, 11, 3397-416. 
Othman, R., Vladisavljević, G.T., Hemaka Bandulasena, H.C., Nagy, Z.K., 2015. Production 
of polymeric nanoparticles by micromixing in a co-flow microfluidic glass capillary 
device. Chemical Engineering Journal, 280, 316-29. 
Ou, Z.Q., Schmierer, D.M., Strachan, C.J., Rades, T., McDowell, A., 2014. Influence of 
postharvest processing and storage conditions on key antioxidants in puha (Sonchus 
oleraceus L.). The Journal of Pharmacy and Pharmacology, 66 (7), 998-1008. 
Pan, R., Xu, W., Ding, Y., Lu, S., Chen, P., 2016. Uptake mechanism and direct translocation 
of a new CPP for siRNA delivery. Molecular Pharmaceutics, 13 (4), 1366-74. 
Park, K., Skidmore, S., Hadar, J., Garner, J., Park, H., Otte, A., Soh, B.K., Yoon, G., Yu, D., 
Yun, Y., Lee, B.K., Jiang, X., Wang, Y., 2019. Injectable, long-acting PLGA 
formulations: Analyzing PLGA and understanding microparticle formation. Journal of 
Controlled Release, 304, 125-34. 
Park, T.G., 1995. Degradation of poly(lactic-co-glycolic acid) microspheres: Effect of 
copolymer composition. Biomaterials, 16 (15), 1123-30. 
Partikel, K., Korte, R., Stein, N.C., Mulac, D., Herrmann, F.C., Humpf, H.-U., Langer, K., 
2019. Effect of nanoparticle size and PEGylation on the protein corona of PLGA 
nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 141, 70-80. 
Patel, L.N., Wang, J., Kim, K.J., Borok, Z., Crandall, E.D., Shen, W.C., 2009. Conjugation with 
cationic cell-penetrating peptide increases pulmonary absorption of insulin. Molecular 




Patel, R.R., Chaurasia, S., Khan, G., Chaubey, P., Kumar, N., Mishra, B., 2016. Cromolyn 
sodium encapsulated PLGA nanoparticles: An attempt to improve intestinal permeation. 
International Journal of Biological Macromolecules, 83, 249-58. 
Patel, S.G., Sayers, E.J., He, L., Narayan, R., Williams, T.L., Mills, E.M., Allemann, R.K., Luk, 
L.Y.P., Jones, A.T., Tsai, Y.-H., 2019. Cell-penetrating peptide sequence and 
modification dependent uptake and subcellular distribution of green florescent protein 
in different cell lines. Scientific Reports, 9 (1), 6298. 
Pauw, B.R., 2013. Everything SAXS: Small-angle scattering pattern collection and correction. 
Journal of Physics: Condensed Matter, 25 (38), 383201. 
Pelaz, B., del Pino, P., Maffre, P., Hartmann, R., Gallego, M., Rivera-Fernández, S., de la 
Fuente, J.M., Nienhaus, G.U., Parak, W.J., 2015. Surface functionalization of 
nanoparticles with polyethylene glycol: Effects on protein adsorption and cellular 
uptake. ACS Nano, 9 (7), 6996-7008. 
Pelkmans, L., Helenius, A., 2002. Endocytosis via caveolae. Traffic, 3 (5), 311-20. 
Peterson, L.W., Artis, D., 2014. Intestinal epithelial cells: Regulators of barrier function and 
immune homeostasis. Nature Reviews Immunology, 14, 141. 
Pinto, M., Robine, S., Appay, M.D., Lacroix, B., Assmann, P.F., Fogh, J., Zweibaum, A., 1983. 
Enterocyte-like differentiation and polarization of the human-colon carcinoma cell-line 
Caco-2 in culture. Biology of the Cell, 47, 323-30. 
Pooga, M., Hallbrink, M., Zorko, M., Langel, Ü., 1998. Cell penetration by transportan. FASEB 
Journal, 12 (1), 67-77. 
Price, S.R., Kinnear, C., Balog, S., 2019. Particokinetics and in vitro dose of high aspect ratio 
nanoparticles. Nanoscale, 11 (12), 5209-14. 
Putnam, C.D., Hammel, M., Hura, G.L., Tainer, J.A., 2007. X-ray solution scattering (SAXS) 
combined with crystallography and computation: Defining accurate macromolecular 
structures, conformations and assemblies in solution. Quarterly Reviews of Biophysics, 
40 (3), 191-285. 
Quintanar-Guerrero, D., Allemann, E., Fessi, H., Doelker, E., 1998. Preparation techniques and 
mechanisms of formation of biodegradable nanoparticles from preformed polymers. 
Drug Development and Industrial Pharmacy, 24 (12), 1113-28. 
Ramaker, K., Henkel, M., Krause, T., Rockendorf, N., Frey, A., 2018. Cell penetrating peptides: 
A comparative transport analysis for 474 sequence motifs. Drug Delivery, 25 (1), 928-
37. 
Reifarth, M., Hoeppener, S., Schubert, U.S., 2018. Uptake and intracellular fate of engineered 
nanoparticles in mammalian cells: Capabilities and limitations of transmission electron 
microscopy—polymer-based nanoparticles. Advanced Materials, 30 (9), 1703704. 
Reix, N., Parat, A., Seyfritz, E., Van der Werf, R., Epure, V., Ebel, N., Danicher, L., Marchioni, 
E., Jeandidier, N., Pinget, M., Frere, Y., Sigrist, S., 2012. In vitro uptake evaluation in 
Caco-2 cells and in vivo results in diabetic rats of insulin-loaded PLGA nanoparticles. 
International Journal of Pharmaceutics, 437 (1-2), 213-20. 
Rieux, A.d., Ragnarsson, E.G.E., Gullberg, E., Préat, V., Schneider, Y.-J., Artursson, P., 2005. 
Transport of nanoparticles across an in vitro model of the human intestinal follicle 
associated epithelium. European Journal of Pharmaceutical Sciences, 25 (4), 455-65. 
Ruczyński, J., Rusiecka, I., Turecka, K., Kozłowska, A., Alenowicz, M., Gągało, I., Kawiak, 
A., Rekowski, P., Waleron, K., Kocić, I., 2019. Transportan 10 improves the 
pharmacokinetics and pharmacodynamics of vancomycin. Scientific Reports, 9 (1), 
3247. 
Ruland, W., 1971. Small-angle scattering of two-phase systems: Determination and 
significance of systematic deviations from Porod's law. Journal of Applied 




Ruozi, B., Belletti, D., Tombesi, A., Tosi, G., Bondioli, L., Forni, F., Vandelli, M.A., 2011. 
AFM, ESEM, TEM, and CLSM in liposomal characterization: A comparative study. 
International Journal of Nanomedicine, 6, 557-63. 
Ruozi, B., Belletti, D., Vandelli, M.A., Pederzoli, F., Veratti, P., Forni, F., Tosi, G., Tonelli, 
M., Zapparoli, M., 2014. AFM/TEM complementary structural analysis of surface-
functionalized nanoparticles. Journal of Physical Chemistry & Biophysics, 4 (4). 
Ryser, H.J., Hancock, R., 1965. Histones and basic polyamino acids stimulate the uptake of 
albumin by tumor cells in culture. Science, 150 (3695), 501-3. 
Saarinen, J., Gutter, F., Lindman, M., Agopov, M., Fraser-Miller, S.J., Scherliess, R., Jokitalo, 
E., Santos, H.A., Peltonen, L., Isomaki, A., Strachan, C.J., 2019. Cell-nanoparticle 
interactions at (sub)-nanometer resolution analyzed by electron microscopy and 
correlative coherent anti-Stokes Raman scattering. Biotechnology Journal, 14 (4), 
e1800413. 
Saleh, A.F., Arzumanov, A., Abes, R., Owen, D., Lebleu, B., Gait, M.J., 2010. Synthesis and 
splice-redirecting activity of branched, arginine-rich peptide dendrimer conjugates of 
peptide nucleic acid oligonucleotides. Bioconjugate Chemistry, 21 (10), 1902-11. 
Sanada, Y., Akiba, I., Sakurai, K., Shiraishi, K., Yokoyama, M., Mylonas, E., Ohta, N., Yagi, 
N., Shinohara, Y., Amemiya, Y., 2013. Hydrophobic molecules infiltrating into the 
poly(ethylene glycol) domain of the core/shell interface of a polymeric micelle: 
Evidence obtained with anomalous small-angle X-ray scattering. Journal of the 
American Chemical Society, 135 (7), 2574-82. 
Scanlon, D.B., Finlayson, J., 2004. Prep/semiprep separation of peptides, in: Aguilar, M.-I. 
(Ed.), Methods in Molecular Biology, ed. Humana Press Inc. 
Scott, A.J., Penlidis, A., 2017. Copolymerization, in, Reference Module in Chemistry, 
Molecular Sciences and Chemical Engineering, ed. 
Shahbazi, S., Bolhassani, A., 2018. Comparison of six cell penetrating peptides with different 
properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines. 
International Immunopharmacology, 62, 170-80. 
Shai, Y., 2013. ATR-FTIR studies in pore forming and membrane induced fusion peptides. 
Biochimica et Biophysica Acta, 1828 (10), 2306-13. 
Shang, L., Nienhaus, G.U., 2013. Small fluorescent nanoparticles at the nano–bio interface. 
Materials Today, 16 (3), 58-66. 
Sharma, G., Sharma, A.R., Nam, J.-S., Doss, G.P.C., Lee, S.-S., Chakraborty, C., 2015. 
Nanoparticle based insulin delivery system: The next generation efficient therapy for 
Type 1 diabetes. Journal of Nanobiotechnology, 13 (1), 74. 
Sharma, N., Mishra, S., Sharma, S., Deshpande, R.D., Sharma, R.K., 2013. Preparation and 
optimization of nanoemulsions for targeting drug delivery. International Journal of Drug 
Development and Research, 5 (4), 37-48. 
Sharma, S., Parmar, A., Kori, S., Sandhir, R., 2016. PLGA-based nanoparticles: A new 
paradigm in biomedical applications. TrAC Trends in Analytical Chemistry, 80, 30-40. 
Sheng, J., Han, L., Qin, J., Ru, G., Li, R., Wu, L., Cui, D., Yang, P., He, Y., Wang, J., 2015. N-
trimethyl chitosan chloride-coated PLGA nanoparticles overcoming multiple barriers to 
oral insulin absorption. ACS Applied Materials & Interfaces, 7 (28), 15430-41. 
Sheng, J., He, H., Han, L., Qin, J., Chen, S., Ru, G., Li, R., Yang, P., Wang, J., Yang, V.C., 
2016. Enhancing insulin oral absorption by using mucoadhesive nanoparticles loaded 
with LMWP-linked insulin conjugates. Journal of Controlled Release, 233, 181-90. 
Shi, J., Guo, S., Wu, Y., Chen, G., Lai, J., Xu, X., 2019. Behaviour of cell penetrating peptide 
TAT-modified liposomes loaded with salvianolic acid B on the migration, proliferation, 




Siafaka, P.I., Ustundag Okur, N., Karavas, E., Bikiaris, D.N., 2016. Surface modified 
multifunctional and stimuli responsive nanoparticles for drug targeting: Current status 
and uses. International Journal of Molecular Sciences, 17 (9). 
Silva, S., Almeida, A.J., Vale, N., 2019. Combination of cell-penetrating peptides with 
nanoparticles for therapeutic application: A review. Biomolecules, 9 (1), 22. 
Singh, B., Bhatowa, R., Tripathi, C.B., Kapil, R., 2011a. Developing micro-/nanoparticulate 
drug delivery systems using "design of experiments". International Journal of 
Pharmaceutical Investigation, 1 (2), 75-87. 
Singh, B., Kapil, R., Nandi, M., Ahuja, N., 2011b. Developing oral drug delivery systems using 
formulation by design: Vital precepts, retrospect and prospects. Expert Opinion on Drug 
Delivery, 8 (10), 1341-60. 
Siu, F.Y., Ye, S., Lin, H., Li, S., 2018. Galactosylated PLGA nanoparticles for the oral delivery 
of resveratrol: enhanced bioavailability and in vitro anti-inflammatory activity. 
International Journal of Nanomedicine, 13, 4133-44. 
Solans, C., Solé, I., 2012. Nano-emulsions: Formation by low-energy methods. Current Opinion 
in Colloid & Interface Science, 17 (5), 246-54. 
Sonam, Chaudhary, H., Kumar, V., 2014. Taguchi design for optimization and development of 
antibacterial drug-loaded PLGA nanoparticles. International Journal of Biological 
Macromolecules, 64, 99-105. 
Steinbach, J.M., Seo, Y.E., Saltzman, W.M., 2016. Cell penetrating peptide-modified 
poly(lactic-co-glycolic acid) nanoparticles with enhanced cell internalization. Acta 
Biomaterialia, 30, 49-61. 
Streck, S., Neumann, H., Nielsen, H.M., Rades, T., McDowell, A., 2019a. Comparison of bulk 
and microfluidics methods for the formulation of poly-lactic-co-glycolic acid (PLGA) 
nanoparticles modified with cell-penetrating peptides of different architectures. 
International Journal of Pharmaceutics: X, 1, 100030. 
Streck, S., Clulow, A.J., Nielsen, H.M., Rades, T., Boyd, B.J., McDowell, A., 2019b. The 
distribution of cell-penetrating peptides on polymeric nanoparticles prepared using 
microfluidics and elucidated with small angle X-ray scattering. Journal of Colloid and 
Interface Science, 555, 438-48. 
Streck, S., Hong, L., Boyd, B.J., McDowell, A., 2019c. Microfluidics for the production of 
nanomedicines: Considerations for polymer and lipid-based systems. Pharmaceutical 
Nanotechnology, 7 (6), 1-21. 
Stroock, A.D., Dertinger, S.K., Ajdari, A., Mezic, I., Stone, H.A., Whitesides, G.M., 2002. 
Chaotic mixer for microchannels. Science, 295 (5555), 647-51. 
Su, Y., Doherty, T., Waring, A.J., Ruchala, P., Hong, M., 2009. Roles of arginine and lysine 
residues in the translocation of a cell-penetrating peptide from (13)C, (31)P, and (19)F 
solid-state NMR. Biochemistry, 48 (21), 4587-95. 
Sun, J., Zhang, L., Wang, J., Feng, Q., Liu, D., Yin, Q., Xu, D., Wei, Y., Ding, B., Shi, X., 
Jiang, X., 2015. Tunable rigidity of (polymeric core)–(lipid shell) nanoparticles for 
regulated cellular uptake. Advanced Materials, 27 (8), 1402-07. 
Tan, H.Y., Trier, S., Rahbek, U.L., Dufva, M., Kutter, J.P., Andresen, T.L., 2018. A multi-
chamber microfluidic intestinal barrier model using Caco-2 cells for drug transport 
studies. PLoS One, 13 (5), e0197101. 
Tantra, R., Knight, A., 2011. Cellular uptake and intracellular fate of engineered nanoparticles: 
A review on the application of imaging techniques. Nanotoxicology, 5 (3), 381-92. 
Tariq, M., Alam, M.A., Singh, A.T., Iqbal, Z., Panda, A.K., Talegaonkar, S., 2015. 
Biodegradable polymeric nanoparticles for oral delivery of epirubicin: In vitro, ex vivo, 




Tefas, L.R., Tomuta, I., Achim, M., Vlase, L., 2015. Development and optimization of 
quercetin-loaded PLGA nanoparticles by experimental design. Clujul Medical, 88 (2), 
214-23. 
Thomas, D.G., Smith, J.N., Thrall, B.D., Baer, D.R., Jolley, H., Munusamy, P., Kodali, V., 
Demokritou, P., Cohen, J., Teeguarden, J.G., 2018. ISD3: A particokinetic model for 
predicting the combined effects of particle sedimentation, diffusion and dissolution on 
cellular dosimetry for in vitro systems. Particle and Fibre Toxicology, 15 (1), 6. 
Thwala, L.N., Preat, V., Csaba, N.S., 2017. Emerging delivery platforms for mucosal 
administration of biopharmaceuticals: A critical update on nasal, pulmonary and oral 
routes. Expert Opinion on Drug Delivery, 14 (1), 23-36. 
Torchilin, V.P., 2014. Multifunctional, stimuli-sensitive nanoparticulate systems for drug 
delivery. Nature Reviews Drug Discovery, 13 (11), 813-27. 
Totaro, K.A., Liao, X., Bhattacharya, K., Finneman, J.I., Sperry, J.B., Massa, M.A., Thorn, J., 
Ho, S.V., Pentelute, B.L., 2016. Systematic investigation of EDC/sNHS-mediated 
bioconjugation reactions for carboxylated peptide substrates. Bioconjugate Chemistry, 
27 (4), 994-1004. 
Toth, M.J., Kim, T., Kim, Y., 2017. Robust manufacturing of lipid-polymer nanoparticles 
through feedback control of parallelized swirling microvortices. Lab on a Chip, 17 (16), 
2805-13. 
Totterman, A.M., Schipper, N.G., Thompson, D.O., Mannermaa, J.P., 1997. Intestinal safety of 
water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: Effects 
on human intestinal epithelial Caco-2 cells. The Journal of Pharmacy and 
Pharmacology, 49 (1), 43-8. 
Trehin, R., Krauss, U., Beck-Sickinger, A.G., Merkle, H.P., Nielsen, H.M., 2004. Cellular 
uptake but low permeation of human calcitonin-derived cell penetrating peptides and 
Tat(47-57) through well-differentiated epithelial models. Pharmaceutical Research, 21 
(7), 1248-56. 
Tunsirikongkon, A., Pyo, Y.C., Kim, D.H., Lee, S.E., Park, J.S., 2019. Optimization of 
polyarginine-conjugated PEG lipid grafted proliposome formulation for enhanced 
cellular association of a protein drug. Pharmaceutics, 11 (6). 
Utada, A.S., Chu, L.Y., Fernandez-Nieves, A., Link, D.R., Holtze, C., Weitz, D.A., 2007. 
Dripping, jetting, drops, and wetting: The magic of microfluidics. MRS Bulletin, 32 (9), 
702-08. 
Vaidya, B., Parvathaneni, V., Kulkarni, N.S., Shukla, S.K., Damon, J.K., Sarode, A., Kanabar, 
D., Garcia, J.V., Mitragotri, S., Muth, A., Gupta, V., 2019. Cyclodextrin modified 
erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-
small cell lung cancer. International Journal of Biological Macromolecules, 122, 338-
47. 
Valencia, P.M., Basto, P.A., Zhang, L., Rhee, M., Langer, R., Farokhzad, O.C., Karnik, R., 
2010. Single-step assembly of homogenous lipid-polymeric and lipid-quantum dot 
nanoparticles enabled by microfluidic rapid mixing. ACS Nano, 4 (3), 1671-9. 
Valencia, P.M., Farokhzad, O.C., Karnik, R., Langer, R., 2012. Microfluidic technologies for 
accelerating the clinical translation of nanoparticles. Nature Nanotechnology, 7, 623. 
Valencia, P.M., Pridgen, E.M., Rhee, M., Langer, R., Farokhzad, O.C., Karnik, R., 2013. 
Microfluidic platform for combinatorial synthesis and optimization of targeted 
nanoparticles for cancer therapy. ACS Nano, 7 (12), 10671-80. 
van Bracht, E., Versteegden, L.R., Stolle, S., Verdurmen, W.P., Woestenenk, R., Raave, R., 
Hafmans, T., Oosterwijk, E., Brock, R., van Kuppevelt, T.H., Daamen, W.F., 2014. 
Enhanced cellular uptake of albumin-based lyophilisomes when functionalized with 




van Oppen, L.M.P.E., Pille, J., Stuut, C., van Stevendaal, M., van der Vorm, L.N., Smeitink, 
J.A.M., Koopman, W.J.H., Willems, P.H.G.M., van Hest, J.C.M., Brock, R., 2019. 
Octa-arginine boosts the penetration of elastin-like polypeptide nanoparticles in 3D 
cancer models. European Journal of Pharmaceutics and Biopharmaceutics, 137, 175-84. 
Vasconcelos, A., Vega, E., Perez, Y., Gomara, M.J., Garcia, M.L., Haro, I., 2015. Conjugation 
of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol 
nanoparticles improves ocular drug delivery. International Journal of Nanomedicine, 
10, 609-31. 
Vithani, K., Hawley, A., Jannin, V., Pouton, C., Boyd, B.J., 2017. Inclusion of digestible 
surfactants in solid SMEDDS formulation removes lag time and influences the 
formation of structured particles during digestion. The AAPS Journal, 19 (3), 754-64. 
Vives, E., Brodin, P., Lebleu, B., 1997. A truncated HIV-1 Tat protein basic domain rapidly 
translocates through the plasma membrane and accumulates in the cell nucleus. The 
Journal of Biological Chemistry, 272 (25), 16010-7. 
von Roemeling, C., Jiang, W., Chan, C.K., Weissman, I.L., Kim, B.Y.S., 2017. Breaking down 
the barriers to precision cancer nanomedicine. Trends in Biotechnology, 35 (2), 159-71. 
Vuddanda, P.R., Mishra, A., Singh, S.K., Singh, S., 2015. Development of polymeric 
nanoparticles with highly entrapped herbal hydrophilic drug using nanoprecipitation 
technique: An approach of quality by design. Pharmaceutical Development and 
Technology, 20 (5), 579-87. 
Wang, J.T., Wang, J., Han, J.J., 2011. Fabrication of advanced particles and particle-based 
materials assisted by droplet-based microfluidics. Small, 7 (13), 1728-54. 
Wang, Y., Kim, R., Hinman, S.S., Zwarycz, B., Magness, S.T., Allbritton, N.L., 2018. 
Bioengineered systems and designer matrices that recapitulate the intestinal stem cell 
niche. Cellular and Molecular Gastroenterology and Hepatology, 5 (3), 440-53.e1. 
Wassel, R.A., Grady, B., Kopke, R.D., Dormer, K.J., 2007. Dispersion of super paramagnetic 
iron oxide nanoparticles in poly(d,l-lactide-co-glycolide) microparticles. Colloids and 
Surfaces A: Physicochemical and Engineering Aspects, 292 (2), 125-30. 
Water, J.J., Kim, Y., Maltesen, M.J., Franzyk, H., Foged, C., Nielsen, H.M., 2015. Hyaluronic 
acid-based nanogels produced by microfluidics-facilitated self-assembly Improves the 
safety profile of the cationic host defense peptide novicidin. Pharmaceutical Research, 
32 (8), 2727-35. 
Whitesides, G.M., 2006. The origins and the future of microfluidics. Nature, 442 (7101), 368-
73. 
Williams, M.S., Longmuir, K.J., Yager, P., 2008. A practical guide to the staggered herringbone 
mixer. Lab on a Chip, 8 (7), 1121-29. 
Win, K.Y., Feng, S.S., 2005. Effects of particle size and surface coating on cellular uptake of 
polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials, 26 (15), 
2713-22. 
Winey, M., Meehl, J.B., O'Toole, E.T., Giddings, T.H., Jr., 2014. Conventional transmission 
electron microscopy. Molecular Biology of the Cell, 25 (3), 319-23. 
Wu, X.S., Wang, N., 2001. Synthesis, characterization, biodegradation, and drug delivery 
application of biodegradable lactic/glycolic acid polymers. Part II: Biodegradation. 
Journal of Biomaterials Science Polymer Edition, 12 (1), 21-34. 
Xia, H., Gao, X., Gu, G., Liu, Z., Hu, Q., Tu, Y., Song, Q., Yao, L., Pang, Z., Jiang, X., Chen, 
J., Chen, H., 2012. Penetratin-functionalized PEG-PLA nanoparticles for brain drug 
delivery. International Journal of Pharmaceutics, 436 (1-2), 840-50. 
Xie, H., Smith, J.W., 2010. Fabrication of PLGA nanoparticles with a fluidic nanoprecipitation 




Xu, H., Kona, S., Su, L.-C., Tsai, Y.-T., Dong, J.-F., Brilakis, E.S., Tang, L., Banerjee, S., 
Nguyen, K.T., 2013a. Multi-ligand poly(L-lactic-co-glycolic acid) nanoparticles inhibit 
activation of endothelial cells. Journal of Cardiovascular Translational Research, 6 (4), 
570-78. 
Xu, J., Zhang, S., Machado, A., Lecommandoux, S., Sandre, O., Gu, F., Colin, A., 2017. 
Controllable microfluidic production of drug-loaded PLGA nanoparticles using 
partially water-miscible mixed solvent microdroplets as a precursor. Scientific Reports, 
7 (1), 4794. 
Xu, S., Olenyuk, B.Z., Okamoto, C.T., Hamm-Alvarez, S.F., 2013b. Targeting receptor-
mediated endocytotic pathways with nanoparticles: Rationale and advances. Advanced 
Drug Delivery Reviews, 65 (1), 121-38. 
Yadav, K.S., Sawant, K.K., 2010. Modified nanoprecipitation method for preparation of 
cytarabine-loaded PLGA nanoparticles. AAPS PharmSciTech, 11 (3), 1456-65. 
Yadav, S.C., Kumari, A., Yadav, R., 2011. Development of peptide and protein 
nanotherapeutics by nanoencapsulation and nanobioconjugation. Peptides, 32 (1), 173-
87. 
Yang, B., Lowe, J.P., Schweins, R., Edler, K.J., 2015. Small angle neutron scattering studies 
on the internal structure of poly(lactide-co-glycolide)-block-poly(ethylene glycol) 
nanoparticles as drug delivery vehicles. Biomacromolecules, 16 (2), 457-64. 
Ye, D., Dawson, K.A., Lynch, I., 2015. A TEM protocol for quality assurance of in vitro cellular 
barrier models and its application to the assessment of nanoparticle transport 
mechanisms across barriers. The Analyst, 140 (1), 83-97. 
Yong, K.W., Yuen, D., Chen, M.Z., Porter, C.J.H., Johnston, A.P.R., 2019. Pointing in the right 
direction: Controlling the orientation of proteins on nanoparticles improves targeting 
efficiency. Nano Letters, 19 (3), 1827-31. 
Yoo, J., Lee, D., Gujrati, V., Rejinold, N.S., Lekshmi, K.M., Uthaman, S., Jeong, C., Park, I.K., 
Jon, S., Kim, Y.C., 2017. Bioreducible branched poly(modified nona-arginine) cell-
penetrating peptide as a novel gene delivery platform. Journal of Controlled Release, 
246, 142-54. 
Zabihi, F., Xin, N., Li, S., Jia, J., Cheng, T., Zhao, Y., 2014. Polymeric coating of fluidizing 
nano-curcumin via anti-solvent supercritical method for sustained release. The Journal 
of Supercritical Fluids, 89, 99-105. 
Zhai, P., Chen, X.B., Schreyer, D.J., 2015. PLGA/alginate composite microspheres for 
hydrophilic protein delivery. Materials Science and Engineering: C Materials for 
Biological Applications, 56, 251-59. 
Zhang, C., Ren, W., Liu, Q., Tan, Z., Li, J., Tong, C., 2019. Transportan-derived cell-
penetrating peptide delivers siRNA to inhibit replication of influenza virus in vivo. Drug 
Design, Development and Therapy, 13, 1059-68. 
Zhang, D., Wang, J., Xu, D., 2016. Cell-penetrating peptides as noninvasive transmembrane 
vectors for the development of novel multifunctional drug-delivery systems. Journal of 
Controlled Release, 229, 130-39. 
Zhang, F., Skoda, M.W.A., Jacobs, R.M.J., Martin, R.A., Martin, C.M., Schreiber, F., 2007. 
Protein interactions studied by SAXS:  Effect of ionic strength and protein concentration 
for BSA in aqueous solutions. The Journal of Physical Chemistry B, 111 (1), 251-59. 
Zhang, L., Feng, Q., Wang, J., Zhang, S., Ding, B., Wei, Y., Dong, M., Ryu, J.-Y., Yoon, T.-
Y., Shi, X., Sun, J., Jiang, X., 2015. Microfluidic synthesis of hybrid nanoparticles with 
controlled lipid layers: Understanding flexibility-regulated cell–nanoparticle 




Zhang, Z., Tsai, P.C., Ramezanli, T., Michniak-Kohn, B.B., 2013. Polymeric nanoparticles-
based topical delivery systems for the treatment of dermatological diseases. Wiley 
Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 5 (3), 205-18. 
Zhao, J., Zhou, R., Fu, X., Ren, W., Ma, L., Li, R., Zhao, Y., Guo, L., 2014a. Cell-penetrable 
lysine dendrimers for anti-cancer drug delivery: Synthesis and preliminary biological 
evaluation. Archiv der Pharmazie, 347 (7), 469-77. 
Zhao, Z., Li, Y., Zhang, Y., Chen, A.-Z., Li, G., Zhang, J., Xie, M.-B., 2014b. Development of 
silk fibroin modified poly(l-lactide)–poly(ethylene glycol)–poly(l-lactide) 
nanoparticles in supercritical CO2. Powder Technology, 268, 118-25. 
Zhigaltsev, I.V., Belliveau, N., Hafez, I., Leung, A.K., Huft, J., Hansen, C., Cullis, P.R., 2012. 
Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous 
and triglyceride cores using millisecond microfluidic mixing. Langmuir, 28 (7), 3633-
40. 
Zhou, X., Chen, Q., Ma, Y., Huang, Y., Gou, S., Xiao, B., 2019. Porous polymeric 
microparticles as an oral drug platform for effective ulcerative colitis treatment. Journal 
of Pharmaceutical Sciences, 108 (7), 2238-42. 
Zhu, S., Chen, S., Gao, Y., Guo, F., Li, F., Xie, B., Zhou, J., Zhong, H., 2016a. Enhanced oral 
bioavailability of insulin using PLGA nanoparticles co-modified with cell-penetrating 
peptides and Engrailed secretion peptide (Sec). Drug Delivery, 23 (6), 1980-91. 
Zhu, X., Wu, J., Shan, W., Tao, W., Zhao, L., Lim, J.-M., D'Ortenzio, M., Karnik, R., Huang, 
Y., Shi, J., Farokhzad, O.C., 2016b. Polymeric nanoparticles amenable to simultaneous 
installation of exterior targeting and interior therapeutic proteins. Angewandte Chemie, 
55 (10), 3309-12. 
Zhu, X., Lu, N., Zhou, Y., Xuan, S., Zhang, J., Giampieri, F., Zhang, Y., Yang, F., Yu, R., 
Battino, M., Wang, Z., 2019. Targeting pancreatic cancer cells with peptide-
functionalized polymeric magnetic nanoparticles. International Journal of Molecular 
Sciences, 20 (12). 
Zhuang, J., Wang, D., Li, D., Yang, Y., Lu, Y., Wu, W., Wu, W., Qi, J., 2018. The influence of 
nanoparticle shape on bilateral exocytosis from Caco-2 cells. Chinese Chemical Letters, 
29 (12), 1815-18. 
Zu, M., Ma, L., Zhang, X., Xie, D., Kang, Y., Xiao, B., 2019. Chondroitin sulfate-
functionalized polymeric nanoparticles for colon cancer-targeted chemotherapy. 














Input factors and output responses for the individual runs of the bulk nanoprecipitation method 
from the design of experiments study.  Data obtained for the centre point is shown as mean ± 





Time (h) Size (nm) PDI 
Level Level Level   
-1 0 1 -1 0 1 -1 0 1   
2   0.5   0.5   103.7 0.205 
2   0.5     4 107.5 0.335 
2     5 0.5   188.5 0.204 
2     5   4 235.1 0.225 
 13.5   2.75   2.25  154.8 ± 6.1 
0.149 ± 
0.024 
  25 0.5    0.5  149.4 0.187 
  25 0.5    4  153.9 0.167 
  25   5  0.5  174.2 0.173 







Input factors and output responses for the individual runs of the microfluidics method from the 
design of experiments study.  Data obtained for the centre point is shown as mean ± SD (n = 6). 
Total Flow Rate (TFR) 
mL/min 
Flow Rate Ratio (FRR) Size (nm) PDI 
Level Level   
-1 0 1 -1 0 1   
2   1 : 1   194.8 0.055 
2   1 : 1   196.8 0.080 
2   
 
 12 : 1 136.4 0.165 
2   
 




6.5 : 1  172.7 ± 1.5 0.143 ± 0.014 
 
 12 1 : 1   194.2 0.056 
 
















Standard curves of RP-HPLC methods for RRH (50-1000 µg/mL) (A), TAT (100-1000 µg/mL) 






Stacked RP-HPLC chromatograms of the RRH standards (50-1000 µg/mL) (A), TAT standards 






Small angle X-ray scattering profile of the AuNPs used in this study along with the fitting of 
the spherical structure factors. The dashed blue and red lines indicate the fitting models for 
spheres with radii of 2.2 and 4.4 nm, respectively.  Polydispersity of 0.17 (standard deviation 
in radius over the mean radius) was incorporated into the two sphere models according to the 
manufacturers specified standard deviation in mean radius.  The black line is the sum of the two 
models. Note that the background for each individual sphere model is half of the observed 
background in the recorded data.  SASView fitting software was used for the data modelling 
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where ϕ = particle volume fraction, V = particle volume, Δρ = SLD contrast, r = particle radius. 
 
Sphere 1 – radius = 22 Å (fixed), polydispersity = 0.17 (fixed), particle SLD = 1.23 × 10-4 Å-2 
(for Au, fixed), solvent SLD = 9.47 × 10-6 Å-2 (for water, fixed), background = 0.0009 cm-1 
(fixed) and volume fraction of particles = (1.41 ± 0.01) × 10-5. 
 
Sphere 2 – radius = 44 Å (fixed), polydispersity = 0.17 (fixed), particle SLD = 1.23 × 10-4 Å-2 
(for Au, fixed), solvent SLD = 9.47 × 10-6 Å-2 (for water, fixed), background = 0.0009 cm-1 







Monitoring of transepithelial electrical resistance (TEER) value of Caco-2 cell monolayer 
between day 17 and day 22 after seeding on cell culture inserts with a permeable membrane.  











Confocal images of Caco-2 cell monolayer incubated for 2 h with RRH- (A), TAT- (B) and 
bTAT-tagged PLGA-FPR nanoparticles (C) prepared using the post-microfluidics conjugation 
approach.  The z-stack images of Caco-2 cells with CPP-tagged PLGA have had a slice 
thickness of 0.75 µm or 1.25 µm for RRH- or TAT- and bTAT-tagged PLGA-FPR 
nanoparticles, respectively.  The white arrow is pointing towards red fluorescence of PLGA-
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